Rotavirus vaccines

ABSTRACT

The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.

This application is a divisional of U.S. application Ser. No.17/811,250, filed Jul. 7, 2022, which is a divisional of U.S.application Ser. No. 15/774,416, filed May 8, 2018, now U.S. Pat. No.11,413,346, which is a national phase application under 35 U.S.C. § 371of International Application No. PCT/EP2016/077185, filed Nov. 9, 2016,the entire contents of each of which are hereby incorporated byreference. International Application No. PCT/EP2016/077185 claimsbenefit of European Application No. 15003204.3, filed Nov. 9, 2015.

This application contains a Sequence Listing XML, which has beensubmitted electronically and is hereby incorporated by reference in itsentirety. Said Sequence Listing XML, created on Sep. 6, 2023, is namedCRVCP0196USD2.xml and is 7,313,261 bytes in size.

The present invention relates according to a first aspect to mRNAsequences. According to further aspects the invention relates tocompositions, vaccines and kits comprising said mRNA sequences.According to a further aspect of the invention the mRNA sequences may beused for treatment and prophylaxis of rotavirus infections.

Rotavirus infections are the globally leading cause of severe diarrhoeain children younger than five years of age and account for 50% ofhospitalisations for childhood diarrhoea. Although rotavirus infectionsare usually an easily managed disease of childhood, worldwide still morethan 450,000 children under five years die from rotavirus infection eachyear. More than 80% of all rotavirus-related deaths occur inresource-poor countries.

Rotaviruses belong to the family of Reoviridae and have been subdividedinto eight species, namely five serological species (rotavirus A to E)and two additional tentative species (rotavirus F and G). These speciesare commonly referred to as “RV groups”. Three species thereof (A, B andC) can infect humans and animals. The other species D, E, F and G havebeen identified in animals, mostly in birds. Rotavirus A is responsiblefor more than 90% of all human infections and is most important forhuman infection and disease. It is transmitted by the faecal-oral routeand targets enterocytes in the villi of the small intestine, leading tocell damage and gastroenteritis.

The virus possess a double stranded, segmented RNA genome that encodessix structural and six non-structural proteins and forms non-envelopedparticles with three-layered icosahedral capsids. The six structuralproteins (VPs—viral proteins) form the virus particle (virion) and arecalled VP1, VP2, VP3, VP4, VP6 and VP7. The six non-structural proteins(NSPs) are called NSP1, NSP2, NSP3, NSP4, NSP5 and NSP6 and areimportant for viral mRNA translation, for genome replication, genomeencapsidation and capsid assembly. In addition, non-structural proteinsare involved in antagonizing the antiviral host response and insubverting important cellular processes to enable successful virusreplication.

Within the species rotavirus A, there are different strains (serotypesor genotypes), which are classified by a dual system based on thestructural proteins VP7 and VP4. VP7 and VP4 are components of theoutermost protein layer (outer capsid), and both carry neutralizingepitopes. VP7 is a glycoprotein (G) that forms the outer layer orsurface of the virion. VP7 determines the G-type of the strain.According to Matthijnssens J. et al. (Arch Virol. 2011;156(8):1397-1413) there are 27 G-serotypes (G1-G27). VP4 is a surfaceprotein that protrudes as a spike. VP4 is essential for virus-cellinteraction and determines host range and virulence of the virus. VP4 isprotease sensitive (P) and determines the P-type of the virus. There are35 P-serotypes (P[1]-P[35]). This dual classification system may also beapplied to other rotavirus species.

In humans, around 90% of infections are caused by G1, G2, G3 or G4 andalso G9 and G12. With respect to the P-types P[4], P[6] and P[8] are themost prevalent, as described by Zeller et al. (Journal of ClinicalMicrobiology (2012), vol 50, no. 3, pp: 966-976). Importantly, infectionwith one virus is not able to induce cross-protection against infectionby a different serotype.

While the virus is endemic worldwide with almost every child having beeninfected by the age of five, rotavirus infection is most problematic inthe developing world: the majority of deaths occur in Africa and Asia,of which India is the country most heavily affected.

At present, there are two licensed oral vaccines available, which areboth based on live-attenuated forms of the virus. RotaTeq® (Merck) isbased on a bovine rotavirus strain engineered to express outer layerproteins from human strains. Rotarix® (GlaxoSmithKline) is based on alive-attenuated human rotavirus strain. Both vaccines are given orallyand exhibit high efficacy in the developed world. However, the efficacyof oral rotavirus vaccination is significantly reduced in developingcountries. This is likely to be caused by several factors. Firstly, thevirus-based vaccine can be inactivated by pre-existing antibodies, e.g.transferred to babies by breastfeeding. Secondly, malnutrition can havea negative impact on the efficacy of oral vaccinations. Furthermore,unrelated infections of the gastrointestinal tract which are moreprevalent in developing countries compared to developed countries, mightbe a major factor in reducing vaccine efficacy.

The Chinese patent application CN 102703475 A describes an approach toobtain recombinant bovine rotavirus strains by introducing a recombinantplasmid containing a NSP4 mutant gene resulting in toxicity weakenedrecombinant bovine rotavirus, which may be used as attenuated vaccinecandidate strains.

The U.S. Pat. No. 4,636,385 discloses a method for producing a liverotavirus vaccine against bovine and human rotaviruses by isolation astrain of live bovine rotavirus which does not hemagglutinate primatered blood cells.

The Korean patent application KR 20020061300 A describes the cloning ofVP4 and VP7 genes of black goat rotavirus for the purpose of vaccinedevelopment.

The Japanese patent application JP 2000139473 A discloses a plantcomprising plant cells into which a gene coding for VP6 protein ofrotavirus was incorporated. The plant is described to be useful for theproduction of a vaccine against rotavirus.

Nevertheless, there is a still an urgent need for providing new andimproved vaccines, which are particularly important for developingcountries. Preferably, the new and improved vaccine should allowparenteral delivery and thus avoid efficacy reduction induced via oralvaccine delivery. Moreover, the new vaccine should allow cost-effectiveproduction. Furthermore, especially for the use in developing countries,there is an urgent need for a temperature stabile rotavirus vaccinewhich is not dependent on cooling (cold chain) for storage anddistribution. Furthermore there is an urgent need of a rotavirus vaccinewhich is effective against different rotavirus serotypes.

This object is solved by the subject matter of the claims. Particularly,the object underlying the present invention is solved according to afirst aspect by an mRNA sequence and by a composition as defined in theclaims. According to further aspects of the invention the object issolved by a vaccine, a kit and by a method of treatment or prophylaxisof rotavirus infections as defined in the further claims.

For the sake of clarity and readability the following scientificbackground information and definitions are provided. Any technicalfeatures disclosed thereby can be part of each and every embodiment ofthe invention. Additional definitions and explanations are provided inthe context of this disclosure.

Immune system: The immune system may protect organisms from infection.If a pathogen breaks through a physical barrier of an organism andenters this organism, the innate immune system provides an immediate,but non-specific response. If pathogens evade this innate response,vertebrates possess a second layer of protection, the adaptive immunesystem. Here, the immune system adapts its response during an infectionto improve its recognition of the pathogen. This improved response isthen retained after the pathogen has been eliminated, in the form of animmunological memory, and allows the adaptive immune system to mountfaster and stronger attacks each time this pathogen is encountered.According to this, the immune system comprises the innate and theadaptive immune system. Each of these two parts contains so calledhumoral and cellular components.

Immune response: An immune response may typically either be a specificreaction of the adaptive immune system to a particular antigen (socalled specific or adaptive immune response) or an unspecific reactionof the innate immune system (so called unspecific or innate immuneresponse).

Adaptive immune system: The adaptive immune system is composed of highlyspecialized, systemic cells and processes that eliminate or preventpathogenic growth. The adaptive immune response provides the vertebrateimmune system with the ability to recognize and remember specificpathogens (to generate immunity), and to mount stronger attacks eachtime the pathogen is encountered. The system is highly adaptable becauseof somatic hypermutation (a process of increased frequency of somaticmutations), and V(D)J recombination (an irreversible geneticrecombination of antigen receptor gene segments). This mechanism allowsa small number of genes to generate a vast number of different antigenreceptors, which are then uniquely expressed on each individuallymphocyte. Because the gene rearrangement leads to an irreversiblechange in the DNA of each cell, all of the progeny (offspring) of thatcell will then inherit genes encoding for the same receptor specificity,including the Memory B cells and Memory T cells that are the keys tolong-lived specific immunity. Immune network theory is a theory of howthe adaptive immune system works, that is based on interactions betweenthe variable regions of the receptors of T cells, B cells and ofmolecules made by T cells and B cells that have variable regions.

Adaptive immune response: The adaptive immune response is typicallyunderstood to be antigen-specific. Antigen specificity allows for thegeneration of responses that are tailored to specific antigens,pathogens or pathogen-infected cells. The ability to mount thesetailored responses is maintained in the body by “memory cells”. Should apathogen infect the body more than once, these specific memory cells areused to quickly eliminate it. In this context, the first step of anadaptive immune response is the activation of naïve antigen-specific Tcells or different immune cells able to induce an antigen-specificimmune response by antigen-presenting cells. This occurs in the lymphoidtissues and organs through which naïve T cells are constantly passing.Cell types that can serve as antigen-presenting cells are inter aliadendritic cells, macrophages, and B cells. Each of these cells has adistinct function in eliciting immune responses. Dendritic cells take upantigens by phagocytosis and macropinocytosis and are stimulated bycontact with e.g. a foreign antigen to migrate to the local lymphoidtissue, where they differentiate into mature dendritic cells.Macrophages ingest particulate antigens such as bacteria and are inducedby infectious agents or other appropriate stimuli to express MHCmolecules. The unique ability of B cells to bind and internalize solubleprotein antigens via their receptors may also be important to induce Tcells. Presenting the antigen on MHC molecules leads to activation of Tcells which induces their proliferation and differentiation into armedeffector T cells. The most important function of effector T cells is thekilling of infected cells by CD8+ cytotoxic T cells and the activationof macrophages by Th1 cells which together make up cell-mediatedimmunity, and the activation of B cells by both Th2 and Th1 cells toproduce different classes of antibody, thus driving the humoral immuneresponse. T cells recognize an antigen by their T cell receptors whichdo not recognize and bind antigen directly, but instead recognize shortpeptide fragments e.g. of pathogen-derived protein antigens, which arebound to MHC molecules on the surfaces of other cells.

Cellular immunity/cellular immune response: Cellular immunity relatestypically to the activation of macrophages, natural killer cells (NK),antigen-specific cytotoxic T-lymphocytes, and the release of variouscytokines in response to an antigen. In a more general way, cellularimmunity is not related to antibodies but to the activation of cells ofthe immune system. A cellular immune response is characterized e.g. byactivating antigen-specific cytotoxic T-lymphocytes that are able toinduce apoptosis in body cells displaying epitopes of an antigen ontheir surface, such as virus-infected cells, cells with intracellularbacteria, and cancer cells displaying tumor antigens; activatingmacrophages and natural killer cells, enabling them to destroypathogens; and stimulating cells to secrete a variety of cytokines thatinfluence the function of other cells involved in adaptive immuneresponses and innate immune responses.

Humoral immunity/humoral immune response: Humoral immunity referstypically to antibody production and the accessory processes that mayaccompany it. A humoral immune response may be typically characterized,e.g., by Th2 activation and cytokine production, germinal centerformation and isotype switching, affinity maturation and memory cellgeneration. Humoral immunity also typically may refer to the effectorfunctions of antibodies, which include pathogen and toxinneutralization, classical complement activation, and opsonin promotionof phagocytosis and pathogen elimination.

Innate immune system: The innate immune system, also known asnon-specific immune system, comprises the cells and mechanisms thatdefend the host from infection by other organisms in a non-specificmanner. This means that the cells of the innate system recognize andrespond to pathogens in a generic way, but unlike the adaptive immunesystem, it does not confer long-lasting or protective immunity to thehost. The innate immune system may be e.g. activated by ligands ofpathogen-associated molecular patterns (PAMP) receptors, e.g. Toll-likereceptors (TLRs) or other auxiliary substances such aslipopolysaccharides, TNF-alpha, CD40 ligand, or cytokines, monokines,lymphokines, interleukins or chemokines, immunostimulatory nucleicacids, immunostimulatory RNA (isRNA), CpG-DNA, antibacterial agents, oranti-viral agents. Typically a response of the innate immune systemincludes recruiting immune cells to sites of infection, through theproduction of chemical factors, including specialized chemicalmediators, called cytokines; activation of the complement cascade;identification and removal of foreign substances present in organs,tissues, the blood and lymph, by specialized white blood cells;activation of the adaptive immune system through a process known asantigen presentation; and/or acting as a physical and chemical barrierto infectious agents.

Adjuvant/adjuvant component: An adjuvant or an adjuvant component in thebroadest sense is typically a (e.g. pharmacological or immunological)agent or composition that may modify, e.g. enhance, the efficacy ofother agents, such as a drug or vaccine. Conventionally the term refersin the context of the invention to a compound or composition that servesas a carrier or auxiliary substance for immunogens and/or otherpharmaceutically active compounds. It is to be interpreted in a broadsense and refers to a broad spectrum of substances that are able toincrease the immunogenicity of antigens incorporated into orco-administered with an adjuvant in question. In the context of thepresent invention an adjuvant will preferably enhance the specificimmunogenic effect of the active agents of the present invention.Typically, “adjuvant” or “adjuvant component” has the same meaning andcan be used mutually. Adjuvants may be divided, e.g., into immunopotentiators, antigenic delivery systems or even combinations thereof.The term “adjuvant” is typically understood not to comprise agents whichconfer immunity by themselves. An adjuvant assists the immune systemunspecifically to enhance the antigen-specific immune response by e.g.promoting presentation of an antigen to the immune system or inductionof an unspecific innate immune response. Furthermore, an adjuvant maypreferably e.g. modulate the antigen-specific immune response by e.g.shifting the dominating Th2-based antigen specific response to a moreTh1-based antigen specific response or vice versa. Accordingly, anadjuvant may favourably modulate cytokine expression/secretion, antigenpresentation, type of immune response etc.

Antigen: The term “antigen” refers typically to a substance which may berecognized by the immune system and may be capable of triggering anantigen-specific immune response, e.g. by formation of antibodies orantigen-specific T-cells as part of an adaptive immune response. Anantigen may be a protein or peptide. In this context, the first step ofan adaptive immune response is the activation of naïve antigen-specificT cells by antigen-presenting cells. This occurs in the lymphoid tissuesand organs through which naïve T cells are constantly passing. The threecell types that can serve as antigen-presenting cells are dendriticcells, macrophages, and B cells. Each of these cells has a distinctfunction in eliciting immune responses. Tissue dendritic cells take upantigens by phagocytosis and macropinocytosis and are stimulated byinfection to migrate to the local lymphoid tissue, where theydifferentiate into mature dendritic cells. Macrophages ingestparticulate antigens such as bacteria and are induced by infectiousagents to express MHC class II molecules. The unique ability of B cellsto bind and internalize soluble protein antigens via their receptors maybe important to induce T cells. By presenting the antigen on MHCmolecules leads to activation of T cells which induces theirproliferation and differentiation into armed effector T cells. The mostimportant function of effector T cells is the killing of infected cellsby CD8+ cytotoxic T cells and the activation of macrophages by Th1 cellswhich together make up cell-mediated immunity, and the activation of Bcells by both Th2 and Th1 cells to produce different classes ofantibody, thus driving the humoral immune response. T cells recognize anantigen by their T cell receptors which does not recognize and bindantigen directly, but instead recognize short peptide fragments e.g. ofpathogens' protein antigens, which are bound to MHC molecules on thesurfaces of other cells.

T cells: T cells fall into two major classes that have differenteffector functions. The two classes are distinguished by the expressionof the cell-surface proteins CD4 and CD8. These two types of T cellsdiffer in the class of MHC molecule that they recognize. There are twoclasses of MHC molecules—MHC class I and MHC class II molecules—whichdiffer in their structure and expression pattern on tissues of the body.CD4+ T cells bind to a MHC class II molecule and CD8+ T cells to a MHCclass I molecule. MHC class I and MHC class II molecules have distinctdistributions among cells that reflect the different effector functionsof the T cells that recognize them. MHC class I molecules presentpeptides of cytosolic and nuclear origin e.g. from pathogens, commonlyviruses, to CD8+ T cells, which differentiate into cytotoxic T cellsthat are specialized to kill any cell that they specifically recognize.Almost all cells express MHC class I molecules, although the level ofconstitutive expression varies from one cell type to the next. But notonly pathogenic peptides from viruses are presented by MHC class Imolecules, also self-antigens like tumor antigens are presented by them.MHC class I molecules bind peptides from proteins degraded in thecytosol and transported in the endoplasmic reticulum. The CD8+ T cellsthat recognize MHC class I:peptide complexes at the surface of infectedcells are specialized to kill any cells displaying foreign peptides andso rid the body of cells infected with viruses and other cytosolicpathogens. The main function of CD4+ T cells (CD4+ helper T cells) thatrecognize MHC class II molecules is to activate other effector cells ofthe immune system. Thus MHC class II molecules are normally found on Blymphocytes, dendritic cells, and macrophages, cells that participate inimmune responses, but not on other tissue cells. Macrophages, forexample, are activated to kill the intravesicular pathogens theyharbour, and B cells to secrete immunoglobulins against foreignmolecules. MHC class II molecules are prevented from binding to peptidesin the endoplasmic reticulum and thus MHC class II molecules bindpeptides from proteins which are degraded in endosomes. They can capturepeptides from pathogens that have entered the vesicular system ofmacrophages, or from antigens internalized by immature dendritic cellsor the immunoglobulin receptors of B cells. Pathogens that accumulate inlarge numbers inside macrophage and dendritic cell vesicles tend tostimulate the differentiation of Th1 cells, whereas extracellularantigens tend to stimulate the production of Th2 cells. Th1 cellsactivate the microbicidal properties of macrophages and induce B cellsto make IgG antibodies that are very effective of opsonisingextracellular pathogens for ingestion by phagocytic cells, whereas Th2cells initiate the humoral response by activating naïve B cells tosecrete IgM, and induce the production of weakly opsonising antibodiessuch as IgG1 and IgG3 (mouse) and IgG2 and IgG4 (human) as well as IgAand IgE (mouse and human).

Epitope (also called “antigen determinant”): An “epitope” is a portionof an antigen that is recognized by the immune system (e.g., by anantibody, an immunoglobulin receptor, a B cell receptor or a T cellreceptor). An epitope can be linear or conformational. Commonly, anepitope is a polypeptide or polysaccharide in a naturally occurringantigen. T cell epitopes may comprise fragments preferably having alength of about 6 to about 20 or even more amino acids, e.g. fragmentsas processed and presented by MHC class I molecules, preferably having alength of about 8 to about 10 amino acids, e.g. 8, 9, or 10, (or even11, or 12 amino acids), or fragments as processed and presented by MHCclass II molecules, preferably having a length of about 13 or more aminoacids, e.g. 13, 14, 15, 16, 17, 18, 19, 20 or even more amino acids,wherein these fragments may be selected from any part of the amino acidsequence. These fragments are typically recognized by T cells in form ofa complex consisting of the peptide fragment and an MHC molecule. B cellepitopes are typically fragments located on the outer surface of(native) protein or peptide antigens. Accordingly, a B-cell epitope ispreferably exposed on the surface of the antigen or pathogen, and can belinear or conformational. Normally, a B-cell epitope will include atleast about 5 amino acids but can be as small as 3-4 amino acids.

Vaccine: A vaccine is typically understood to be a prophylactic ortherapeutic material providing at least one epitope, one antigen or oneantigenic function. The epitope, antigen or antigenic function maystimulate the body's adaptive immune system to provide an adaptiveimmune response.

Antigen-providing mRNA: An antigen-providing mRNA or anepitope-providing mRNA may typically be an mRNA, having at least oneopen reading frame that can be translated by a cell or an organismprovided with that mRNA. The product of this translation is a peptide orprotein that may act as an antigen, preferably as an immunogen. Theproduct may also be a fusion protein composed of more than oneimmunogen, e.g. a fusion protein that consist of two or more epitopes,peptides or proteins, wherein the epitopes, peptides or proteins may belinked by linker sequences.

5′-CAP-Structure: A 5′-CAP is typically a modified nucleotide,particularly a guanine nucleotide, added to the 5′ end of an mRNAmolecule. Preferably, the 5′-CAP is added using a 5′-5′-triphosphatelinkage (also named m7GpppN). Further examples of 5′-CAP structuresinclude glyceryl, inverted deoxy abasic residue (moiety), 4′,5′methylene nucleotide, 1-(beta-D-erythrofuranosyl) nucleotide, 4′-thionucleotide, carbocyclic nucleotide, 1,5-anhydrohexitol nucleotide,L-nucleotides, alpha-nucleotide, modified base nucleotide,threo-pentofuranosyl nucleotide, acyclic 3′,4′-seco nucleotide, acyclic3,4-dihydroxybutyl nucleotide, acyclic 3,5 dihydroxypentyl nucleotide,3′-3′-inverted nucleotide moiety, 3′-3′-inverted abasic moiety,3′-2′-inverted nucleotide moiety, 3′-2′-inverted abasic moiety,1,4-butanediol phosphate, 3′-phosphoramidate, hexylphosphate, aminohexylphosphate, 3′-phosphate, 3′phosphorothioate, phosphorodithioate, orbridging or non-bridging methylphosphonate moiety. These modified 5′-CAPstructures may be used in the context of the present invention to modifythe mRNA sequence. Further modified 5′-CAP structures which may be usedin the context of the present invention are CAP1 (methylation of theribose of the adjacent nucleotide of m7GpppN), CAP2 (methylation of theribose of the 2^(nd) nucleotide downstream of the m7GpppN), CAP3(methylation of the ribose of the 3^(rd) nucleotide downstream of them7GpppN), CAP4 (methylation of the ribose of the 4^(th) nucleotidedownstream of the m7GpppN), ARCA (anti-reverse CAP analogue), modifiedARCA (e.g. phosphothioate modified ARCA), inosine, N1-methyl-guanosine,2′-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine,2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

Nucleic acid: The term nucleic acid means any DNA or RNA molecule and isused synonymous with polynucleotide. Wherever herein reference is madeto a nucleic acid or nucleic acid sequence encoding for a particularprotein and/or peptide, said nucleic acid or nucleic acid sequence,respectively, preferably also comprises regulatory sequences allowing ina suitable host, e.g. a human being, its expression, i.e. transcriptionand/or translation of the nucleic acid sequence encoding for theparticular protein or peptide.

Peptide: A peptide is a polymer of amino acid monomers. Usually themonomers are linked by peptide bonds. The term “peptide” does not limitthe length of the polymer chain of amino acids. In some embodiments ofthe present invention a peptide may for example contain less than 50monomer units. Longer peptides are also called polypeptides, typicallyhaving 50 to 600 monomeric units, more specifically 50 to 300 monomericunits.

Pharmaceutically effective amount: A pharmaceutically effective amountin the context of the invention is typically understood to be an amountthat is sufficient and/or efficient to induce an immune response.

Protein: A protein typically consists of one or more peptides and/orpolypeptides folded into 3-dimensional form, facilitating a biologicalfunction.

Poly(C) sequence: A poly(C) sequence is typically a long sequence ofcytosine nucleotides, typically about 10 to about 200 cytosinenucleotides, preferably about 10 to about 100 cytosine nucleotides, morepreferably about 10 to about 70 cytosine nucleotides or even more,preferably about 20 to about 50, or even about 20 to about 30 cytosinenucleotides. A poly(C) sequence may preferably be located 3′ of thecoding region comprised by a nucleic acid.

Poly(A) tail: A poly(A) tail also called “3′-poly(A) tail” is typicallya long sequence of adenosine nucleotides of up to about 400 adenosinenucleotides, e.g. from about 25 to about 400, preferably from about 50to about 400, more preferably from about 50 to about 300, even morepreferably from about 50 to about 250, most preferably from about 60 toabout 250 adenosine nucleotides, added to the 3′ end of a RNA.

Stabilized nucleic acid: A stabilized nucleic acid, typically, exhibitsa modification increasing resistance to in vivo degradation (e.g.degradation by an exo- or endo-nuclease) and/or ex vivo degradation(e.g. by the manufacturing process prior to vaccine administration, e.g.in the course of the preparation of the vaccine solution to beadministered). Stabilization of RNA can, e.g., be achieved by providinga 5′-CAP-Structure, a poly(A) tail, or any other UTR-modification. Itcan also be achieved by backbone-modification or modification of the G/Ccontent of the nucleic acid. Various other methods are known in the artand conceivable in the context of the invention.

Carrier/polymeric carrier: A carrier in the context of the invention maytypically be a compound that facilitates transport and/or complexationof another compound. Said carrier may form a complex with said othercompound. A polymeric carrier is a carrier that is formed of a polymer.

Cationic component: The term “cationic component” typically refers to acharged molecule, which is positively charged (cation) at a pH value oftypically about 1 to 9, preferably of a pH value of or below 9 (e.g. 5to 9), of or below 8 (e.g. 5 to 8), of or below 7 (e.g. 5 to 7), mostpreferably at physiological pH values, e.g. about 7.3 to 7.4.Accordingly, a cationic peptide, protein or polymer according to thepresent invention is positively charged under physiological conditions,particularly under physiological salt conditions of the cell in vivo. Acationic peptide or protein preferably contains a larger number ofcationic amino acids, e.g. a larger number of Arg, His, Lys or Orn thanother amino acid residues (in particular more cationic amino acids thananionic amino acid residues like Asp or Glu) or contains blockspredominantly formed by cationic amino acid residues. The definition“cationic” may also refer to “polycationic” components.

3′-untranslated region (3′-UTR): A 3′-UTR is typically the part of anmRNA which is located between the protein coding region (i.e. the openreading frame) and the poly(A) sequence of the mRNA. A 3′-UTR of themRNA is not translated into an amino acid sequence. The 3′-UTR sequenceis generally encoded by the gene which is transcribed into therespective mRNA during the gene expression process. The genomic sequenceis first transcribed into pre-mature mRNA, which comprises optionalintrons. The pre-mature mRNA is then further processed into mature mRNAin a maturation process. This maturation process comprises the steps of5′-capping, splicing the pre-mature mRNA to excise optional introns andmodifications of the 3′-end, such as polyadenylation of the 3′-end ofthe pre-mature mRNA and optional endo- or exonuclease cleavages etc. Inthe context of the present invention, a 3′-UTR corresponds to thesequence of a mature mRNA which is located 3′ to the stop codon of theprotein coding region, preferably immediately 3′ to the stop codon ofthe protein coding region, and which extends to the 5′-side of thepoly(A) sequence, preferably to the nucleotide immediately 5′ to thepoly(A) sequence. The term “corresponds to” means that the 3′-UTRsequence may be an RNA sequence, such as in the mRNA sequence used fordefining the 3′-UTR sequence, or a DNA sequence which corresponds tosuch RNA sequence. In the context of the present invention, the term “a3′-UTR of a gene”, such as “a 3′-UTR of an albumin gene”, is thesequence which corresponds to the 3′-UTR of the mature mRNA derived fromthis gene, i.e. the mRNA obtained by transcription of the gene andmaturation of the pre-mature mRNA. The term “3′-UTR of a gene”encompasses the DNA sequence and the RNA sequence of the 3′-UTR.

5′-untranslated region (5′-UTR): A 5′-UTR is typically understood to bea particular section of messenger RNA (mRNA). It is located 5′ of theopen reading frame of the mRNA. Typically, the 5′-UTR starts with thetranscriptional start site and ends one nucleotide before the startcodon of the open reading frame. The 5′-UTR may comprise elements forcontrolling gene expression, also called regulatory elements. Suchregulatory elements may be, for example, ribosomal binding sites or a5′-Terminal Oligopyrimidine Tract. The 5′-UTR may beposttranscriptionally modified, for example by addition of a 5′-CAP. Inthe context of the present invention, a 5′UTR corresponds to thesequence of a mature mRNA which is located between the 5′-CAP and thestart codon. Preferably, the 5′-UTR corresponds to the sequence whichextends from a nucleotide located 3′ to the 5′-CAP, preferably from thenucleotide located immediately 3′ to the 5′-CAP, to a nucleotide located5′ to the start codon of the protein coding region, preferably to thenucleotide located immediately 5′ to the start codon of the proteincoding region. The nucleotide located immediately 3′ to the 5′-CAP of amature mRNA typically corresponds to the transcriptional start site. Theterm “corresponds to” means that the 5′-UTR sequence may be an RNAsequence, such as in the mRNA sequence used for defining the 5′-UTRsequence, or a DNA sequence which corresponds to such RNA sequence. Inthe context of the present invention, the term “a 5′-UTR of a gene”,such as “a 5′-UTR of a TOP gene”, is the sequence which corresponds tothe 5′-UTR of the mature mRNA derived from this gene, i.e. the mRNAobtained by transcription of the gene and maturation of the pre-maturemRNA. The term “5′-UTR of a gene” encompasses the DNA sequence and theRNA sequence of the 5′-UTR.

5′ Terminal Oligopyrimidine Tract (TOP): The 5′ terminal oligopyrimidinetract (TOP) is typically a stretch of pyrimidine nucleotides located atthe 5′ terminal region of a nucleic acid molecule, such as the 5′terminal region of certain mRNA molecules or the 5′ terminal region of afunctional entity, e.g. the transcribed region, of certain genes. Thesequence starts with a cytidine, which usually corresponds to thetranscriptional start site, and is followed by a stretch of usuallyabout 3 to 30 pyrimidine nucleotides. For example, the TOP may comprise3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30 or even more nucleotides. The pyrimidinestretch and thus the 5′ TOP ends one nucleotide 5′ to the first purinenucleotide located downstream of the TOP. mRNA that contains a 5′terminal oligopyrimidine tract is often referred to as TOP mRNA.Accordingly, genes that provide such messenger RNAs are referred to asTOP genes. TOP sequences have, for example, been found in genes andmRNAs encoding peptide elongation factors and ribosomal proteins.

TOP motif: In the context of the present invention, a TOP motif is anucleic acid sequence which corresponds to a 5′ TOP as defined above.Thus, a TOP motif in the context of the present invention is preferablya stretch of pyrimidine nucleotides having a length of 3-30 nucleotides.Preferably, the TOP-motif consists of at least 3 pyrimidine nucleotides,preferably at least 4 pyrimidine nucleotides, preferably at least 5pyrimidine nucleotides, more preferably at least 6 nucleotides, morepreferably at least 7 nucleotides, most preferably at least 8 pyrimidinenucleotides, wherein the stretch of pyrimidine nucleotides preferablystarts at its 5′ end with a cytosine nucleotide. In TOP genes and TOPmRNAs, the TOP-motif preferably starts at its 5′ end with thetranscriptional start site and ends one nucleotide 5′ to the firstpurine residue in said gene or mRNA. A TOP motif in the sense of thepresent invention is preferably located at the 5′end of a sequence whichrepresents a 5′-UTR or at the 5′ end of a sequence which codes for a5′-UTR. Thus, preferably, a stretch of 3 or more pyrimidine nucleotidesis called “TOP motif” in the sense of the present invention if thisstretch is located at the 5′ end of a respective sequence, such as themRNA, the 5′-UTR element of the mRNA, or the nucleic acid sequence whichis derived from the 5′-UTR of a TOP gene as described herein. In otherwords, a stretch of 3 or more pyrimidine nucleotides which is notlocated at the 5′-end of a 5′-UTR or a 5′-UTR element but anywherewithin a 5′-UTR or a 5′-UTR element is preferably not referred to as“TOP motif”.

TOP gene: TOP genes are typically characterised by the presence of a 5′terminal oligopyrimidine tract. Furthermore, most TOP genes arecharacterized by a growth-associated translational regulation. However,also TOP genes with a tissue specific translational regulation areknown. As defined above, the 5′-UTR of a TOP gene corresponds to thesequence of a 5′-UTR of a mature mRNA derived from a TOP gene, whichpreferably extends from the nucleotide located 3′ to the 5′-CAP to thenucleotide located 5′ to the start codon. A 5′-UTR of a TOP genetypically does not comprise any start codons, preferably no upstreamAUGs (uAUGs) or upstream open reading frames (uORFs). Therein, upstreamAUGs and upstream open reading frames are typically understood to beAUGs and open reading frames that occur 5′ of the start codon (AUG) ofthe open reading frame that should be translated. The 5′-UTRs of TOPgenes are generally rather short. The lengths of 5′-UTRs of TOP genesmay vary between 20 nucleotides up to 500 nucleotides, and are typicallyless than about 200 nucleotides, preferably less than about 150nucleotides, more preferably less than about 100 nucleotides. Exemplary5′-UTRs of TOP genes in the sense of the present invention are thenucleic acid sequences extending from the nucleotide at position 5 tothe nucleotide located immediately 5′ to the start codon (e.g. the ATG)in the sequences according to SEQ ID NOs: 1-1363, SEQ ID NO: 1395, SEQID NO: 1421 and SEQ ID NO: 1422 of the international patent applicationWO2013/143700 or homologs or variants thereof, whose disclosure isincorporated herewith by reference. In this context a particularlypreferred fragment of a 5′UTR of a TOP gene is a 5′-UTR of a TOP genelacking the 5′ TOP motif. The term “5′UTR of a TOP gene” preferablyrefers to the 5′-UTR of a naturally occurring TOP gene.

Fragment of a nucleic acid sequence, particularly an mRNA: A fragment ofa nucleic acid sequence consists of a continuous stretch of nucleotidescorresponding to a continuous stretch of nucleotides in the full-lengthnucleic acid sequence which is the basis for the nucleic acid sequenceof the fragment, which represents at least 20%, preferably at least 30%,more preferably at least 40%, more preferably at least 50%, even morepreferably at least 60%, even more preferably at least 70%, even morepreferably at least 80%, and most preferably at least 90% of thefull-length nucleic acid sequence. Such a fragment, in the sense of thepresent invention, is preferably a functional fragment of thefull-length nucleic acid sequence.

Identity of a sequence: In order to determine the percentage to whichtwo sequences are identical, e.g. nucleic acid sequences or amino acidsequences as defined herein, preferably the amino acid sequences encodedby a nucleic acid sequence as defined herein or the amino acid sequencesthemselves, the sequences can be aligned in order to be subsequentlycompared to one another. Therefore, e.g. a position of a first sequencemay be compared with the corresponding position of the second sequence.If a position in the first sequence is occupied by the same component(residue) as is the case at a position in the second sequence, the twosequences are identical at this position. If this is not the case, thesequences differ at this position. If insertions occur in the secondsequence in comparison to the first sequence, gaps can be inserted intothe first sequence to allow a further alignment. If deletions occur inthe second sequence in comparison to the first sequence, gaps can beinserted into the second sequence to allow a further alignment. Thepercentage to which two sequences are identical is then a function ofthe number of identical positions divided by the total number ofpositions including those positions which are only occupied in onesequence. The percentage to which two sequences are identical can bedetermined using a mathematical algorithm. A preferred, but notlimiting, example of a mathematical algorithm which can be used is thealgorithm of Karlin et al. (1993), PNAS USA, 90:5873-5877 or Altschul etal. (1997), Nucleic Acids Res., 25:3389-3402. Such an algorithm isintegrated in the BLAST program. Sequences which are identical to thesequences of the present invention to a certain extent can be identifiedby this program.

Variant of a nucleic acid sequence, particularly an mRNA: A variant of anucleic acid sequence refers to a variant of nucleic acid sequenceswhich forms the basis of a nucleic acid sequence. For example, a variantnucleic acid sequence may exhibit one or more nucleotide deletions,insertions, additions and/or substitutions compared to the nucleic acidsequence from which the variant is derived. Preferably, a variant of anucleic acid sequence is at least 40%, preferably at least 50%, morepreferably at least 60%, more preferably at least 70%, even morepreferably at least 80%, even more preferably at least 90%, mostpreferably at least 95% identical to the nucleic acid sequence thevariant is derived from. Preferably, the variant is a functionalvariant. A “variant” of a nucleic acid sequence may have at least 70%,75%, 80%, 85%, 90%, 95%, 98% or 99% nucleotide identity over a stretchof 10, 20, 30, 50, 75 or 100 nucleotide of such nucleic acid sequence.

The mRNA sequence according to the invention comprises at least onecoding region, encoding at least one epitope of a protein, or of afragment, variant or derivative thereof, of a virus of the genusrotavirus. This mRNA sequence may form the basis for an mRNA basedvaccine which is a subunit vaccine. Such a subunit vaccine isparticularly advantageous in treatment and especially prophylaxis ofrotavirus infections. The design as subunit vaccine is especiallyadvantageous since a subunit vaccine is significantly less risky interms of side effects associated with live vaccines in general. Thevaccine based on the inventive mRNA allows parenteral delivery that isnot affected by possible efficacy reductions which may occur via theoral route. Generally, protein-based vaccines, as they are known in theprior art, are suboptimal in developing countries due to their highproduction costs. In contrast, the mRNA-based vaccines according to thepresent invention allow very cost-effective production. Therefore, incomparison with known vaccines the vaccine based on the inventive mRNAcan be produced significantly cheaper, which is very advantageousparticularly for use in developing countries. One further advantage of avaccine based on the inventive mRNA may be its temperature-stable naturein comparison with the life oral rotavirus vaccines available or withother protein or peptide-based vaccine compositions.

Because of these advantages the vaccine based on the present inventionmay be used especially for widely used prophylaxis or treatment ofrotavirus infections particularly in developing countries, whererotavirus infections are a severe problem.

According to the invention the mRNA sequence comprises at least onecoding region encoding at least one epitope of a protein or of afragment, variant or derivative thereof of a virus of the genusrotavirus. In this context the rotavirus species may be selected formthe species A, B, C, D, E, F, G or H, wherein it is particularlypreferred that the rotavirus is selected from species A or B or C.Species A, B and C are known to infect humans and various animals. In anespecially preferred embodiment the selected rotavirus species isrotavirus A (RVA) which is particularly important for human infections.

The rotavirus may be selected from any one of the following G-serotypesand P-serotypes: G1, G2, G3, G4, G5, G6, G7, G8, G9, G10, G11, G12, G13,G14, G15, G16, G17, G18, G19, G20, G21, G22, G23, G24, G25, G26, G27,P[1], P[2], P[3], P[4], P[5], P[6], P[7], P[8], P[9], P[10], P[11],P[12], P[13], P[14], P[15], P[16], P[17], P[18], P[19], P[20], P[21],P[22], P[23], P[24], P[25], P[26], P[27], P[28], P[29], P[30], P[31],P[32], P[33], P[34], or P[35]. In this context the serotypes G1, G2, G3,G4, G9, G12, P[4], P[6] or P[8] are particularly preferred.

Preferably, the inventive mRNA sequence encodes at least one epitope ofa protein, or of a fragment, variant or derivative thereof of a virus ofthe genus rotavirus, which is at least 60% identical, more preferably atleast 70% identical, more preferably at least 80% identical, morepreferably at least 90% identical, more preferably at least 95%identical, or most preferably at least 99% identical with the wild typeprotein or fragment thereof, respectively the wild type epitope. Thepercentage of identities may refer to the identity of amino acidsequences of the protein or to the identity of nucleotide sequences ofthe mRNA.

The term wild type is to be understood according to the skilled person'sgeneral understanding in the art and denotes the protein, the fragmentthereof or the epitope in the form of its occurrence in nature withoutany mutation or amino acid amendment by man. In the context of theinvention the term wild type protein corresponds to the protein of therespective isolated rotavirus.

In other embodiments the amino acid sequence of the encoded protein, thefragment thereof or the epitope may be mutated. For example it may beparticularly preferred that glycosylation sites in the encoded aminoacid sequence are mutated which means that encoded amino acids which maybe glycosylated after translation in vivo are exchanged to a differentamino acid. Preferably, codons encoding asparagine which are predictedto be glycosylated (N glycosylation sites) are mutated to encodeglutamine.

Preferably, the protein of a virus of the genus rotavirus is selectedfrom a structural protein of rotavirus, especially from VP1 (preferablyaccording to SEQ ID NO: 1) or VP2 (preferably according to SEQ ID NO: 2)or VP3 (preferably according to SEQ ID NO: 3) or VP4 (preferablyaccording to SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQID NO: 13 or SEQ ID NO: 14; SEQ ID Nos: 42-44; 46; 48; 5076) or VP6(preferably according to SEQ ID NO: 15) or VP7 (preferably according toSEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ IDNO: 25 or SEQ ID NO: 26). Moreover, it is possible, that the protein isselected from a non-structural protein of rotavirus, especially fromNSP1 (preferably according to SEQ ID NO: 27) or NSP2 (preferablyaccording to SEQ ID NO: 28) or NSP3 (preferably according to SEQ ID NO:29) or NSP4 (preferably according to SEQ ID NO: 30, SEQ ID NO: 31, SEQID NO: 32, SEQ ID NO: 33, SEQ ID NO:34, SEQ ID NO: 35, SEQ ID NO: 36 orSEQ ID NO: 37) or NSP5 (preferably according to SEQ ID NO: 38) or NSP6(preferably according to SEQ ID NO: 39).

It is especially preferred that the protein is selected from VP4 or VP7or a cleavage product of VP4. These proteins are particularly preferredbecause they are the components of the outermost protein layer of therotavirus which may be especially relevant for an immune response. In anespecially preferred embodiment the protein derives from a cleavageproduct of VP4, preferably VP5* (preferably according to SEQ ID NO: 40)or VP8* (preferably according to SEQ ID NO: 41, SEQ ID NO: 45, SEQ IDNO: 47 or SEQ ID NO: 49, wherein VP8* is particularly preferred.Although VP5* and VP8* are cleavage products of the protein VP4 they arenevertheless referred to as proteins. Moreover, the proteins VP2, VP6,NSP2 and/or NSP4 may be especially preferred in other embodiments.

The amino acid sequences as shown in the sequence listing derive fromdifferent rotavirus A strains, in particular from Human rotavirus AEcu534, Human rotavirus A RVA/Human_wt/VNM/30378/2009/G26P[19], Humanrotavirus A RVA/Human-tc/IDN/57M/1980/G4P[10], Human rotavirus ARVA/Human-wt/BEL/BE1058/2008/G2P[4], Human rotavirus ARVA/Human-wt/BEL/BE1128/2009/G1P[8], Human rotavirus ARVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8], Human rotavirus Astrain CMH222, Human rotavirus A Wa variant VirWa, Human rotavirusHMG035, Lamb rotavirus Lp14, Murine rotavirus EB, Murine rotavirus EHP,Porcine rotavirus A 61/07/Ire, Porcine rotavirus A strain 134/04-15,Porcine rotavirus A34, Porcine rotavirus A46, Rabbit rotavirus 160/01,Rotavirus A 344-04-1, Rotavirus A Ch-02V0002G3, Rotavirus A Ch-06V0661,Rotavirus A FGP51, Rotavirus A Hu/BEL/F01322/2009/G3P[6], Rotavirus Ahuman-wt/ITA/ME848/12/2012/G12P9, Rotavirus ARVA/Cow-wt/ARG/791_BA/1999/G10P[5], Rotavirus ARVA/Cow-wt/ARG/B1191_B_BA/2000/G10P[11], Rotavirus ARVA/Human-TC/USA/Rotarix/2009/G1P[8], Rotavirus ARVA/Human-wt/BEL/B4106/2000/G3P[14], Rotavirus ARVA/Human-wt/Bel/BE00112/2009/G1P[8], Rotavirus ARVA/Human-wt/BGD/Dhaka6/2001/G11P[25], Rotavirus ARVA/Vaccine/USA/RotaTeq-BrB-9/1996/G4P7[5], Rotavirus ARVA/Vaccine/USA/RotaTeq-SC2-9/1992/G2P7[5], Rotavirus ARVA/Vaccine/USA/RotaTeq-W178-8/1992/G3P7[5], Rotavirus ARVA/Vaccine/USA/RotaTeq-W179-4/1992/G6P1A[8], Rotavirus ARVA/Vaccine/USA/RotaTeq-W179-9/1992/G1P7[5], Rotavirus A Tu-03V0001E10,Rotavirus A turkey-tc/GER/03V0002E10/2003/G22P[35], Rotavirus strainTUCH, Bovine rotavirus A AzuK-1, Bovine rotavirus A Dai-10, Bovinerotavirus H1, Bovine Rotavirus Strain Hg18, Bovine rotavirus WC3, Equinerotavirus H2, Equine rotavirus L338.

Nevertheless, the proteins may also derive from all other strains withthe following Taxonomy ID or taxID: 1699092, 1637496, 1604860, 1560372,1537146, 1496075, 1481391, 1461314, 1461313, 1461312, 1461311, 1461310,1461309, 1461308, 1461307, 1461306, 1461305, 1461304, 1461303, 1461302,1461301, 1461300, 1461299, 1461298, 1461297, 1461296, 1461295, 1461294,1461293, 1461292, 1461291, 1461290, 1461289, 1461288, 1461287, 1461286,1461285, 1460005, 1459051, 1459048, 1459047, 1459046, 1459045, 1454907,1454906, 1454905, 1454904, 1454903, 1454902, 1454901, 1454900, 1454899,1454898, 1454897, 1454896, 1454895, 1454894, 1454893, 1454892, 1454891,1454890, 1454889, 1454888, 1454887, 1454886, 1454885, 1454884, 1454883,1452758, 1452757, 1424309, 1420855, 1417760, 1399970, 1386847, 1349389,1348384, 1340801, 1337059, 1327767, 1307516, 1307515, 1307514, 1307513,1307512, 1307511, 1307510, 1307509, 1307508, 1307507, 1307506, 1307505,1307170, 1307169, 1307168, 1307167, 1307166, 1307165, 1307164, 1307163,1307162, 1307161, 1304751, 1302703, 1302702, 1302701, 1302700, 1302699,1302698, 1271535, 1271534, 1265591, 1260938, 1231331, 1211022, 1211021,1211020, 1211019, 1211018, 1211017, 1211016, 1204231, 1204230, 1193399,1193398, 1193397, 1193396, 1193395, 1193394, 1193393, 1193392, 1193391,1193390, 1193389, 1193388, 1193387, 1193386, 1187998, 1187994, 1184798,1184797, 1184796, 1184795, 1184792, 1184791, 1184790, 1184789, 1184788,1184787, 1184786, 1184785, 1184784, 1184783, 1184782, 1184781, 1184780,1184779, 1184778, 1184777, 1184776, 1184775, 1184774, 1184773, 1184772,1184771, 1184770, 1184769, 1184768, 1182925, 1182528, 1182527, 1182526,1182525, 1182524, 1182523, 1182522, 1179682, 1179680, 1179678, 1169021,1169020, 1169019, 1169018, 1169017, 1169016, 1169015, 1169014, 1169013,1169012, 1169011, 1169010, 1169009, 1169008, 1168279, 1168278, 1168277,1168276, 1168275, 1168274, 1168273, 1168272, 1168271, 1168270, 1168269,1168268, 1168267, 1168266, 1168265, 1168264, 1168263, 1168262, 1168261,1168260, 1168259, 1168258, 1168257, 1168256, 1168255, 1168254, 1168253,1168252, 1168251, 1168250, 1168249, 1168248, 1168247, 1168246, 1168245,1159003, 1159002, 1159001, 1159000, 1148771, 1146936, 1146935, 1146934,1133028, 1133027, 1133026, 1133025, 1133024, 1133023, 1129884, 1129883,1129882, 1129881, 1129880, 1129879, 1129878, 1129877, 1129876, 1129875,1129874, 1127364, 1127363, 1127362, 1127361, 1127360, 1127359, 1127358,1094389, 1094388, 1094387, 1094386, 1092563, 1092562, 1092561, 1077213,1077212, 1077211, 1077210, 1077209, 1077208, 1074901, 1074900, 1074899,1074898, 1073965, 1068803, 1056490, 1056489, 1055980, 1052890, 1052889,1052888, 1049161, 1046565, 1004946, 1004945, 1004944, 1004943, 1004942,1004941, 1004888, 1004887, 1004886, 1004885, 1004884, 1004883, 1004882,1004881, 1004880, 1004879, 1004878, 1004877, 1004876, 1004875, 1004874,1004873, 1004872, 1004871, 1004870, 1004869, 1004868, 1004867, 1004866,1004865, 1004864, 1004863, 1004862, 1004861, 1004860, 1004859, 1004858,1004857, 1004856, 1004855, 1004854, 1004853, 1004852, 1004851, 1004850,1004849, 1004848, 1004847, 1004846, 1004845, 1004844, 1004843, 1004842,1004841, 1004840, 1004839, 1004838, 1004837, 1004835, 1004834, 1004833,1004832, 1004831, 1004830, 1004829, 1004828, 1004827, 1004826, 1004825,1004824, 1004823, 1004822, 1004821, 1004820, 1004819, 1004818, 1004817,1004816, 1004815, 1004814, 1004813, 1004812, 1004811, 1004810, 1004809,1004808, 1004807, 1004806, 1004805, 1004804, 1004803, 1004802, 1004801,1004800, 1004799, 1004798, 1004797, 1004796, 1004795, 1004794, 1004793,999467, 999466, 994995, 994994, 993362, 984291, 984290, 984289, 984288,984287, 984286, 984285, 984284, 984283, 981020, 981019, 981018, 981017,980178, 980177, 980176, 980175, 980174, 980173, 980172, 980094, 980093,980092, 980091, 980090, 948991, 948990, 948989, 931249, 915344, 910402,909654, 909653, 909652, 909651, 909650, 909649, 909648, 909647, 909646,909645, 909644, 909643, 909642, 909641, 909640, 909639, 909638, 909637,909636, 909635, 909634, 909633, 909632, 909631, 909630, 909629, 905892,905891, 905890, 905889, 905888, 905887, 905886, 905885, 905884, 905883,905882, 905881, 905880, 905879, 905878, 905877, 905876, 905875, 905874,905873, 905872, 905871, 905870, 905869, 905868, 905867, 905866, 905865,905864, 905863, 905862, 905861, 905860, 905859, 905858, 905857, 905856,905855, 905854, 905853, 905852, 905851, 905850, 889507, 889506, 889505,889098, 889097, 889096, 889095, 889091, 889090, 889089, 889087, 889086,889085, 884200, 882810, 882809, 882808, 882807, 882806, 882805, 882804,882803, 879654, 879553, 879552, 879551, 879550, 879549, 864624, 864623,862183, 862182, 862181, 862180, 862179, 862178, 862177, 862176, 862175,862174, 862173, 862172, 862171, 862170, 862169, 862168, 862167, 861475,861474, 861473, 861472, 861471, 861470, 861469, 861468, 861467, 861466,861465, 861464, 861463, 861462, 861461, 861460, 861458, 758915, 758914,758913, 758912, 758911, 758910, 758909, 758908, 758907, 758906, 758905,758904, 758903, 758902, 758901, 758900, 758899, 758898, 758897, 758896,758895, 758894, 758893, 758892, 758891, 758890, 758889, 757426, 757025,757024, 757023, 757022, 757021, 757020, 757019, 757018, 757017, 757016,757015, 757014, 757013, 757012, 757011, 757010, 757009, 757008, 757007,757006, 757005, 757004, 757003, 757002, 757001, 757000, 756999, 756998,756997, 756996, 756995, 756994, 756993, 756992, 756991, 756990, 756071,756070, 756069, 756068, 749226, 748551, 748550, 748549, 746014, 743963,743962, 743959, 743958, 743957, 743956, 743954, 743493, 713948, 713947,713946, 713945, 713944, 713943, 713942, 713941, 713940, 713939, 713938,713937, 713936, 713935, 713934, 713933, 713932, 705080, 703409, 697626,697625, 697624, 697623, 697622, 697621, 697620, 697619, 697618, 697298,693632, 686194, 686193, 686192, 686191, 686190, 686189, 686188, 686187,686186, 686185, 686184, 686183, 686182, 686181, 686180, 686179, 686178,686177, 686176, 686175, 686174, 686173, 686172, 686171, 686170, 686169,686168, 686167, 686166, 686165, 686164, 686163, 686162, 686161, 686160,686159, 686158, 686157, 686156, 686155, 686154, 686153, 686152, 686151,686150, 686149, 686148, 686147, 686146, 686145, 686144, 686143, 686142,686141, 686140, 686139, 686138, 686137, 686136, 684598, 684597, 684596,684595, 684594, 679019, 672377, 670792, 670791, 670788, 670787, 670786,670785, 666970, 666969, 666968, 666967, 666966, 666965, 664658, 664646,664644, 663259, 663258, 663257, 663256, 663255, 663254, 663253, 663252,663251, 663250, 663249, 663248, 663247, 663246, 663245, 663244, 662783,661085, 661084, 661083, 661082, 661081, 661080, 661079, 661078, 661077,661076, 661075, 661074, 661073, 661072, 661071, 661070, 661069, 661068,661067, 661066, 661065, 661064, 661063, 661062, 661061, 661060, 661059,661058, 661057, 661056, 661055, 661054, 661053, 661052, 652664, 652649,650120, 644773, 641364, 641363, 641362, 641361, 641360, 641359, 641358,641357, 641356, 641355, 641354, 641353, 641352, 641351, 641350, 641349,641348, 641347, 641346, 641345, 641344, 641343, 641342, 641341, 641340,641339, 641338, 641337, 641336, 641335, 641334, 641333, 641332, 641331,641330, 641329, 641328, 641327, 641326, 641325, 641324, 641323, 641322,641321, 641320, 641319, 641318, 641317, 641316, 641315, 641314, 641313,641312, 639281, 639280, 639279, 639278, 639277, 639276, 639275, 639274,639273, 639272, 639271, 639270, 639269, 639268, 639267, 639266, 639265,639264, 639263, 639262, 639261, 639260, 639259, 639258, 639257, 639256,639255, 639254, 639253, 639252, 639251, 639250, 639249, 639248, 639247,639246, 639245, 639244, 639243, 639242, 638299, 638288, 638287, 638286,638285, 638284, 638281, 638280, 638279, 638276, 638275, 626776, 626346,626345, 626344, 587025, 584720, 584719, 578843, 578842, 578841, 578840,578839, 578838, 578837, 578834, 578832, 578831, 578830, 578829, 578828,578827, 574986, 574985, 574984, 573023, 573022, 573021, 573020, 573019,573018, 573017, 573016, 573015, 573014, 573013, 572153, 571650, 571648,566029, 566028, 561309, 560626, 560613, 557247, 557245, 557243, 557242,557241, 557232, 556181, 552809, 545676, 531928, 531927, 529839, 529838,529837, 529836, 529835, 529834, 529833, 529832, 529831, 529830, 529829,529828, 529827, 526810, 526809, 526808, 526807, 526806, 526805, 526804,526803, 526802, 526801, 526800, 526799, 526798, 526797, 526796, 526795,526794, 526793, 526792, 526791, 523819, 523177, 517318, 517317, 517316,517315, 517314, 517313, 517312, 517311, 517310, 517309, 517308, 517307,517306, 517305, 517116, 517115, 517114, 517113, 517112, 517111, 517110,516714, 500141, 500140, 500139, 500138, 500137, 500136, 500135, 500134,500133, 500132, 500131, 500130, 500129, 500128, 500127, 500126, 500125,500124, 500123, 500122, 500121, 500120, 500119, 500118, 500117, 500116,500115, 500114, 500113, 498924, 492519, 492511, 492509, 492508, 492507,492506, 490299, 490298, 490297, 490296, 490295, 490294, 490293, 490292,490291, 487340, 487339, 487338, 487337, 487336, 487335, 487334, 487333,487332, 487331, 487330, 487329, 487328, 487327, 487326, 487325, 487324,487323, 487322, 487321, 486187, 486186, 481539, 481538, 478084, 471094,468920, 468919, 468918, 468917, 460769, 458288, 458287, 458286, 458285,458284, 458283, 458282, 458281, 458280, 458279, 458278, 458277, 458276,458275, 458274, 458273, 458272, 458271, 458270, 458269, 458267, 450149,449582, 449126, 444186, 444185, 444184, 429343, 420252, 419438, 418976,416558, 416557, 408599, 408598, 407261, 407260, 407259, 407258, 407257,407256, 401627, 401074, 397542, 391897, 380901, 380390, 380389, 375192,374507, 370535, 370534, 370533, 370532, 370531, 370529, 359942, 356494,348136, 335103, 335102, 335100, 334591, 308425, 308418, 295016, 293396,292226, 290547, 290544, 290543, 290542, 290541, 290255, 290254, 285424,285423, 285422, 285421, 285420, 285419, 285418, 285262, 285002, 273497,263599, 263598, 263596, 263595, 240592, 238845, 237917, 215680, 204932,204519, 200686, 200685, 200684, 199305, 199304, 199303, 195702, 195701,195700, 195481, 195480, 195478, 195477, 195476, 195475, 183407, 183405,183403, 180231, 173527, 171615, 161240, 161239, 148357, 141270, 141265,139395, 121794, 111609, 107263, 106517, 106330, 105506, 105505, 105503,105502, 104626, 104625, 104624, 101363, 101362, 101361, 101360, 101359,101358, 101357, 101355, 101353, 101352, 101351, 101350, 96046, 94432,80340, 79955, 79954, 79953, 79952, 79951, 79732, 79694, 79065, 79064,76592, 76591, 76590, 75918, 73036, 73034, 72140, 72139, 72138, 72137,72136, 72135, 72134, 72133, 72132, 71031, 70865, 69831, 61856, 57726,57202, 53982, 53981, 53980, 53979, 53978, 53977, 53976, 53975, 53974,53965, 53964, 53963, 49892, 48539, 45408, 44572, 42567, 39013, 39012,39011, 39010, 39009, 37324, 37137, 37136, 36443, 36442, 36441, 36440,36439, 36437, 36436, 36435, 36434, 36433, 36432, 36427, 35337, 35336,35334, 35333, 33723, 33722, 31590, 31589, 31588, 31587, 31586, 31583,31581, 31580, 31579, 31578, 31577, 31574, 31571, 31570, 31569, 31568,31567, 31566, 31565, 31564, 31563, 28877, 28876, 28875, 28327, 28326,12705, 12584, 12578, 10978, 10971, 10970, 10969, 10968, 10967, 10963,10962, 10961, 10960, 10959, 10958, 10957, 10956, 10955, 10954, 10953,10952, 10951, 10950, 10949, 10948, 10947, 10946, 10944, 10943, 10942,10941, 10939, 10937, 10935, 10934, 10933, 10931, 10930, 10929, 10928,10927, 10926, 10925, 10923, 10922, 10921, 10919, 10918, 10917, 10916,10915, 10913, 10912. 10912.

A Taxonimy ID or taxID is a stable unique identifier for each taxon (fora species, a family, an order, or any other group in the taxonomydatabase). The taxID is seen in the GenBank records as a “source”feature table entry; for example, /db_xref=“taxon:<9606>” is the taxIDfor Homo sapiens, and the line is therefore found in all recent humansequence records).

In the context of the invention additionally to the here disclosed aminoacid sequences according to SEQ ID NO: 1-827 also amino acid sequencesof different rotavirus strains or rotavirus isolates can be usedaccording to the invention and are incorporated herewith. Thesedifferent rotavirus isolates show preferably an identity of at least70%, more preferably of at least 80% and most preferably of at least 90%with the amino acid sequences according to SEQ ID NO: 1-827.

The invention relates to mRNA sequences encoding at least one epitope ofa protein as mentioned above, but also of a fragment, variant ofderivative thereof. The terms “fragment”, “variant” and “derivative”should be understood as follows:

Fragments of proteins: “Fragments” of proteins (or peptides) in thecontext of the present invention may, typically, comprise a sequence ofa protein or peptide as defined herein, which is, with regard to itsamino acid sequence (or its encoded nucleic acid molecule), N-terminallyand/or C-terminally truncated compared to the amino acid sequence of theoriginal (native) protein (or its encoded nucleic acid molecule). Suchtruncation may thus occur either on the amino acid level orcorrespondingly on the nucleic acid level. A sequence identity withrespect to such a fragment as defined herein may therefore preferablyrefer to the entire protein or peptide as defined herein or to theentire (coding) nucleic acid molecule of such a protein or peptide. Forexample such fragment may have a length of about 6 to about 20 or evenmore amino acids, e.g. fragments as processed and presented by MHC classI molecules, preferably having a length of about 8 to about 10 aminoacids, e.g. 8, 9, or 10, (or even 6, 7, 11, or 12 amino acids), orfragments as processed and presented by MHC class II molecules,preferably having a length of about 13 or more amino acids, e.g. 13, 14,15, 16, 17, 18, 19, 20 or even more amino acids, wherein these fragmentsmay be selected from any part of the amino acid sequence. Thesefragments are typically recognized by T-cells in form of a complexconsisting of the peptide fragment and an MHC molecule, i.e. thefragments are typically not recognized in their native form. Fragmentsof proteins or peptides may comprise at least one epitope of thoseproteins or peptides. Furthermore also domains of a protein, like theextracellular domain, the intracellular domain or the transmembranedomain and shortened or truncated versions of a protein may beunderstood to comprise a fragment of a protein.

Variants of proteins: “Variants” of proteins (or peptides) as defined inthe context of the present invention may be generated, having an aminoacid sequence which differs from the original sequence in one or moremutation(s), such as one or more substituted, inserted and/or deletedamino acid(s). Preferably, these fragments and/or variants have the samebiological function or specific activity compared to the full-lengthnative protein, e.g. its specific antigenic property. “Variants” ofproteins or peptides as defined in the context of the present inventionmay comprise conservative amino acid substitution(s) compared to theirnative, i.e. non-mutated physiological, sequence. Those amino acidsequences as well as their encoding nucleotide sequences in particularfall under the term variants as defined herein. Substitutions in whichamino acids, which originate from the same class, are exchanged for oneanother are called conservative substitutions. In particular, these areamino acids having aliphatic side chains, positively or negativelycharged side chains, aromatic groups in the side chains or amino acids,the side chains of which can enter into hydrogen bridges, e.g. sidechains which have a hydroxyl function. This means that e.g. an aminoacid having a polar side chain is replaced by another amino acid havinga likewise polar side chain, or, for example, an amino acidcharacterized by a hydrophobic side chain is substituted by anotheramino acid having a likewise hydrophobic side chain (e.g. serine(threonine) by threonine (serine) or leucine (isoleucine) by isoleucine(leucine)). Insertions and substitutions are possible, in particular, atthose sequence positions which cause no modification to thethree-dimensional structure or do not affect the binding region.Modifications to a three-dimensional structure by insertion(s) ordeletion(s) can easily be determined e.g. using CD spectra (circulardichroism spectra) (Urry, 1985, Absorption, Circular Dichroism and ORDof Polypeptides, in: Modern Physical Methods in Biochemistry, Neubergeret al. (ed.), Elsevier, Amsterdam). A “variant” of a protein or peptidemay have at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% amino acididentity over a stretch of 10, 20, 30, 50, 75 or 100 amino acids of suchprotein or peptide. Furthermore, variants of proteins or peptides asdefined herein, which may be encoded by a nucleic acid molecule, mayalso comprise those sequences, wherein nucleotides of the encodingnucleic acid sequence are exchanged according to the degeneration of thegenetic code, without leading to an alteration of the respective aminoacid sequence of the protein or peptide, i.e. the amino acid sequence orat least part thereof may not differ from the original sequence withinthe above meaning.

Derivatives of a protein: A derivative of a protein (or peptide) istypically understood to be a molecule that is derived from anothermolecule, such as said peptide or protein. A “derivative” of a peptideor protein also encompasses fusions comprising a peptide or protein usedin the present invention. For example, the fusion comprises a label,such as, for example, an epitope, e.g., a FLAG epitope or a V5 epitope.For example, the epitope is a FLAG epitope. Such a tag is useful for,for example, purifying the fusion protein.

In the following the term “rotavirus protein” is used. This term has tobe understood to relate to rotavirus proteins as mentioned above butalso to fragments, variants or derivatives thereof.

VP8* is a protein (or protein cleavage product) that is generated uponnaturally occurring proteolytic cleavage of the viral cell surfaceprotein VP4 to VP5* and VP8*. VP4 is one of two rotavirus proteinspresent on the outermost layer of the virus and forms trimeric spikes onthe viral surface. A variety of studies employing VP8* as a proteinvaccine have shown its ability to induce neutralising antibodies againstrotaviruses in mice and guinea pigs (Larralde G et al., J Virol. 1991,65(6):3213-3218; Dunn S J et al, Arch Virol. 1995; 140(11):1969-1978;Gil M T et al, Viral Immunol. 2000; 13(2):187-200; Pérez Filgueira D Met al, Arch Virol. 2004, 149(12):2337-2348; Wen et al, Vaccine. 2012,30(43):6121-6126) as well as in gnotobiotic pigs (Wen et al, Vaccine.2014 Jul. 31; 32(35):4420-4427). Now, the inventors were able todemonstrate, that an mRNA-based subunit vaccine comprising a codingregion encoding for at least one epitope of especially VP8* isparticularly effective in inducing antigen-specific immune responsesagainst rotavirus.

The at least one epitope of a protein or of a fragment, variant orderivative thereof of a virus of the genus rotavirus is preferablyderived from one of the serotypes of rotavirus A. For example, theprotein VP4 or the protein cleavage product VP5* or especially VP8* maypreferably be derived from one of the serotypes P[1]-P[35] (preferably aprotein sequence according to any of SEQ ID NOs: 40-76 is chosen).Preferably, the protein VP4 or the protein cleavage product VP5* orespecially VP8* is selected from one of the serotypes P[4] or P[6] orP[8], most preferably a protein sequence according to any of SEQ ID Nos:41; 45; 47; or 49 is chosen. The protein VP7 is preferably selected fromone of the serotypes G1 or G2 or G3 or G4 or G9 or G12, most preferablya protein sequence according to any of SEQ ID Nos. 1-26 is chosen.

In this context VP8* is particularly preferred, wherein the inventivemRNA sequence encodes the VP8* protein, preferably the wild type VP8*protein, or a fragment, variant or derivative thereof, which preferablyderives from the serotypes P[4] (preferably according to SEQ ID NO: 45)or P[6] (preferably according to SEQ ID NO: 47) or P[8] (preferablyaccording to SEQ ID NO: 41 or SEQ ID NO: 49) of rotavirus A as will beoutlined in more detail below. The term wild type is to be understoodaccording to the skilled person's general understanding in the art anddenotes the protein in the form of its occurrence in nature without anymutation or amino acid amendment by man. The serotypes P[4] and P[6] andP[8] are the most prevalent P-serotypes important for rotavirusinfections and are especially effective in the inventive approach.

In the following the term “VP8* coding region” is used. This term is tobe understood that the coding region may encode complete (full-length)VP8*, or a fragment, variant or derivative thereof, also considering thepossible percentage of identity of the amino acid sequences (ornucleotide sequences) as outlined above.

Preferably, the amino acid sequence of VP8* derived from serotype P[4]according to SEQ ID NO: 45 (derived from Human rotavirus ARVA/Human-wt/BEL/BE1058/2008/G2P[4]; JN849123.1; GI:371455744) may serveas a basis for advantageous designs of the inventive mRNA sequence.

Preferably, the amino acid sequence of VP8* derived from serotype P[6]according to SEQ ID NO: 47 (derived from Rotavirus AHu/BEL/F01322/2009/G3P[6]; JF460826.1; GI:37531451) may serve as a basisfor advantageous designs of the inventive mRNA sequence.

Preferably, the amino acid sequence of VP8* derived from serotype P[8]according to SEQ ID NO: 41 (derived from Human rotavirus ARVA/Human-wt/BEL/BE1128/2009/G1P[8]; JN849135.1; GI:371455756) may serveas a basis for advantageous designs of the inventive mRNA sequence.Preferably, the amino acid sequence of VP8* derived from serotype P[8]according to SEQ ID NO: 49 (derived from Human rotavirus A Wa variantVirWa; ACR22783.1) may serve as a basis for advantageous designs of theinventive mRNA sequence.

Preferably, the inventive mRNA sequence encodes an amino acid sequencewhich is at least 60% identical, more preferably at least 70% identical,more preferably at least 80% identical, more preferably at least 90%identical, more preferably at least 95% identical, or most preferably atleast 99% identical to the sequence according to SEQ ID NO: 41 or 45 or47 or 49.

Preferred protein designs of VP8* for protein-based vaccines represent ashortened form of VP8* that facilitates protein isolation from producercells (usually bacterial cells), since the full length protein isinsoluble in the bacterial expression system. Given that conditions forcytoplasmatic expression in bacteria are not directly transferable toexpression and export via the secretory pathway in eukaryotic cells,current mRNA designs feature full length VP8* due to the presence ofpredicted T-cell epitopes in fragments removed in a shortened form ofVP8*. Therefore, according to a preferred embodiment of the inventivemRNA sequence the full length VP8* is encoded. Nevertheless, it may alsobe preferred to apply a shortened form of VP8* for the inventive mRNAsequence.

In particularly preferred embodiments the inventive mRNA sequenceencodes the following shortened forms of VP8*: amino acids (aa) 2-240;2-230; 11-223; 11-240, 21-240; 4-223; 65-223 or 64-223. Particularlypreferred in this context are the amino acid sequences as shown in Table1.

TABLE 1 amino acid sequences Amino acids of VP8* Serotyp P[4] SerotypP[6] Serotyp P[8]  2-240 SEQ ID NO. 77 SEQ ID NO. 78 SEQ ID Nos. 79-80 2-230 SEQ ID NO. 173 SEQ ID NO. 174 SEQ ID NOs. 175-176 11-223 SEQ IDNO. 269 SEQ ID NO. 270 SEQ ID NOs. 271-272 11-240 SEQ ID NO. 365 SEQ IDNO. 366 SEQ ID Nos 367-368 21-240 SEQ ID NO. 461 SEQ ID NO. 462 SEQ IDNOs. 463-464 41-223 SEQ ID NO. 557 SEQ ID NO. 558 SEQ ID NOs. 559-56065-223 SEQ ID NO. 653 SEQ ID NO. 654 SEQ ID Nos. 655-656 64-223 SEQ IDNO. 749 SEQ ID NO. 750

Preferably, the inventive mRNA sequence encodes at least one amino acidsequence which is at least 60% identical, more preferably at least 70%identical, more preferably at least 80% identical, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the amino acid sequences asshown in Table 1 or to a respective fragment thereof.

It is possible to apply the unmodified coding sequences to the inventivemRNA sequences. For example, unmodified nucleotide sequences encodingthe VP8* are shown in Table 2 Column A respectively.

Nevertheless, in especially preferred embodiments of the inventionoptimized and modified nucleotide sequences are used as will be outlinedin more detail below.

In preferred embodiments of the invention the G/C content of the codingregion of the mRNA sequence is increased compared to the G/C content ofthe coding region of its particular wild type coding sequence, i.e. theunmodified mRNA. For example, coding regions with an increased G/Ccontent encoding VP8* are shown in Table 2 Column B respectively.

In especially preferred designs the inventive mRNA sequence comprisesUTRs e.g. as 5′-UTR a 5′-UTR derived from 32 L TOP UTR (according to SEQID NO. 3189), as 3′-UTR a 3′-UTR derived from human albumin 3′-UTR(according to SEQ ID NO. 3205), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 2 Column D. Alternatively the inventivemRNA sequence comprises a 3′-UTR derived from alpha globin 3′-UTR(according to SEQ ID NO. 3199), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 2 Column C.

TABLE 2 inventive mRNA sequences encoding VP8* Amino Serotyp P[4]Serotyp P[6] Serotyp P[8] acids of SEQ ID NO(s) SEQ ID NO(s) SEQ IDNO(s) VP8* A B C D A B C D A B C D  1-240 828 878 1626 2386 829 879 16272387 830-   880- 1628- 2388- 831   881 1629  2389   1-230 974 1722 2482975 1723 2483   976- 1724- 2484-  977 1725  2485  11-223 1070 1818 25781071 1819 2579 1072- 1820- 2580- 1073  1821  2581  11-240 1166 1914 26741167 1915 2675 1168- 1916- 2676- 1169  1917  2677  21-240 1262 2010 27701263 2011 2771 1264- 2012- 2772- 1265  2013  2773  41-223 1358 2106 28661359 2107 2867 1360- 2108- 2868- 1361  2109  2869  65-223 833 1454 22022962 835 1455 2203 2963 836- 1456- 2204- 2964- 837  1457  2205  2965 64-223 832 1550 2298 3058 834 1551 2298 3059 Column A = SEQ ID Nos.regarding wild type CDS (coding sequences) Column B = SEQ ID Nos.regarding CDS (coding sequences) with an increased G/C content Column C= SEQ ID Nos. regarding mRNA sequences comprising a CDS with anincreased G/C content and comprising a 3'-UTR derived from alpha globin(according to SEQ ID No. 3199), a histon stem-loop sequence (accordingto SEQ ID No. 3207) and a poly(A) sequence and a poly(C) sequence.Column D = SEQ ID Nos. regarding mRNA sequences comprising a CDS with anincreased G/C content and comprising a 5'-UTR derived from 32L TOP UTR(according to SEQ ID NO. 3189), a 3'-UTR derived from albumin 3'-UTR(according to SEQ ID No. 3205), a histon stem-loop sequence (accordingto SEQ ID No. 3207) and a poly(A) sequence and a poly(C) sequence.

Preferably, the inventive mRNA sequence comprises or consists of anucleotide sequence as shown in Table 2 or which is at least 60%identical, more preferably at least 70% identical, more preferably atleast 80% identical, more preferably at least 85%, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the sequences shown in Table2.

Using mRNA as a basis poses challenges concerning antigen localisationthat differ from a protein-based approach. During the viral life cycle,VP4 is produced in the cytoplasm and associates with the assemblingviral particle on the cytoplasmatic side of the endoplasmatic reticulum(ER) membrane. In a process mediated by a viral accessory protein, thecomplex then buds into the ER, allowing assembly with the ER residentglycoprotein VP7. In polarised cells, the virus then leaves the infectedcell via the secretory pathway (reviewed on Trask et al, Nat RevMicrobiol. 2012 Jan. 23; 10(3):165-177) and is activated by cleavage ofVP4 into VP5* and VP8* by trypsin-like proteases in the intestinallumen. Hence, mRNA-based expression of unmodified VP8* in the absence ofadditional viral proteins may result in translation of the nascentprotein in the cytoplasm of the producing cell, rendering the antigencaught inside the cell. In such a scenario, the antigen as a proteinwould be inaccessible to the immune system unless the producing cellundergoes cell death. Anyway this might be sufficient to induce animmune response.

Nevertheless, in preferred embodiments of the inventive mRNA sequence,the mRNA sequence encoding at least one epitope of a rotavirus proteinor a fragment, variant or derivative thereof, particularly VP8* or afragment, variant or derivative thereof, is artificially modified andamended, thereby enhancing the immune responses.

In an especially preferred embodiment of the inventive mRNA sequence themRNA sequence encoding at least one epitope of a rotavirus protein or afragment, variant or derivative thereof, particularly VP8* or afragment, variant or derivative thereof, is combined with at least onesequence section encoding a helper peptide for enhancement ofimmunogenicity. In preferred embodiments the helper peptide is locatedat the 5′-end of the coding region, encoding the at least one epitope ofa rotavirus protein or a fragment, variant or derivative thereof.Preferably, the helper peptide is derived from Tetanus toxin, or afragment, variant or derivative thereof. By addition of an mRNA sequenceencoding such a peptide it is possible to increase immune responses. Inthe context of a protein-based approach it has already been shown by Wenet al. (Vaccine. 2014 Jul. 31; 32(35):4420-4427) that the N-terminal P2helper peptide derived from tetanus toxin was able to increase immuneresponses against VP8*. Now, the inventors were able to show that theaddition of a sequence encoding a helper peptide may be particularlyeffective in enhancing the immune response in an mRNA-based vaccineapproach.

Preferably, the amino acid sequence of P2 helper peptide of tetanustoxin according to SEQ ID NO: 3147 (GenBank X04436 derived fromKovacs-Nolan et al.; PMID 16978788; P2: aa 830-844) may serve as a basisfor advantageous designs of the inventive mRNA sequence.

If the sequence section encoding the rotavirus protein is combined witha sequence section encoding a helper peptide at the 5′-end of thesequence section encoding the rotavirus protein a peptide linker mayoptionally separate the rotavirus protein from the helper peptide.

Preferably, the sequence section encoding the peptide linker is codingfor a flexible or a rigid linker. Flexible linkers are especiallypreferred, wherein joined domains allow a certain degree of movement orinteraction. They are preferably composed of small, non-polar (e.g. Gly)or polar (e.g. Ser or Thr) amino acids. The small size of these aminoacids provides flexibility, and allows for mobility of the connectingfunctional domains, as described by Chen et al. (Adv Drug Deliv Reb.2013; 65(10):1357-1369). The incorporation of Ser or Thr can maintainthe stability of the linker in aqueous solutions by forming hydrogenbonds with the water molecules, and therefore reduces an interactionbetween the linker and the protein moieties. Rigid linkers generallymaintain the distance between the protein domains and they may be basedon helical structures and/or they have a sequence that is rich inproline.

A typical sequence of a flexible linker is composed of repeats of theamino acids Glycine and Serine. For instance, the linker may have thefollowing sequence: GS, GSG, SGG. In some embodiments, the same sequenceis repeated multiple times (e.g. two, three, four, five or six times) tocreate a longer linker. In other embodiments, a single amino acid suchas S or G can be used as a linker.

Preferably, the sequence section encoding the peptide linker codes for aflexible linker comprising sequences consisting of at least one stretchof glycine and/or serine residues. The term “stretch” describes asequence of consecutive identical amino acids. More preferably, theflexible linker comprises more than one stretch of glycine and/or serineresidues. Advantageously, the stretch or stretches consist(s) of fourand/or five amino acids.

Preferably, the amino acid sequences of the peptide linker according toSEQ ID NO: 3174 (derived from publication: PMID 16227284) or SEQ ID NOs:3175-3176 may serve as a basis for advantageous designs of the inventivemRNA sequence.

Preferred amino acid sequences comprising P2 helper peptide, optionallya peptide linker and VP8* proteins (full-length and shortened forms) areshown in Table 3:

TABLE 3 amino acid sequences for VP8* additionally comprising the P2helper peptide and optionally a peptide linker Amino acids of VP8*Serotyp P[4] Serotyp P[6] Serotyp P[8]  2-240 SEQ ID NO. 81, SEQ ID NO.82, SEQ ID Nos. 83-84, 797 798 799  2-230 SEQ ID NO. 177 SEQ ID NO. 178SEQ ID NOs. 179-180 11-223 SEQ ID NO. 273 SEQ ID NO. 274 SEQ ID NOs.275-276 11-240 SEQ ID NO. 369 SEQ ID NO. 370 SEQ ID Nos 371-372 21-240SEQ ID NO. 465 SEQ ID NO. 466 SEQ ID NOs. 467-468 41-223 SEQ ID NO. 561SEQ ID NO. 562 SEQ ID NOs. 563-564 65-223 SEQ ID NO. 657 SEQ ID NO. 658SEQ ID Nos. 559-660, 802-803 64-223 SEQ ID NO. 751, SEQ ID NO. 752, 800801

Preferably, the inventive mRNA sequence encodes at least one amino acidsequence which is at least 60% identical, more preferably at least 70%identical, more preferably at least 80% identical, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the amino acid sequences asshown in Table 3 or to a respective fragment thereof.

Additionally to the amino acid sequences in Table 3 also the inventivemRNA sequences encoding the respective amino acid sequences aredisclosed. In this context it is possible to apply unmodified nucleotidesequences or mRNA sequences wherein the G/C content of the coding regionis increased compared to the G/C content of the coding region of itsparticular wild type coding sequence, i.e. the unmodified mRNA.Furthermore, mRNA sequences additionally comprising UTR sequences aredisclosed in Table 4.

In especially preferred designs the inventive mRNA sequence comprisesUTRs e.g. as 5′-UTR a 5′-UTR derived from 32 L TOP UTR (according to SEQID NO. 3189), as 3′-UTR a 3′-UTR derived from human albumin 3′-UTR(according to SEQ ID NO. 3205), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 4 Column D. Alternatively the inventivemRNA sequence comprises a 3′-UTR derived from alpha globin 3′-UTR(according to SEQ ID NO. 3199), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 4 Column C.

TABLE 4 mRNA sequences encoding VP8* and additionally encoding the P2helper peptide and optionally a peptide linker Amino acids Serotyp P[4]Serotyp P[6] Serotyp P[8] of SEQ ID NO(s) SEQ ID NO(s) SEQ ID NO(s) VP8*A B C D A B C D A B C D  1-240 838 882 2346 2390 839 883 2347 2391 840   884- 2348; 2392- 1598 1630 1599 1631  885 1632- 2393  1600  1633  1-230 978 1726 2486 979 1727 2487   980- 1728- 2488-  981 1729  2489 11-223 1074 1822 2582 1075 1823 2583 1076- 1824- 2584- 1077  1825  2585 11-240 1170 1918 2678 1171 1919 2679 1172- 1920- 2680- 1173  1921  2681 21-240 1266 2014 2774 1267 2015 2775 1268- 2016- 2776- 1269  2017  2777 41-223 1362 2110 2870 1363 2111 2871 1364- 2112- 2872- 1365  2113  2873 65-223 1458 2206 2966 1459 2207 2967 843- 1460- 2351- 2968- 844  1461;2352; 2969  1603- 2208- 1604  2209  64-223 841 1552 2349 3060 842 15532350 3061 1601 2300 1602 2301 Column A = SEQ ID Nos. regarding wild typeCDS (coding sequences) Column B = SEQ ID Nos. regarding CDS (codingsequences) with an increased G/C content Column C = SEQ ID Nos.regarding mRNA sequences comprising a CDS with an increased G/C contentand comprising a 3'-UTR derived from alpha globin (according to SEQ IDNo. 3199), a histon stem-loop sequence (according to SEQ ID No. 3207)and a poly(A) sequence and a poly(C) sequence. Column D = SEQ ID Nos.regarding mRNA sequences comprising a CDS with an increased G/C contentand comprising a 5'-UTR derived from 32L TOP UTR (according to SEQ IDNO. 3189), a 3'-UTR derived from albumin 3'-UTR (according to SEQ ID No.3205), a histon stem-loop sequence (according to SEQ ID No. 3207) and apoly(A) sequence and a poly(C) sequence.

Preferably, the inventive mRNA sequence comprises or consists of anucleotide sequence as shown in Table 4 or which is at least 60%identical, more preferably at least 70% identical, more preferably atleast 80% identical, more preferably at least 85%, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the sequences shown in Table4.

In an especially preferred embodiment the inventive mRNA additionallycomprises at least one sequence section encoding a signal peptide (seetherefore for example the preferred construct “secreted” shown in FIG. 1). In this context a signal peptide is preferably a peptide which leadsto a co-translational transport of the encoded protein or peptide intothe endoplasmatic reticulum (ER). By addition of a sequence encoding forsuch a signal peptide the resulting protein or peptide is effectivelycotranslationally translocated into the secretory pathway of theproducing cell.

In preferred embodiments the signal peptide derives from tissueplasminogen activator (TPA) or albumin, especially human serum albumin(HSA), or CD5 (CD—cluster of differentiation) or HLA-A2 (HLA—humanleucocyte antigen) or luciferase, especially Gaussian luciferase, orimmunoglobulin (e.g. IgG or IgE heavy chain) or IL-2 (human IL-2) orchymotrypsinogen (human chymotrypsinogen), or a fragment, variant orderivative thereof. By inclusion of a signal peptide that is aimed toallow co-translational transport of VP8* into the ER followed by proteinsecretion it is possible to increase antigen accessibility to the immunesystem.

Preferably, the amino acid sequence of the signal peptide of tissueplasminogen activator according to SEQ ID NO: 3148 (derived fromNM_000930.3; GI:132626665; 1-21aa/1-63 bp) may serve as a basis foradvantageous designs of the inventive mRNA sequence.

Moreover, the amino acid sequence of the signal peptide of human serumalbumin (HSA) according to SEQ ID NO: 3149 may serve as a basis foradvantageous designs of the inventive mRNA sequence.

Moreover, the amino acid sequence of the signal peptide of CD5 accordingto SEQ ID NO: 3151 may serve as a basis for advantageous designs of theinventive mRNA sequence.

Moreover, the amino acid sequence of the signal peptide of HLA-A2according to SEQ ID NOs: 3152-3153 may serve as a basis for advantageousdesigns of the inventive mRNA sequence.

Moreover, the amino acid sequence of the signal peptide of Gaussialuciferase according to SEQ ID NO: 3154 may serve as a basis foradvantageous designs of the inventive mRNA sequence.

Moreover, the amino acid sequence of the signal peptide ofimmunoglobulin IgG heavy chain according to SEQ ID NO: 3155 may serve asa basis for advantageous designs of the inventive mRNA sequence.

Moreover, the amino acid sequence of the signal peptide of human IL-2according to SEQ ID NO: 3156 may serve as a basis for advantageousdesigns of the inventive mRNA sequence.

Moreover, the amino acid sequence of the signal peptide of humanchymotrypsinogen according to SEQ ID NO: 3157 may serve as a basis foradvantageous designs of the inventive mRNA sequence.

Moreover, the amino acid sequence of the signal peptide of animmunoglobulin (human, heavy chain) according to SEQ ID NO: 3158 mayserve as a basis for advantageous designs of the inventive mRNAsequence.

Moreover, the amino acid sequence of the signal peptide of animmunoglobulin (human, heavy chain) according to SEQ ID NO: 3159 mayserve as a basis for advantageous designs of the inventive mRNAsequence.

Preferred amino acid sequences of the combination of a signal peptideand VP8* (full-length and shortened forms) are shown in Table 5:

TABLE 5 amino acid sequences for VP8* additionally comprising a signalpeptide Amino acids of VP8* SEQ ID Nos.  2-240  85-104  2-230 181-20011-223 277-296 11-240 373-392 21-240 469-488 41-223 565-584 65-223661-680 64-223 753-762

Preferably, the inventive mRNA sequence encodes at least one amino acidsequence which is at least 60% identical, more preferably at least 70%identical, more preferably at least 80% identical, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the amino acid sequences asshown in Table 5 or to a respective fragment thereof.

Additionally to the amino acid sequences in Table 5 also the inventivemRNA sequences encoding the respective amino acid sequences aredisclosed. In this context it is possible to apply unmodified nucleotidesequences or mRNA sequences wherein the G/C content of the coding regionis increased compared to the G/C content of the coding region of itsparticular wild type coding sequence, i.e. the unmodified mRNA.Furthermore, mRNA sequences additionally comprising UTR sequences aredisclosed in Table 6.

In especially preferred designs the inventive mRNA sequence comprisesUTRs e.g. as 5′-UTR a 5′-UTR derived from 32 L TOP UTR (according to SEQID NO. 3189), as 3′-UTR a 3′-UTR derived from human albumin 3′-UTR(according to SEQ ID NO. 3205), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 6 Column D. Alternatively the inventivemRNA sequence comprises a 3′-UTR derived from alpha globin 3′-UTR(according to SEQ ID NO. 3199), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 6 Column C.

TABLE 6 mRNA sequences encoding VP8* and additionally encoding a signalpeptide Amino acids SEQ ID NO(s) of VP8* A B C D  2-240 — 886-9051634-1653 2394-2413  2-230 —  982-1001 1730-1749 2490-2509 11-223 —1078-1097 1826-1845 2586-2605 11-240 — 1174-1193 1922-1941 2682-270121-240 — 1270-1289 2018-2037 2778-2797 41-223 — 1366-1385 2114-21332874-2893 65-223 — 1462-1481 2210-2229 2970-2989 64-223 — 1554-15632302-2311 3062-3071 Column A = SEQ ID Nos. regarding wild type CDS(coding sequences) Column B = SEQ ID Nos. regarding CDS (codingsequences) with an increased G/C content Column C = SEQ ID Nos.regarding mRNA sequences comprising a CDS with an increased G/C contentand comprising a 3′-UTR derived from alpha globin (according to SEQ IDNo. 3199), a histon stem-loop sequence (according to SEQ ID No. 3207)and a poly(A) sequence and a poly(C) sequence. Column D = SEQ ID Nos.regarding mRNA sequences comprising a CDS with an increased G/C contentand comprising a 5′-UTR derived from 32L TOP UTR (according to SEQ IDNO. 3189), a 3′-UTR derived from albumin 3′-UTR (according to SEQ ID No.3205), a histon stem-loop sequence (according to SEQ ID No. 3207) and apoly(A) sequence and a poly(C) sequence.

Preferably, the inventive mRNA sequence comprises or consists of anucleotide sequence as shown in Table 6 or which is at least 60%identical, more preferably at least 70% identical, more preferably atleast 80% identical, more preferably at least 85%, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the sequences shown in Table6.

Preferably, the signal peptide is applied in mRNA sequences encoding atleast one epitope of a rotavirus protein according to the invention incombination with a helper peptide and optionally in combination with apeptide linker (as disclosed above).

Preferred amino acid sequences of the combination ofa signal peptide, ahelper peptide and optionally a peptide linker together with VP8*(full-length and shortened forms) are shown in Table 7:

TABLE 7 amino acid sequences for VP8* additionally comprising a signalpeptide, the P2 helper peptide and optionally a peptide linker Aminoacids of VP8* SEQ ID Nos.  2-240 105-124  2-230 201-220 11-223 297-31611-240 393-412 21-240 489-508 41-223 585-604 65-223 681-700 64-223763-772

Preferably, the inventive mRNA sequence encodes at least one amino acidsequence which is at least 60% identical, more preferably at least 70%identical, more preferably at least 80% identical, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the amino acid sequences asshown in Table 7 or to a respective fragment thereof.

Additionally to the amino acid sequences in Table 7 also the inventivemRNA sequences encoding the respective amino acid sequences aredisclosed. In this context it is possible to apply unmodified nucleotidesequences or mRNA sequences wherein the G/C content of the coding regionis increased compared to the G/C content of the coding region of itsparticular wild type coding sequence, i.e. the unmodified mRNA.Furthermore, mRNA sequences additionally comprising UTR sequences aredisclosed in Table 8.

In especially preferred designs the inventive mRNA sequence comprisesUTRs e.g. as 5′-UTR a 5′-UTR derived from 32 L TOP UTR (according to SEQID NO. 3189), as 3′-UTR a 3′-UTR derived from human albumin 3′-UTR(according to SEQ ID NO. 3205), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 8 Column D. Alternatively the inventivemRNA sequence comprises a 3′-UTR derived from alpha globin 3′-UTR(according to SEQ ID NO. 3199), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 8 Column C.

TABLE 8 mRNA sequences encoding VP8* and additionally encoding a signalpeptide, the P2 helper peptide and optionally a peptide linker SEQ IDNO(s) Amino acids A B C D  2-240 —  906-925 1654-1673 2414-2433  2-230 —1002-1021 1750-1769 2510-2529 11-223 — 1098-1117 1846-1865 2606-262511-240 — 1194-1213 1942-1961 2702-2721 21-240 — 1290-1309 2038-20572798-2817 41-223 — 1386-1405 2134-2153 2894-2913 65-223 — 1482-15012230-2249 2990-3009 64-223 — 1564-1573 2312-2321 3072-3081 Column A =SEQ ID Nos. regarding wild type CDS (coding sequences) Column B = SEQ IDNos. regarding CDS (coding sequences) with an increased G/C contentColumn C = SEQ ID Nos. regarding mRNA sequences comprising a CDS with anincreased G/C content and comprising a 3′-UTR derived from alpha globin(according to SEQ ID No. 3199), a histon stem-loop sequence (accordingto SEQ ID No. 3207) and a poly(A) sequence and a poly(C) sequence.Column D = SEQ ID Nos. regarding mRNA sequences comprising a CDS with anincreased G/C content and comprising a 5′-UTR derived from 32 L TOP UTR(according to SEQ ID NO. 3189), a 3′-UTR derived from albumin 3′-UTR(according to SEQ ID No. 3205), a histon stem-loop sequence (accordingto SEQ ID No. 3207) and a poly(A) sequence and a poly(C) sequence.

Preferably, the inventive mRNA sequence comprises or consists of anucleotide sequence as shown in Table 8 or which is at least 60%identical, more preferably at least 70% identical, more preferably atleast 80% identical, more preferably at least 85%, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the sequences shown in Table8.

Nevertheless, the signal peptide may also be applied in an mRNA sequenceencoding the at least one epitope of a rotavirus protein according tothe invention without the helper peptide.

In a particularly preferred embodiment of the inventive mRNA sequencethe coding region encoding at least one epitope of a rotavirus protein,or a fragment, variant or derivative thereof, is mutated to delete atleast one predicted or potential glycosylation site. As described e.g.by Chauhan et al. (PLOS ONE (2013) Vol. 8 issue 6, e67008) glycosylationis an important post-translational or co-translational modification ofproteins. The majority of proteins synthesized in the roughendoplasmatic reticulum (ER) undergo glycosylation. There are mainly twotypes of glycosylation: a) In N-glycosylation, the addition of sugarchains takes place at the amide nitrogen on the side-chain of theasparagine or arginine. b) In O-glycosylation, the addition of sugarchains takes place on the hydroxyl oxygen on the side-chain ofhydroxylysine, hydroxyproline, serine, tyrosine or threonine. Moreover,phospho-glycans linked through the phosphate of a phospho-serine andC-linked glycans, a rare form of glycosylation where a sugar is added toa carbon on a tryptophan side-chain, are known. Since VP8* or some otherrotavirus proteins are not glycosylated in the viral life cycle (PrasadB. V. V. et al., 1988,199(2):269-275), entry in the ER might lead tomodifications by glycosylation that could lead to epitope shielding andtherefore prevent an efficient immune response. Therefore, it isparticularly advantageous to delete the potential glycosylation sites ofthe encoded rotavirus protein. By mutation of the relevant amino acidsthe glycosylation is prevented. In this context preferably at least onecodon coding for an asparagine, arginine, serine, threonine, tyrosine,lysine, proline or tryptophan is mutated in such a way that a differentamino acid is encoded thereby deleting at least one predicted orpotential glycosylation site. The predicted glycosylation sites may bepredicted by using artificial neural networks that examine the sequencefor common glycosylation sites, e.g. N-glycosylation sites may bepredicted by using the NetNGlyc 1.0 Server.

In an especially preferred embodiment of the inventive mRNA sequenceencoding at least one epitope of a rotavirus protein at least one codoncoding for asparagine (N) is mutated into a codon coding for glutamine(Q). Thereby, the sequence is modified to encode for Q instead of N atpredicted N-glycosylation sites, for example at predictedN-glycosylation sites of the encoded VP8* protein, or a fragment,variant or derivative thereof. In this context the term “mutated VP8*means that at least one (predicted) glycosylation site is mutated.

It is preferred that not all predicted glycosylation sites of the codingregion encoding at least one epitope of a rotavirus protein, or afragment, variant or derivative thereof, are mutated to partiallyprevent glycosylation of the resulting protein or peptide. This aspectof the invention may apply for e.g. all N-glycosylation sites or for allO-glycosylation sites or for all glycosylation sites irrespective oftheir biochemical nature.

It is particularly preferred that all predicted glycosylation sites ofthe coding region encoding at least one epitope of a rotavirus protein,or a fragment, variant or derivative thereof, are mutated to completelyprevent glycosylation of the resulting protein or peptide. This aspectof the invention may apply for e.g. all N-glycosylation sites or for allO-glycosylation sites or for all glycosylation sites irrespective oftheir biochemical nature.

A preferred amino acid sequence for mutated VP8* of P-serotype P[4] isshown in SEQ ID NO. 125, wherein N-glycosylation modifications were doneat N67Q; N91Q; N132Q; N148Q; N230Q.

A preferred amino acid sequence for mutated VP8* of P-serotype P[6] isshown in SEQ ID No. 126, wherein N-glycosylation modifications were doneat N67Q; N91Q; N132Q; N146Q.

A preferred amino acid sequence for mutated VP8* of P-serotype P[6] isshown in SEQ ID No. 3210, wherein N-glycosylation modifications weredone at N67Q; N91Q; N132Q; N146Q and.

A preferred amino acid sequence for mutated VP8* of P-serotype P[8] isshown in SEQ ID NO. 127 and SEQ ID NO. 128, wherein N-glycosylationmodifications were done at N67Q; N91Q; N132Q.

Preferred amino acid sequences of mutated VP8* (full-length andshortened forms optional in combination with helper peptide (and peptidelinker) and/or signal peptide) comprising N-glycosylation modificationsare shown in Table 9:

TABLE 9 amino acid sequences for mutated VP8* (full-length and shortenedforms) Additional helper Additional peptide P2, Protein helper peptideAdditional peptide sequence P2 and helper peptide Additional linker andAmino of mutated additional signal P2 and signal signal acids of VP8*peptide peptide linker peptide peptide VP8* SEQ ID Nos. SEQ ID Nos. SEQID Nos. SEQ ID Nos. SEQ ID Nos.  2-240 125-128; 804-806 129-132; 3211 133-152;  153-172; 3210 3212-3216 3217-3221  2-230 221-224; 225-228;3223  229-248;  249-268; 3222 3224-3228 3229-3233 11-223 317-320;321-324; 3235  325-344;  345-364; 3234 3236-3240 3241-3245 11-240413-416; 417-420; 3247  421-440;  441-460; 3246 3248-3252 3253-325721-240 509-512; 513-516; 3259  517-536;  537-556; 3258 3260-32643265-3269 41-223 605-608; 609-612; 3271  613-632;  633-652; 32703272-3276 3277-3281 65-223 701-704; 809-810 705-708; 3283  709-728; 729-748; 3282 3284-3288 3289-3293 64-223 773-774; 807-808 775-776; 3295 777-786;  787-796; 3294 3296-3300 3301-3305

Preferably, the inventive mRNA sequence encodes at least one amino acidsequence which is at least 60% identical, more preferably at least 70%identical, more preferably at least 80% identical, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the amino acid sequences asshown in Table 9 or to a respective fragment thereof.

Additionally to the amino acid sequences in Table 9 also the inventivemRNA sequences encoding the respective amino acid sequences aredisclosed. In this context it is possible to apply unmodified nucleotidesequences or mRNA sequences wherein the G/C content of the coding regionis increased compared to the G/C content of the coding region of itsparticular wild type coding sequence, i.e. the unmodified mRNA.Furthermore, mRNA sequences additionally comprising UTR sequences aredisclosed in Tables 10-13.

In especially preferred designs the inventive mRNA sequence comprisesUTRs e.g. as 5′-UTR a 5′-UTR derived from 32 L TOP UTR (according to SEQID NO. 3189), as 3′-UTR a 3′-UTR derived from human albumin 3′-UTR(according to SEQ ID NO. 3205), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Tables 10-13 Column D. Alternatively theinventive mRNA sequence comprises a 3′-UTR derived from alpha globin3′-UTR (according to SEQ ID NO. 3199), a histone stem-loop (according toSEQ ID NO. 3207), a poly(A) sequence, and a poly(C) sequence. RespectivemRNA sequences are shown in Tables 10-13 Column C.

TABLE 10 mRNA sequences encoding mutated VP8* (full-length and shortenedforms) Amino acids SEQ ID NO(s) of VP8* A B C D  1-240  926-929; 33061674-1675; 3402 2434-2437; 3498  1-230 1022-1025; 3318 1770-1773; 34142530-2533; 3510 11-223 1118-1121; 3330 1866-1869; 3426 2626-2629; 352211-240 1214-1217; 3342 1962-1965; 3438 2722-2725; 3534 21-240 1310-1313;3354 2058-2061; 3450 2818-2821; 3546 41-223 1406-1409; 3366 2154-2157;3462 2914-2917; 3558 65-223 1502-1505; 3378 2250-2253; 3474 3010-3013;3570 64-223 1574-1575; 3390 2322-2323; 3486 3082-3083; 3582

TABLE 11 mRNA sequences encoding mutated VP8* (full-length and shortenedforms) and the P2 helper peptide and optionally a peptide linker Aminoacids SEQ ID NO(s) of VP8* A B C D  2-240  930-933; 3307 1678-1681; 34032438-2441; 3106-3108; 3499  2-230 1026-1029; 3319 1774-1777; 34152534-2537; 3511 11-223 1122-1125; 3331 1870-1873; 3427 2630-2633; 352311-240 1218-1221; 3343 1966-1969; 3439 2726-2729; 3535 21-240 1314-1317;3355 2062-2065; 3451 2822-2825; 3547 41-223 1410-1413; 3367 2158-2161;3463 2918-2921; 3559 65-223 1506-1509; 3379 2254-2257; 3475 3014-3017;3111-3112; 3571 64-223 1576-1577; 3391 2324-2325; 3487 3084-3085;3109-3110; 3583

TABLE 12 mRNA sequences encoding mutated VP8* (full-length and shortenedforms) and a signal peptide Amino acids SEQ ID NO(s) of VP8* A B C D 2-240  934-953; 3308-3312 1682-1701; 2442-2461; 3404-3408 3500-3504 2-230 1030-1049; 3320-3324 1778-1797; 2538-2557; 3416-3420 3512-351611-223 1126-1145; 3332-3336 1874-1893; 2634-2653; 3428-3432 3524-352811-240 1222-1241; 3344-3348 1970-1989; 2730-2749; 3440-3444 3536-354021-240 1318-1337; 3356-3360 2066-2085; 2826-2845; 3452-3456 3548-355241-223 1414-1433; 3368-3372 2162-2181; 2922-2941; 3464-3468 3560-356465-223 1510-1529; 3380-3384 2258-2277; 3018-3037; 3476-3480 3572-357664-223 1578-1587; 3392-3396 2326-2335; 3086-3095; 3488-3492 3584-3588

TABLE 13 mRNA sequences encoding mutated VP8*(full-length and shortenedforms), the P2 helper peptide, optionally a peptide linker and a signalpeptide Amino acids SEQ ID NO(s) of VP8* A B C D  2-240 845-847 954-973; 1605-1607; 1702-1721; 2353- 2462-2481; 3113- 3313-3317;3313-3317 2355; 3409-3413 3115; 3505-3509  2-230 1050-1069; 3325-33291798-1817; 3421- 2558-2577; 3517-3521 3425 11-223 1146-1165; 3337-33411894-1913; 3433- 2654-2673; 3529-3533 3437 11-240 1242-1261; 3349-33531990-2009; 3445- 2750-2769; 3541-3545 3449 21-240 1338-1357; 3361-33652086-2105; 3457- 2846-2865; 3553-3557 3461 41-223 1434-1453; 3373-33772182-2201; 3469- 2942-2961; 3565-3569 3473 65-223 850-851 1530-1549;1610-1611; 2278-2297; 2358- 3038-3057; 3118- 3385-3389 2359; 3481-34853119; 3577-3581 64-223 848-849 1588-1597; 1608-1609; 2336-2345; 2356-3096-3105; 3116- 3397-3401 2357; 3493-3497 3117; 3589-3593 Column A =SEQ ID Nos. regarding wild type CDS (coding sequences) Column B = SEQ IDNos. regarding CDS (coding sequences) with an increased G/C contentColumn C = SEQ ID Nos. regarding mRNA sequences comprising a CDS with anincreased G/C content and comprising a 3′-UTR derived from alpha globin(according to SEQ ID No. 3199), a histon stem-loop sequence (accordingto SEQ ID No. 3207) and a poly(A) sequence and a poly(C) sequence.Column D = SEQ ID Nos. regarding mRNA sequences comprising a CDS with anincreased G/C content and comprising a 5′-UTR derived from 32 L TOP UTR(according to SEQ ID NO. 3189), a 3′-UTR derived from albumin 3′-UTR(according to SEQ ID No. 3205), a histon stem-loop sequence (accordingto SEQ ID No. 3207) and a poly(A) sequence and a poly(C) sequence.

Preferably, the inventive mRNA sequence comprises or consists of anucleotide sequence as shown in Tables 10-13 or which is at least 60%identical, more preferably at least 70% identical, more preferably atleast 80% identical, more preferably at least 85%, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the sequences shown inTables 10-13.

In a particularly preferred embodiment of the inventive mRNA sequencethe sequence additionally comprises at least one sequence sectionencoding a transmembrane domain of a protein, or a fragment, variant orderivative thereof. The addition of a sequence encoding a transmembranedomain of a protein of a fragment, variant of derivative thereof mayenhance the expression of the antigen on the surface of the expressingcell. By addition of a transmembrane domain to the translated productaccording to this aspect of the invention it is possible to furtherenhance the immune response, wherein the translated rotavirus protein,e.g. VP8*, anchors to the plasma membrane thereby increasing immuneresponses by antigen clustering.

According to a preferred embodiment of the invention the transmembranedomain is selected from the transmembrane domain of hemagglutinin (HA)of Influenza virus, or Env of HIV-1 (Human Immunodeficiency Virus), orEIAV (equine infectious anemia virus), or MLV (murine leukemia virus),or mouse mammary tumor virus, or G protein of VSV (vesicular stomatitisvirus), or Rabies virus, or a fragment, variant or derivative of theseproteins. Preferably, the at least one sequence section encoding thetransmembrane domain is located 3′ of the coding region, encoding atleast one epitope of a rotavirus protein or fragment, variant orderivative thereof. That means that in the translated product thetransmembrane domain is fused to the C-term of the rotavirus protein(see therefore for example the preferred construct “Transmembrane” shownin FIG. 1 ).

The transmembrane domain of hemagglutinin of influenza virus isespecially preferred. Preferably, the amino acid sequence of thetransmembrane domain of Influenza hemagglutinin (HA) according to SEQ IDNO: 3160 (derived from CY148227.1; GI:538117274;HA/Netherlands/602/2009) may serve as a basis for advantageous designsof the inventive mRNA sequence.

Moreover, the amino acid sequence of the transmembrane domains of Env ofHIV-1 according to SEQ ID NOs: 3161-3163 (derived from BAF32550.1;GI:114842138) may serve as a basis for advantageous designs of theinventive mRNA sequence. In addition, the amino acid sequence of thetransmembrane domains of Env of EIAV according to SEQ ID NOs: 3164-3166(derived from AAC03762.1; GI:2905989) or the amino acid sequence of thetransmembrane domain of Env of MLV according to the SEQ ID NO:3167(derived from AAA46526.1; GI:332067) may serve as a basis foradvantageous designs of the inventive mRNA sequence.

Further preferred amino acid sequences are the transmembrane domains ofEnv of mouse mammery tumor virus according to SEQ ID NOs: 3168-3169(derived from BAA03768.1; GI:391744).

Moreover, the amino acid sequence of the transmembrane domains of the Gprotein of VSV according to SEQ ID NO: 3170 (derived from CAA24525.1;GI:61840) or of the G protein of Rabies according to SEQ ID NO: 3171(derived from AEV43288.1; GI:359374323) may serve as a basis foradvantageous designs of the inventive mRNA sequence.

In an especially preferred embodiment of the inventive mRNA sequence asequence section encoding the transmembrane domain (preferably thetransmembrane of Influenza HA according to SEQ ID NO. 3160) is fused tothe 3′-end of the VP8* coding region, wherein preferably also sequencesections encoding a signal peptide, preferably tissue plasminogenactivator according to SEQ ID NO. 3148, and/or a helper peptide,preferably P2 helper peptide of tetanus toxin according to SEQ ID NO.3147, and optionally a peptide linker are added to the 5′-end of theVP8* coding region. Preferably also feature mutations of theN-glycosylation sites are added, as described above. Preferredconstructs refer to VP8* and to the shortened forms of VP8*, preferablyof the serotypes P[4], P[6] and P[8].

Preferred amino acid sequences are shown in Table 14:

TABLE 14 amino acid sequences for mutated VP8* (full-length andshortened forms) additionally comprising a transmembrane domain, and asignal peptide, the P2 helper peptide and optionally a peptide linkerAmino acids of VP8* SEQ ID Nos.  2-240 811-813 65-223 816-817 64-223814-815

Preferably, the inventive mRNA sequence comprises a coding region whichencodes for the amino acid sequences according to any one of Table 14 oramino acid sequences which show an identity of at least 60%, preferablyat least 70%, more preferably at least 80%, more preferably at least90%, more preferably at least 95%, or most preferably at least 99% tothe sequences as shown in Table 14.

Additionally to the amino acid sequences in Table 14 also the inventivemRNA sequences encoding the respective amino acid sequences aredisclosed. In this context it is possible to apply unmodified nucleotidesequences or mRNA sequences wherein the G/C content of the coding regionis increased compared to the G/C content of the coding region of itsparticular wild type coding sequence, i.e. the unmodified mRNA.Furthermore, mRNA sequences additionally comprising UTR sequences aredisclosed in Table 15.

In especially preferred designs the inventive mRNA sequence comprisesUTRs e.g. as 5′-UTR a 5′-UTR derived from 32 L TOP UTR (according to SEQID NO. 3189), as 3′-UTR a 3′-UTR derived from human albumin 3′-UTR(according to SEQ ID NO. 3205), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 15 Column D. Alternatively the inventivemRNA sequence comprises a 3′-UTR derived from alpha globin 3′-UTR(according to SEQ ID NO. 3199), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 15 Column C.

TABLE 15 mRNA sequences encoding mutated VP8* (full-length and shortenedforms) additionally encoding a transmembrane domain, and a signalpeptide, the P2 helper peptide and optionally a peptide linker SEQ IDNO(s) Amino acids A B C D  2-240  852-854; 2360-2362 3120-3122 1612-161465-223  857-858; 2365-2366 3125-3126 1617-1618 64-223  855-856;2363-2364 3123-3124 1615-1616 Column A = SEQ ID Nos. regarding wild typeCDS (coding sequences) Column B = SEQ ID Nos. regarding CDS (codingsequences) with an increased G/C content Column C = SEQ ID Nos.regarding mRNA sequences comprising a CDS with an increased G/C contentand comprising a 3′-UTR derived from alpha globin (according to SEQ IDNo. 3199), a histon stem-loop sequence (according to SEQ ID No. 3207)and a poly(A) sequence and a poly(C) sequence. Column D = SEQ ID Nos.regarding mRNA sequences comprising a CDS with an increased G/C contentand comprising a 5′-UTR derived from 32 L TOP UTR (according to SEQ IDNO. 3189), a 3′-UTR derived from albumin 3′-UTR (according to SEQ ID No.3205), a histon stem-loop sequence (according to SEQ ID No. 3207) and apoly(A) sequence and a poly(C) sequence.

Preferably, the inventive mRNA sequence comprises or consists of anucleotide sequence as shown in Table 15 or which is at least 60%identical, more preferably at least 70% identical, more preferably atleast 80% identical, more preferably at least 85%, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the sequences shown in Table15.

In a particularly preferred embodiment of the inventive mRNA sequencethe sequence additionally comprises at least one sequence sectionencoding a peptide or protein enabling VLP (virus like particle)formation. By formation of virus like particles it is possible tofurther increase immune responses by antigen clustering. Generally,virus like particles resemble viruses, but they are non-infectiousbecause they do not contain any viral genetic material. The expressionof viral structural proteins or peptides in the context of the inventivemRNA results in the self-assembly of virus like particles which enhancethe immungenicity of the inventive approach. In general, VLP formationcan be facilitated via two distinct mechanisms for the purpose of theinvention:

-   -   a) The VLP forming protein or peptide is co-expressed with the        rotavirus antigen, resulting in separate translation products        (rotavirus protein construct and VLP forming protein or        peptide). This co-expression may be achievd by using one single        multicistronic mRNA construct or at least two separate mRNA        constructs. The co-expression of the VLP forming proteins or        peptides preferably results in the formation of VLPs with a        lipid envelope. Preferably, viral VLP forming proteins or        peptides such as the Gag protein of HIV-1, EIAV or MLV, or        matrix proteins of vesicular stomatitis virus (VSV) or Rabies or        VP40 of Ebola virus may be used. The design for co-expression        may comprise a first mRNA construct encoding at least one        epitope of a rotavirus protein, e.g. VP8*, in membrane bound        form generated by fusion with a transmembrane domain, e.g.        derived from the HA protein of Influenza virus, and an        N-terminal signal peptide, and at least a second mRNA construct        providing the VLP forming peptide or protein.    -   b) The VPL enabling peptide or protein is fused (directly or        indirectly) to the coding region encoding the at least one        epitope of the rotavirus protein (or fragment, variant or        derivative thereof), that means the sequence section encoding        the VLP enabling peptide or protein is integrated into the mRNA        construct thereby resulting in a fusion protein. The fusion of        the VLP enabling peptide or protein with the rotavirus protein        generally results in VLPs without envelope.

Advantageously, the peptide or protein enabling VLP formation is derivedfrom non-human pathogenic viruses, because potential problems withpre-existing immunity by using proteins derived from the human virusesare avoided. Non-human pathogenic viruses refer to viruses that normallydo not infect humans.

In especially preferred embodiments the peptide or protein enabling VLPformation is derived from Hepatitis B virus core antigen (HBcAg) or fromAlfalfa mosaic virus coat protein (CP).

Hepatitis B virus core antigen (HBcAg), which is able to assemble intoVLPs, is a well-documented carrier of foreign antigens (reviewed inBuonaguro L, Expert Rev Vaccines. 2011; 10(11):1569-1583). Mostlypreferred is Woodchuck Hepatitis virus core protein (WHcAg), as thebasis for VLP formation. The use of Woodchuck Hepatitis virus coreprotein has the particular advantage, that potential problems withpre-existing immunity by using proteins derived from the human HepatitisB (Billaud J N, J Virol. 2005 November; 79(21):13641-13655) are avoided.

Preferably, the peptide or protein enabling VLP formation comprises orconsists of the amino acid sequence of Woodchuck Hepatitis virus coreprotein (WHcAg) according to SEQ ID NO: 3172 (derived from NCBIaccession no.: NC_004107.1; 1-149 with C-terminal C added; derived frompublication: PMID 16227284) may serve as a basis for advantageousdesigns of the inventive mRNA sequence.

In a further preferred embodiment the peptide or protein enabling VLPformation comprises or consists of the amino acid sequence of Alfalfamosaic virus CP (AIMV CP) according to SEQ ID NO: 3173 (derived fromNCBI accession no.: NP_041195.1; derived from publication: PMID24260245) may serve as a basis for advantageous designs of the inventivemRNA sequence.

Preferably, the sequence section encoding the peptide or proteinenabling VLP formation derived from WHcAg is located 5′ of the codingregion encoding the at least one epitope of the rotavirus proteinresulting in an N-terminal fusion to the rotavirus protein. If theconstruct additionally comprises a sequence section(s) encoding a helperpeptide, the sequence section encoding the peptide or protein enablingVLP formation is preferably located 5′ of the helper peptide. If theconstruct additionally comprises sequence sections encoding a signalpeptide, the sequence section encoding the peptide or protein enablingVLP formation is preferably located 3′ of the signal peptide.

The sequence section encoding the peptide or protein enabling VLPformation derived from Alfalfa mosaic virus CP is preferably located 3′of the coding region for the rotavirus protein resulting in C-terminalfusion of CP to the rotavirus protein, wherein preferably the constructadditionally comprises sequence sections encoding a helper peptideand/or a signal peptide at the 5′ end of the coding region for therotavirus protein.

In particular preferred embodiments in the context of fusion proteinsaccording to the invention the sequence section encoding the peptide orprotein enabling VLP formation is separated from the coding region forthe rotavirus protein by at least one sequence section encoding apeptide linker. If the sequence section encoding the rotavirus proteinis combined with a sequence section encoding a helper peptide at the5′-end of the sequence section encoding the peptide linker may separatethe VLP forming peptide or protein from the helper peptide plusrotavirus protein.

Preferably, the sequence section encoding the peptide linker is codingfor a flexible or a rigid linker as disclosed above.

In preferred embodiments the inventive mRNA sequence comprises at leastone sequence section encoding a peptide linker according to SEQ ID Nos.3174-3176 Furthermore, the mRNA sequence according to this aspect of theinvention preferably comprises a sequence section coding for anN-terminal signal peptide, as described above. Preferably, the predictedN-glycosylation sites are mutated, as described above.

In an especially preferred embodiment a relevant portion of WHcAg isfused to the N-term of VP8*, separated by a short peptide linker asdescribed above. Furthermore, the construct preferably contains anN-terminal signal peptide. The predicted N-glycosylation sites areremoved from VP8* (see therefore the preferred construct “VLP” in FIG. 1).

Preferred amino acid sequences are shown in Table 16:

TABLE 16 amino acid sequences for mutated VP8* (full-length andshortened forms) additionally comprising a signal peptide, the VLPenabling protein WHcAg, a peptide linker, and the P2 helper peptideAmino acids of VP8* SEQ ID Nos.  2-240 818-820 65-223 823-824 64-223821-822

Preferably, the inventive mRNA sequence comprises a coding region whichencodes for the amino acid sequences according to any one of Table 16 oramino acid sequences which show an identity of at least 60%, preferablyat least 70%, more preferably at least 80%, more preferably at least90%, more preferably at least 95%, or most preferably at least 99% tothe sequences as shown in Table 16.

Additionally to the amino acid sequences in Table 16 also the inventivemRNA sequences encoding the respective amino acid sequences aredisclosed. In this context it is possible to apply unmodified nucleotidesequences or mRNA sequences wherein the G/C content of the coding regionis increased compared to the G/C content of the coding region of itsparticular wild type coding sequence, i.e. the unmodified mRNA.Furthermore, mRNA sequences additionally comprising UTR sequences aredisclosed in Table 17.

In especially preferred designs the inventive mRNA sequence comprisesUTRs e.g. as 5′-UTR a 5′-UTR derived from 32 L TOP UTR (according to SEQID NO. 3189), as 3′-UTR a 3′-UTR derived from human albumin 3′-UTR(according to SEQ ID NO. 3205), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 17 Column D. Alternatively the inventivemRNA sequence comprises a 3′-UTR derived from alpha globin 3′-UTR(according to SEQ ID NO. 3199), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 17 Column C.

TABLE 17 mRNA sequences encoding mutated VP8* (full-length and shortenedforms) additionally encoding a signal peptide, the VLP enabling proteinWHcAg, a peptide linker, and the P2 helper peptide SEQ ID NO(s) Aminoacids A B C D  2-240 859-861 1619-1621 2367-2369 3127-3129 65-223864-865 1624-1625 2372-2373 3132-3133 64-223 862-863 1622-1623 2370-23713130-3131 Column A = SEQ ID Nos. regarding wild type CDS (codingsequences) Column B = SEQ ID Nos. regarding CDS (coding sequences) withan increased G/C content Column C = SEQ ID Nos. regarding mRNA sequencescomprising a CDS with an increased G/C content and comprising a 3′-UTRderived from alpha globin (according to SEQ ID No. 3199), a histonstem-loop sequence (according to SEQ ID No. 3207) and a poly(A) sequenceand a poly(C) sequence. Column D = SEQ ID Nos. regarding mRNA sequencescomprising a CDS with an increased G/C content and comprising a 5′-UTRderived from 32 L TOP UTR (according to SEQ ID NO. 3189), a 3′-UTRderived from albumin 3′-UTR (according to SEQ ID No. 3205), a histonstem-loop sequence (according to SEQ ID No. 3207) and a poly(A) sequenceand a poly(C) sequence.

Preferably, the inventive mRNA sequence comprises or consists of anucleotide sequence as shown in Table 17 or which is at least 60%identical, more preferably at least 70% identical, more preferably atleast 80% identical, more preferably at least 85%, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the sequences shown in Table17.

In an especially preferred embodiment a relevant portion of the aminoacid sequence of Alfalfa mosaic virus CP is fused to the N-term of VP8*,separated by a short peptide linker as described above. Furthermore, theconstruct preferably contains an N-terminal signal peptide. Thepredicted N-glycosylation sites may be removed from VP8*. The region ofAlfalfa mosaic virus CP may replace the relevant portion of WHcAg in alldisclosed sequences or constructs.

Preferably, the inventive mRNA sequence comprises at least two codingregions, each encoding at least one epitope of a rotavirus proteinrespectively of a protein of a virus of the genus rotavirus, or of afragment, variant or derivative thereof. Preferably, the mRNA sequencecomprises at least three or four coding regions.

In preferred embodiments of this aspect of the invention the rotavirusproteins derive from different serotypes of the rotavirus, whereinpreferably the at least one epitope is derived from the same protein. Inparticular preferred embodiment the at least one epitope is derived fromVP8*. It is possible that the inventive mRNA construct comprises two ormore coding regions each encoding the same or different epitopes of thesame rotavirus protein, e.g. VP8*, of different serotypes, wherein twoor more coding regions encoding the same epitope of the same rotavirusprotein, e.g. VP8*, of different serotypes is preferred.

In further preferred embodiments of this aspect of the invention the twoor more coding regions encodes epitopes of rotavirus proteins derivedfrom the same serotype of rotavirus. It is possible that the m RNAsequence encodes different epitopes of the same rotavirus protein,preferably VP8*, or that the mRNA sequence encodes two or more copies(or repeats) of the same coding region encoding the same epitope or thesame rotavirus protein, preferably VP8*, of the same serotype. It isalso possible that the mRNA construct encodes epitopes of two or moredifferent rotavirus proteins of the same or different serotypes.

To further illustrate this aspect of the invention the followingexamples of preferred inventive mRNA sequences comprise two or morerepeats, for example four repeats (i.e. in summary four times the samesequence), of the same coding region encoding at least one epitope of aVP8* protein, or a fragment, variant or derivative thereof, of a virusof the genus rotavirus. The VP8* coding regions of the repeats arepreferably combined with sequence sections encoding a helper peptide,especially P2 helper peptide of tetanus toxin, and/or a signal peptidefor co-translational transport into the ER, especially tissueplasminogen activator, and/or a transmembrane domain, and/or a peptideor protein enabling VLP formation, especially derived from WHcAg, and/ora peptide linker, as disclosed above or fragments, variants orderivatives thereof.

In preferred embodiments the inventive mRNA sequence comprises at leastone sequence section encoding a peptide linker according to SEQ ID NOs:3174-3176 Preferably, the predicted N-glycosylation sites are mutated,as described above.

VP8* is a relatively small antigen. By the use of repeats of the codingregion within the inventive mRNA sequence it is possible to increaseantigen clustering, thereby increasing immune responses. Generally, thenumber of repeats is only limited by practical consideration. Forexample, four repeats of the VP8* coding region is suitable for theinventive mRNA sequence. In a particularly preferred embodiment of theinvention the secreted form described above was used as a basis forthis, so the repeat design also contains one N-terminal signal peptide(tissue plasminogen activator) followed by four repeats of VP8*, inwhich the predicted N-glycosylation sites were mutated (see thereforethe preferred construct “secreted-repeat” in FIG. 1 ). Preferredconstructs refer to the serotypes P[4], P[6] and P[8].

In a preferred embodiment, the repeats of the coding region may beseparated by a peptide linker as described above. The inventive mRNAsequence therefore may comprise at least one sequence section encoding apeptide linker according to SEQ ID NOs: 3174-3176

Preferred amino acid sequences are shown in Table 18.

TABLE 18 amino acid sequences comprising a signal peptide, 4 repeats ofmutated (mutated glycosylation sites) VP8* and the P2 helper peptideAmino acids of VP8* SEQ ID Nos. 2-240 825-827

Preferably, the inventive mRNA sequence comprises a coding region whichencodes for the amino acid sequences according to any one of Table 18 oramino acid sequences which show an identity of at least 60%, preferablyat least 70%, more preferably at least 80%, more preferably at least90%, more preferably at least 95%, or most preferably at least 99% tothe sequences as shown in Table 18.

Additionally to the amino acid sequences in Table 18 also the inventivemRNA sequences encoding the respective amino acid sequences aredisclosed. In this context it is possible to apply unmodified nucleotidesequences or mRNA sequences wherein the G/C content of the coding regionis increased compared to the G/C content of the coding region of itsparticular wild type coding sequence, i.e. the unmodified mRNA.Furthermore, mRNA sequences additionally comprising UTR sequences aredisclosed in Table 19.

In especially preferred designs the inventive mRNA sequence comprisesUTRs e.g. as 5′-UTR a 5′-UTR derived from 32 L TOP UTR (according to SEQID NO. 3189), as 3′-UTR a 3′-UTR derived from human albumin 3′-UTR(according to SEQ ID NO. 3205), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 19 Column D. Alternatively the inventivemRNA sequence comprises a 3′-UTR derived from alpha globin 3′-UTR(according to SEQ ID NO. 3199), a histone stem-loop (according to SEQ IDNO. 3207), a poly(A) sequence, and a poly(C) sequence. Respective mRNAsequences are shown in Table 19 Column C.

TABLE 19 mRNA sequences encoding a signal peptide, 4 repeats of mutated(mutated glycosylation sites) VP8* and the P2 helper peptide SEQ IDNO(s) Amino acids A B C D 2-240 866-868 2374-2376 3134-3136 Column A =SEQ ID Nos. regarding wild type CDS (coding sequences) Column B = SEQ IDNos. regarding CDS (coding sequences) with an increased G/C contentColumn C = SEQ ID Nos. regarding mRNA sequences comprising a CDS with anincreased G/C content and comprising a 3′-UTR derived from alpha globin(according to SEQ ID No. 3199), a histon stem-loop sequence (accordingto SEQ ID No. 3207) and a poly(A) sequence and a poly(C) sequence.Column D = SEQ ID Nos. regarding mRNA sequences comprising a CDS with anincreased G/C content and comprising a 5′-UTR derived from 32 L TOP UTR(according to SEQ ID NO. 3189), a 3′-UTR derived from albumin 3′-UTR(according to SEQ ID No. 3205), a histon stem-loop sequence (accordingto SEQ ID No. 3207) and a poly(A) sequence and a poly(C) sequence.

Preferably, the inventive mRNA sequence comprises or consists of anucleotide sequence as shown in Table 19 or which is at least 60%identical, more preferably at least 70% identical, more preferably atleast 80% identical, more preferably at least 85%, more preferably atleast 90% identical, more preferably at least 95% identical, or mostpreferably at least 99% identical to any of the sequences shown in Table19.

The inventive mRNA sequence comprising two or more coding regions eachencoding at least one epitope of a rotavirus protein as mentioned in theprevious paragraphs may also be designed as an mRNA sequence with amulticistronic coding region, wherein the term “multicistronic” in thiscontext is meant to describe an mRNA sequence that codes for two or more(same or different) translation products. By the use of an mRNA sequencewith a multicistronic coding region it is possible to induce immuneresponses against different rotavirus serotypes and/or against differentrotavirus antigens/proteins. Generally, it is known that in the contextof rotavirus infections there is no cross-protection against infectionbetween the different serotypes. The inventive mRNA sequence accordingto this aspect of the invention is multivalent to confer full protectionagainst different rotavirus infections.

Each coding region may comprise independently from each other a helperpeptide and/or a signal peptide and/or a transmembrane domain, and/or apeptide or protein enabling VLP formation, and/or a peptide linker. Ineach coding region at least one or all predicted glycosylation sites maybe removed.

Preferably, the inventive mRNA sequence according to this aspect of theinvention combines the coding sequence of two or more VP8* proteinsderived from different serotypes, e.g. serotype P[4], P[6] and P[8].Nevertheless, it is also possible to combine the coding regions of VP8*(or other rotavirus proteins) of one or more serotypes with the codingregions of one or more different antigens of rotavirus, wherein alsoantigens of different serotypes may be applied.

For the design of a multicistronic mRNA construct according to theinvention the at least two coding regions (coding sections), eachencoding at least one epitope of a rotavirus protein, are separated byintermitting sequences, for example by internal ribosomal entry sites(IRES). Preferred examples are IRES of encephalomyocarditis virus (EMCV)and/or IRES of foot-and-mouth disease virus (FMDV). By separating thecoding sections by intermitting sequences it is ensured, that eachcoding section is translated into a separate peptide or protein which isable to induce an immune response. Another possibility to separate thecoding sections of the multicistronic coding region is the use offurther intermitting sequence sections encoding for a self-cleavingpeptide. Preferred examples of self-cleaving peptides are F2A peptidederived from foot-and-mouth diseases virus or self-cleaving peptidesfrom equine rhinitis A virus or Thosea asigna virus or porcineteschovirus-1.

A preferred example of an intermitting sequence is the nucleotidesequence of EMCV-IRES-4 according to SEQ ID NO: 3181 that may serve as abasis for advantageous designs of the inventive mRNA sequence.

Another preferred example is the nucleotide sequence of FMDV IRES strainC, isolate c-s8c1 (drived from GenBank: AJ133357.1; GI:6318187; 5′ UTR578-1038; start codon defined from PMID: 8389904) according to SEQ IDNO: 3182 may serve as a basis for advantageous designs of the inventivemRNA sequence, wherein the alternative start codon on position 454-456was removed by nucleotide changing T454A. Moreover, a point mutationaccording to PMID: 8389904: T86C was introduced.

Moreover, the following sequences encoding self-cleaving peptides may beused, wherein SEQ ID NOs: 3177 and 3179 refer to F2A mod 1 and SEQ IDNOs: 3178 and 3180 refer to F2A mod 2.

Preferably, the inventive mRNA sequence comprises sequences according toany one of the SEQ ID NOs: 3179-3180.

It is further contemplated that different types of intermittingsequences (e.g. IRES sequences and sequences coding for self-cleavingpeptides) can be used in combination in one multicistronic mRNAconstruct. For example, in a multicistronic construct comprising threecoding regions, the intermitting sequence between the first and secondcoding region may be an IRES and the intermitting sequence between thesecond and third coding region may encode a self-cleaving peptide.

In particularly preferred embodiments of this aspect of the invention,the basic (P2 VP8*), secreted (P2 VP8* plus signal peptide) andmembrane-bound (P2 VP8* plus transmembrane domain of Influenza HA plussignal peptide) forms or constructs of P2 VP8* of the serotypes P[8] andP[6] and P[4] as described above or as illustrated in FIG. 1 are encodedin multicistronic constructs either separated via an IRES derived fromEMCV or an IRES derived from FMDV. Since the function of IRES ismediated on the basis of their nucleotide sequence, the IRES sequencesin the final constructs are not sequence-optimized. Alternatively, theself-cleaving peptide F2A peptide derived from FMDV is employed infurther preferred embodiments.

In a particularly preferred embodiment a multicistronic mRNA sequenceencodes VP8* of serotype P[8] and serotype P[6] and serotype P[4].

Particularly preferred mRNA sequences are shown in Table 20.

TABLE 20 mRNA sequences encoding multicistronically P2 helper peptidetogether with VP8* (wild type or mutated; full-length and shortenedforms) of serotype P[8] and serotype P[6] and serotype P[4] separated byan IRES sequence or by a sequence encoding a self-cleaving peptide andoptionally encoding a transmembrane domain SEQ ID NO(s) Amino acids ofVP8* A B C D 2-240 wild type 869-871 2377-2379 3137-3139 2-240glycosylation sites mutated 872-874 2380-2382 3140-3142 2-240glycosylation sites 875-877 2383-2385 3143-3145 mutated and encoding atransmembrane domain Column A = SEQ ID Nos. regarding wild type CDS(coding sequences) Column B = SEQ ID Nos. regarding CDS (codingsequences) with an increased G/C content Column C = SEQ ID Nos.regarding mRNA sequences comprising a CDS with an increased G/C contentand comprising a 3′-UTR derived from alpha globin (according to SEQ IDNo. 3199), a histon stem-loop sequence (according to SEQ ID No. 3207)and a poly(A) sequence and a poly(C) sequence. Column D = SEQ ID Nos.regarding mRNA sequences comprising a CDS with an increased G/C contentand comprising a 5′-UTR derived from 32 L TOP UTR (according to SEQ IDNO. 3189), a 3′-UTR derived from albumin 3′-UTR (according to SEQ ID No.3205), a histon stem-loop sequence (according to SEQ ID No. 3207) and apoly(A) sequence and a poly(C) sequence.

Preferably, the inventive mRNA sequence comprises or consists of anucleotide sequence which is at least 60% identical, more preferably atleast 70% identical, more preferably at least 80% identical, morepreferably at least 90% identical, more preferably at least 95%identical, or most preferably at least 99% identical to any of thesequences as shown in Table 20.

According to an especially preferred embodiment of the invention, the atleast one coding region of the mRNA sequence is modified. Preferably themRNA is stabilized by modifying and increasing the G (guanosine)/C(cytosine) content of the coding region of the mRNA thereof. Therein,the G/C content of the coding region of the mRNA is increased comparedto the G/C content of the coding region of its particular wild typecoding sequence, i.e. the unmodified mRNA. However, the encoded aminoacid sequence of the mRNA is preferably not modified compared to theencoded amino acid sequence of the particular wild type/unmodified mRNA.The term wild type is to be understood according to the skilled person'sgeneral understanding in the art and denotes the nucleic acid or themRNA in the form of its occurrence in nature without any mutation ornucleotide amendment by man.

The modification of the G/C content of the inventive mRNA sequence isbased on the fact that RNA sequences having an increased G (guanosine)/C(cytosine) content are more stable than RNA sequences having anincreased A (adenosine)/U (uracil) content. The codons of a codingsequence or a whole RNA might therefore be varied compared to the wildtype coding sequence or mRNA, such that they include an increased amountof G/C nucleotides while the translated amino acid sequence is retained.In respect to the fact that several codons code for one and the sameamino acid (so-called degeneration of the genetic code), the mostfavourable codons for the stability can be determined (so-calledalternative codon usage). Preferably, the G/C content of the codingregion of the mRNA according to the invention is increased by at least7%, more preferably by at least 15%, particularly preferably by at least20%, compared to the G/C content of the coding region of the wild typeRNA. According to a specific embodiment at least 5%, 10%, 20%, 30%, 40%,50%, 60%, more preferably at least 70%, even more preferably at least80% and most preferably at least 90%, 95% or even 100% of thesubstitutable codons in the region coding for a protein or peptide asdefined herein or its fragment or variant thereof or the whole sequenceof the wild type mRNA sequence or coding sequence are substituted,thereby increasing the G/C content of said sequence. In this context, itis particularly preferable to increase the G/C content of the mRNA tothe maximum (i.e. 100% of the substitutable codons), in particular inthe coding region, compared to the wild type sequence.

By a further embodiment, the inventive mRNA sequence preferablycomprises at least one of the following structural elements: a 5′-and/or 3′-untranslated region element (UTR element), particularly a5′-UTR element which comprises or consists of a nucleic acid sequencewhich is derived from the 5′-UTR of a TOP gene or from a fragment,homolog or a variant thereof, or a 5′- and/or 3′-UTR element which maybe derivable from a gene that provides a stable mRNA or from a homolog,fragment or variant thereof; a histone stem-loop structure, preferably ahistone stem-loop in its 3′ untranslated region; a 5′-CAP structure; apoly-A tail (poly(A) sequence); or a poly(C) sequence as will beoutlined in more detail below.

In a preferred embodiment the mRNA comprises at least one 5′- or 3′-UTRelement. In this context an UTR element comprises or consists of anucleic acid sequence which is derived from the 5′- or 3′-UTR of anynaturally occurring gene or which is derived from a fragment, a homologor a variant of the 5′- or 3′-UTR of a gene. Preferably, the 5′- or3′-UTR element used according to the present invention is heterologousto the coding region of the inventive mRNA sequence. Even if 5′- or3′-UTR elements derived from naturally occurring genes are preferred,also synthetically engineered UTR elements may be used in the context ofthe present invention.

In a particularly preferred embodiment the inventive mRNA sequencefurther comprises at least on 3′-UTR element which is derived from a3′-UTR element of a gene, thereby providing a stabilization of the mRNA.Particularly preferred is a 3′-UTR element which comprises or consistsof a nucleic acid sequence derived from the 3′-UTR of a chordate gene,preferably a vertebrate gene, more preferably a mammalian gene, mostpreferably a human gene, or from a variant of the 3′-UTR of a chordategene, preferably a vertebrate gene, more preferably a mammalian gene,most preferably a human gene.

The term ‘3′-UTR element’ refers to a nucleic acid sequence whichcomprises or consists of a nucleic acid sequence that is derived from a3′-UTR or from a variant of a 3′-UTR. A 3′-UTR element in the sense ofthe present invention may represent the 3′-UTR of an mRNA. Thus, in thesense of the present invention, preferably, a 3′-UTR element may be the3′-UTR of an mRNA, preferably of an artificial mRNA, or it may be thetranscription template for a 3′-UTR of an mRNA. Thus, a 3′-UTR elementpreferably is a nucleic acid sequence which corresponds to the 3′-UTR ofan mRNA, preferably to the 3′-UTR of an artificial mRNA, such as an mRNAobtained by transcription of a genetically engineered vector construct.Preferably, the 3′-UTR element fulfils the function of a 3′-UTR orencodes a sequence which fulfils the function of a 3′-UTR.

Preferably, the mRNA comprises a 3′-UTR element which may be derivablefrom a gene that relates to an mRNA with an enhanced half-life (thatprovides a stable mRNA), for example a 3′-UTR element as defined anddescribed below.

In a particularly preferred embodiment, the 3′-UTR element comprises orconsists of a nucleic acid sequence which is derived from a 3′-UTR of agene selected from the group consisting of an albumin gene, an α-globingene, a β-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene,and a collagen alpha gene, such as a collagen alpha 1(I) gene, or from avariant of a 3′-UTR of a gene selected from the group consisting of analbumin gene, an α-globin gene, a β-globin gene, a tyrosine hydroxylasegene, a lipoxygenase gene, and a collagen alpha gene, such as a collagenalpha 1(I) gene according to SEQ ID NO: 1369-1390 of the patentapplication WO2013/143700 whose disclosure is incorporated herein byreference. In a particularly preferred embodiment, the 3′-UTR elementcomprises or consists of a nucleic acid sequence which is derived from a3′-UTR of an albumin gene, preferably a vertebrate albumin gene, morepreferably a mammalian albumin gene, most preferably a human albumingene according SEQ ID NO: 1369 of the patent application WO2013/143700.The mRNA sequence may comprise or consist of a nucleic acid sequencewhich is derived from the 3′-UTR of the human albumin gene according toGenBank Accession number NM_000477.5, or from a fragment or variantthereof.

In this context it is particularly preferred that the inventive mRNAsequence comprises a 3′-UTR element comprising a corresponding RNAsequence derived from the nucleic acids according to SEQ ID NO:1369-1390 of the patent application WO2013/143700 or a fragment, homologor variant thereof.

Most preferably the 3′-UTR element comprises the nucleic acid sequencederived from a fragment of the human albumin gene according to SEQ IDNO: 1376 of the patent application WO2013/143700.

In another particularly preferred embodiment, the 3′-UTR elementcomprises or consists of a nucleic acid sequence which is derived from a3′-UTR of an α-globin or β-globin gene, preferably a vertebrate α- orβ-globin gene, more preferably a mammalian α- or β-globin gene, mostpreferably a human α- or β-globin gene according to SEQ ID NO: 1370 ofthe patent application WO2013/143700 (3′-UTR of Homo sapiens hemoglobin,alpha 1 (HBA1)), or according to SEQ ID NO: 1371 of the patentapplication WO2013/143700 (3′-UTR of Homo sapiens hemoglobin, alpha 2(HBA2)), or according to SEQ ID NO: 1372 of the patent applicationWO2013/143700 (3′-UTR of Homo sapiens hemoglobin, beta (HBB)).

For example, the 3′-UTR element may comprise or consist of the center,α-complex-binding portion of the 3′-UTR of an α-globin gene,corresponding to SEQ ID NO: 1393 of the patent applicationWO2013/143700.

In this context it is particularly preferred that the 3′-UTR element ofthe inventive mRNA sequence comprises or consists of a corresponding RNAsequence of the nucleic acid sequence according to the above or ahomolog, a fragment or variant thereof.

The term ‘a nucleic acid sequence which is derived from the 3′-UTR of a[ . . . ] gene’ preferably refers to a nucleic acid sequence which isbased on the 3′-UTR sequence of a [ . . . ] gene or on a part thereof,such as on the 3′-UTR of an albumin gene, an α-globin gene, a β-globingene, a tyrosine hydroxylase gene, a lipoxygenase gene, or a collagenalpha gene, such as a collagen alpha 1(I) gene, preferably of an albumingene or on a part thereof. This term includes sequences corresponding tothe entire 3′-UTR sequence, i.e. the full length 3′-UTR sequence of agene, and sequences corresponding to a fragment of the 3′-UTR sequenceof a gene, such as an albumin gene, α-globin gene, β-globin gene,tyrosine hydroxylase gene, lipoxygenase gene, or collagen alpha gene,such as a collagen alpha 1(I) gene, preferably of an albumin gene.

The term ‘a nucleic acid sequence which is derived from a variant of the3′-UTR of a [ . . . ] gene’ preferably refers to a nucleic acid sequencewhich is based on a variant of the 3′-UTR sequence of a gene, such as ona variant of the 3′-UTR of an albumin gene, an α-globin gene, a β-globingene, a tyrosine hydroxylase gene, a lipoxygenase gene, or a collagenalpha gene, such as a collagen alpha 1(I) gene, or on a part thereof asdescribed above. This term includes sequences corresponding to theentire sequence of the variant of the 3′-UTR of a gene, i.e. the fulllength variant 3′-UTR sequence of a gene, and sequences corresponding toa fragment of the variant 3′-UTR sequence of a gene. A fragment in thiscontext preferably consists of a continuous stretch of nucleotidescorresponding to a continuous stretch of nucleotides in the full-lengthvariant 3′-UTR, which represents at least 20%, preferably at least 30%,more preferably at least 40%, more preferably at least 50%, even morepreferably at least 60%, even more preferably at least 70%, even morepreferably at least 80%, and most preferably at least 90% of thefull-length variant 3′-UTR. Such a fragment of a variant, in the senseof the present invention, is preferably a functional fragment of avariant as described herein.

In especially preferred embodiments of the inventive mRNA sequence the3′-UTR element is derived form a nucleic acid sequence according to SEQID NO: 3203 (3′-UTR of human albumin gene) or SEQ ID NO: 3199 (3′-UTR ofα-globin gene) or from a corresponding RNA sequence, a homolog, afragment of a variant thereof.

In a particularly preferred embodiment the mRNA sequence comprises atleast one 5′-untranslated region element (5′-UTR element) whichcomprises or consists of a nucleic acid sequence which is derived fromthe 5′-UTR of a TOP gene or which is derived from corresponding RNAsequence, a fragment, homolog or variant of the 5′-UTR of a TOP gene,wherein it is particularly preferred that the 5′-UTR element does notcomprise a TOP-motif or a 5′-TOP, as defined above.

In some embodiments, the nucleic acid sequence of the 5′-UTR elementwhich is derived from a 5′-UTR of a TOP gene terminates at its 3′-endwith a nucleotide located at position 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10upstream of the start codon (e.g. A(U/T)G) of the gene or mRNA it isderived from. Thus, the 5′-UTR element does not comprise any part of theprotein coding region. Thus, preferably, the only protein coding part ofthe inventive mRNA is provided by the VP8* coding region and optionallyfurther sequence sections as described above.

The nucleic acid sequence which is derived from the 5′-UTR of a TOP geneis preferably derived from a eukaryotic TOP gene, preferably a plant oranimal TOP gene, more preferably a chordate TOP gene, even morepreferably a vertebrate TOP gene, most preferably a mammalian TOP gene,such as a human TOP gene.

For example, the 5′-UTR element is preferably selected from 5′-UTRelements comprising or consisting of a nucleic acid sequence which isderived from a nucleic acid sequence selected from the group consistingof SEQ ID NOs: 1-1363, SEQ ID NO: 1395, SEQ ID NO: 1421 and SEQ ID NO:1422 of the patent application WO2013/143700, whose disclosure isincorporated herein by reference, from the homologs of SEQ ID NOs:1-1363, SEQ ID NO: 1395, SEQ ID NO: 1421 and SEQ ID NO: 1422 of thepatent application WO2013/143700, from a variant thereof, or preferablyfrom a corresponding RNA sequence. The term “homologs of SEQ ID NOs:1-1363, SEQ ID NO: 1395, SEQ ID NO: 1421 and SEQ ID NO: 1422 of thepatent application WO2013/143700” refers to sequences of other speciesthan Homo sapiens, which are homologous to the sequences according toSEQ ID NOs: 1-1363, SEQ ID NO: 1395, SEQ ID NO: 1421 and SEQ ID NO: 1422of the patent application WO2013/143700.

In a preferred embodiment, the 5′-UTR element comprises or consists of anucleic acid sequence which is derived from a nucleic acid sequenceextending from nucleotide position 5 (i.e. the nucleotide that islocated at position 5 in the sequence) to the nucleotide positionimmediately 5′ to the start codon (located at the 3′ end of thesequences), e.g. the nucleotide position immediately 5′ to the ATGsequence, of a nucleic acid sequence selected from SEQ ID NOs: 1-1363,SEQ ID NO: 1395, SEQ ID NO: 1421 and SEQ ID NO: 1422 of the patentapplication WO2013/143700, from the homologs of SEQ ID NOs: 1-1363, SEQID NO: 1395, SEQ ID NO: 1421 and SEQ ID NO: 1422 of the patentapplication WO2013/143700 from a variant thereof, or a corresponding RNAsequence. It is particularly preferred that the 5′-UTR element isderived from a nucleic acid sequence extending from the nucleotideposition immediately 3′ to the 5′-TOP to the nucleotide positionimmediately 5′ to the start codon (located at the 3′ end of thesequences), e.g. the nucleotide position immediately 5′ to the ATGsequence, of a nucleic acid sequence selected from SEQ ID NOs: 1-1363,SEQ ID NO: 1395, SEQ ID NO: 1421 and SEQ ID NO: 1422 of the patentapplication WO2013/143700, from the homologs of SEQ ID NOs: 1-1363, SEQID NO: 1395, SEQ ID NO: 1421 and SEQ ID NO: 1422 of the patentapplication WO2013/143700, from a variant thereof, or a correspondingRNA sequence.

In a particularly preferred embodiment, the 5′-UTR element comprises orconsists of a nucleic acid sequence which is derived from a 5′-UTR of aTOP gene encoding a ribosomal protein or from a variant of a 5′-UTR of aTOP gene encoding a ribosomal protein. For example, the 5′-UTR elementcomprises or consists of a nucleic acid sequence which is derived from a5′-UTR of a nucleic acid sequence according to any of SEQ ID NOs: 67,170, 193, 244, 259, 554, 650, 675, 700, 721, 913, 1016, 1063, 1120,1138, and 1284-1360 of the patent application WO2013/143700, acorresponding RNA sequence, a homolog thereof, or a variant thereof asdescribed herein, preferably lacking the 5′-TOP motif. As describedabove, the sequence extending from position 5 to the nucleotideimmediately 5′ to the ATG (which is located at the 3′end of thesequences) corresponds to the 5′-UTR of said sequences. Preferably, the5′-UTR element comprises or consists of a nucleic acid sequence which isderived from a 5′-UTR of a TOP gene encoding a ribosomal large protein(RPL) or from a homolog, a fragment or variant of a 5′-UTR of a TOP geneencoding a ribosomal large protein (RPL). For example, the 5′-UTRelement comprises or consists of a nucleic acid sequence which isderived from a 5′-UTR of a nucleic acid sequence according to any of SEQID NOs: 67, 259, 1284-1318, 1344, 1346, 1348-1354, 1357, 1358, 1421 and1422 of the patent application WO2013/143700, a corresponding RNAsequence, a homolog thereof, or a variant thereof as described herein,preferably lacking the 5′-TOP motif.

In a particularly preferred embodiment, the 5′-UTR element comprises orconsists of a nucleic acid sequence which is derived from the 5′-UTR ofa ribosomal protein Large 32 gene, preferably from a vertebrateribosomal protein Large 32 (L32) gene, more preferably from a mammalianribosomal protein Large 32 (L32) gene, most preferably from a humanribosomal protein Large 32 (L32) gene, or from a variant of the 5′-UTRof a ribosomal protein Large 32 gene, preferably from a vertebrateribosomal protein Large 32 (L32) gene, more preferably from a mammalianribosomal protein Large 32 (L32) gene, most preferably from a humanribosomal protein Large 32 (L32) gene, wherein preferably the 5′-UTRelement does not comprise the 5′-TOP of said gene. A preferred sequencefor a 5′-UTR element corresponds to SEQ ID NO: 1368 of the patentapplication WO2013/143700.

In a preferred embodiment of the inventive mRNA construct the 5′-UTRelement is derived from a nucleic acid sequence according to SEQ ID NO:3189 or from a corresponding RNA sequence, a homolog, a fragment or avariant thereof.

Accordingly, in a particularly preferred embodiment, the 5′-UTR elementcomprises or consists of a nucleic acid sequence which has an identityof at least about 20%, preferably of at least about 40%, preferably ofat least about 50%, preferably of at least about 60%, preferably of atleast about 70%, more preferably of at least about 80%, more preferablyof at least about 90%, even more preferably of at least about 95%, evenmore preferably of at least about 99% to the nucleic acid sequence asmentioned above, wherein, preferably, the fragment is as describedabove, i.e. being a continuous stretch of nucleotides representing atleast 20% etc. of the full-length 5′-UTR. Preferably, the fragmentexhibits a length of at least about 20 nucleotides or more, preferablyof at least about 30 nucleotides or more, more preferably of at leastabout 40 nucleotides or more. Preferably, the fragment is a functionalfragment as described herein.

In some embodiments, the inventive mRNA sequence comprises a 5′-UTRelement which comprises or consists of a nucleic acid sequence which isderived from the 5′-UTR of a vertebrate TOP gene, such as a mammalian,e.g. a human TOP gene, selected from RPSA, RPS2, RPS3, RPS3A, RPS4,RPS5, RPS6, RPS7, RPS8, RPS9, RPS10, RPS11, RPS12, RPS13, RPS14, RPS15,RPS15A, RPS16, RPS17, RPS18, RPS19, RPS20, RPS21, RPS23, RPS24, RPS25,RPS26, RPS27, RPS27A, RPS28, RPS29, RPS30, RPL3, RPL4, RPL5, RPL6, RPL7,RPL7A, RPL8, RPL9, RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL14,RPL15, RPL17, RPL18, RPL18A, RPL19, RPL21, RPL22, RPL23, RPL23A, RPL24,RPL26, RPL27, RPL27A, RPL28, RPL29, RPL30, RPL31, RPL32, RPL34, RPL35,RPL35A, RPL36, RPL36A, RPL37, RPL37A, RPL38, RPL39, RPL40, RPL41, RPLP0,RPLP1, RPLP2, RPLP3, RPLP0, RPLP1, RPLP2, EEF1A1, EEF1B2, EEF1D, EEF1G,EEF2, EIF3E, EIF3F, EIF3H, EIF2S3, EIF3C, EIF3K, EIF3EIP, EIF4A2,PABPC1, HNRNPA1, TPT1, TUBB1, UBA52, NPM1, ATP5G2, GNB2L1, NME2, UQCRB,or from a homolog or variant thereof, wherein preferably the 5′-UTRelement does not comprise a TOP-motif or the 5′-TOP of said genes, andwherein optionally the 5′-UTR element starts at its 5′-end with anucleotide located at position 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10downstream of the 5′ terminal oligopyrimidine tract (TOP) and whereinfurther optionally the 5′-UTR element which is derived from a 5′-UTR ofa TOP gene terminates at its 3′-end with a nucleotide located atposition 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 upstream of the start codon(A(U/T)G) of the gene it is derived from.

In further particularly preferred embodiments, the 5′-UTR elementcomprises or consists of a nucleic acid sequence which is derived fromthe 5′-UTR of a ribosomal protein Large 32 gene (RPL32), a ribosomalprotein Large 35 gene (RPL35), a ribosomal protein Large 21 gene(RPL21), an ATP synthase, H+ transporting, mitochondrial F1 complex,alpha subunit 1, cardiac muscle (ATP5A1) gene, an hydroxysteroid(17-beta) dehydrogenase 4 gene (HSD17B4), an androgen-induced 1 gene(AIG1), cytochrome c oxidase subunit Vic gene (COX6C), or aN-acylsphingosine amidohydrolase (acid ceramidase) 1 gene (ASAH1) orfrom a variant thereof, preferably from a vertebrate ribosomal proteinLarge 32 gene (RPL32), a vertebrate ribosomal protein Large 35 gene(RPL35), a vertebrate ribosomal protein Large 21 gene (RPL21), avertebrate ATP synthase, H+ transporting, mitochondrial F1 complex,alpha subunit 1, cardiac muscle (ATP5A1) gene, a vertebratehydroxysteroid (17-beta) dehydrogenase 4 gene (HSD17B4), a vertebrateandrogen-induced 1 gene (AIG1), a vertebrate cytochrome c oxidasesubunit Vic gene (COX6C), or a vertebrate N-acylsphingosineamidohydrolase (acid ceramidase) 1 gene (ASAH1) or from a variantthereof, more preferably from a mammalian ribosomal protein Large 32gene (RPL32), a ribosomal protein Large 35 gene (RPL35), a ribosomalprotein Large 21 gene (RPL21), a mammalian ATP synthase, H+transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle(ATP5A1) gene, a mammalian hydroxysteroid (17-beta) dehydrogenase 4 gene(HSD17B4), a mammalian androgen-induced 1 gene (AIG1), a mammaliancyto-chrome c oxidase subunit Vic gene (COX6C), or a mammalianN-acylsphingosine ami-dohydrolase (acid ceramidase) 1 gene (ASAH1) orfrom a variant thereof, most preferably from a human ribosomal proteinLarge 32 gene (RPL32), a human ribosomal protein Large 35 gene (RPL35),a human ribosomal protein Large 21 gene (RPL21), a human ATP syn-thase,H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiacmuscle (ATP5A1) gene, a human hydroxysteroid (17-beta) dehydrogenase 4gene (HSD17B4), a human androgen-induced 1 gene (AIG1), a humancytochrome c oxidase subunit Vic gene (COX6C), or a humanN-acylsphingosine amidohydrolase (acid ceramidase) 1 gene (ASAH1) orfrom a variant thereof, wherein preferably the 5′-UTR element does notcomprise the 5′-TOP of said gene.

Accordingly, in a particularly preferred embodiment, the 5′-UTR elementcomprises or consists of a nucleic acid sequence which has an identityof at least about 40%, preferably of at least about 50%, preferably ofat least about 60%, preferably of at least about 70%, more preferably ofat least about 80%, more preferably of at least about 90%, even morepreferably of at least about 95%, even more preferably of at least about99% to the nucleic acid sequence according to SEQ ID NO: 1368, or SEQ IDNOs: 1412-1420 of the patent application WO2013/143700, or acorresponding RNA sequence, or wherein the at least one 5′-UTR elementcomprises or consists of a fragment of a nucleic acid sequence which hasan identity of at least about 20%, preferably of at least about 40%,preferably of at least about 50%, preferably of at least about 60%,preferably of at least about 70%, more preferably of at least about 80%,more preferably of at least about 90%, even more preferably of at leastabout 95%, even more preferably of at least about 99% to the nucleicacid sequence according to SEQ ID NO: 1368, or SEQ ID NOs: 1412-1420 ofthe patent application WO2013/143700, wherein, preferably, the fragmentis as described above, i.e. being a continuous stretch of nucleotidesrepresenting at least 20% etc. of the full-length 5′-UTR. Preferably,the fragment exhibits a length of at least about 20 nucleotides or more,preferably of at least about 30 nucleotides or more, more preferably ofat least about 40 nucleotides or more. Preferably, the fragment is afunctional fragment as described herein.

Accordingly, in a particularly preferred embodiment, the 5′-UTR elementcomprises or consists of a nucleic acid sequence which has an identityof at least about 20%, preferably of at least about 40%, preferably ofat least about 50%, preferably of at least about 60%, preferably of atleast about 70%, more preferably of at least about 80%, more preferablyof at least about 90%, even more preferably of at least about 95%, evenmore preferably of at least about 99% to the nucleic acid sequenceaccording SEQ ID NO: 1414 of the patent application WO2013/143700(5′-UTR of ATP5A1 lacking the 5′ terminal oligopyrimidine tract) orpreferably to a corresponding RNA sequence, wherein, preferably, thefragment is as described above, i.e. being a continuous stretch ofnucleotides representing at least 20% etc. of the full-length 5′-UTR.Preferably, the fragment exhibits a length of at least about 20nucleotides or more, preferably of at least about 30 nucleotides ormore, more preferably of at least about 40 nucleotides or more.Preferably, the fragment is a functional fragment as described herein.

Preferably, the at least one 5′-UTR element and the at least one 3′-UTRelement act synergistically to increase protein production from theinventive mRNA sequence as described above.

In a particularly preferred embodiment, the inventive mRNA sequencecomprises a histone stem-loop sequence/structure. Such histone stem-loopsequences are preferably selected from histone stem-loop sequences asdisclosed in WO 2012/019780, whose disclosure is incorporated herewithby reference.

A histone stem-loop sequence, suitable to be used within the presentinvention, is preferably selected from at least one of the followingformulae (I) or (II):

-   -   formula (I) (stem-loop sequence without stem bordering        elements):

-   -   formula (II) (stem-loop sequence with stem bordering elements):

wherein:

-   -   stem1 or stem2 bordering elements N₁₋₆ is a consecutive sequence        of 1 to 6, preferably of 2 to 6, more preferably of 2 to 5, even        more preferably of 3 to 5, most preferably of 4 to 5 or 5 N,        wherein each N is independently from another selected from a        nucleotide selected from A, U, T, G and C, or a nucleotide        analogue thereof;    -   stem1 [N₀₋₂GN₃₋₅] is reverse complementary or partially reverse        complementary with element stem2, and is a consecutive sequence        between of 5 to 7 nucleotides;    -   wherein N₀₋₂ is a consecutive sequence of 0 to 2, preferably of        0 to 1, more preferably of 1 N, wherein each N is independently        from another selected from a nucleotide selected from A, U, T, G        and C or a nucleotide analogue thereof;    -   wherein N₃₋₅ is a consecutive sequence of 3 to 5, preferably of        4 to 5, more preferably of 4 N, wherein each N is independently        from another selected from a nucleotide selected from A, U, T, G        and C or a nucleotide analogue thereof, and    -   wherein G is guanosine or an analogue thereof, and may be        optionally replaced by a cytidine or an analogue thereof,        provided that its complementary nucleotide cytidine in stem2 is        replaced by guanosine;    -   loop sequence [N₀₋₄(U/T)N₀₋₄] is located between elements stem1        and stem2, and is a consecutive sequence of 3 to 5 nucleotides,        more preferably of 4 nucleotides;    -   wherein each N₀₋₄ is independent from another a consecutive        sequence of 0 to 4, preferably of 1 to 3, more preferably of 1        to 2 N, wherein each N is independently from another selected        from a nucleotide selected from A, U, T, G and C or a nucleotide        analogue thereof; and    -   wherein U/T represents uridine, or optionally thymidine;    -   stem2 [N₃₋₅CN₀₋₂] is reverse complementary or partially reverse        complementary with element stem1, and is a consecutive sequence        between of 5 to 7 nucleotides;    -   wherein N₃₋₅ is a consecutive sequence of 3 to 5, preferably of        4 to 5, more preferably of 4 N, wherein each N is independently        from another selected from a nucleotide selected from A, U, T, G        and C or a nucleotide analogue thereof;    -   wherein N₀₋₂ is a consecutive sequence of 0 to 2, preferably of        0 to 1, more preferably of 1 N, wherein each N is independently        from another selected from a nucleotide selected from A, U, T, G        or C or a nucleotide analogue thereof; and    -   wherein C is cytidine or an analogue thereof, and may be        optionally replaced by a guanosine or an analogue thereof        provided that its complementary nucleoside guanosine in stem1 is        replaced by cytidine;    -   wherein stem1 and stem2 are capable of base pairing with each        other forming a reverse complementary sequence, wherein base        pairing may occur between stem1 and stem2, e.g. by Watson-Crick        base pairing of nucleotides A and U/T or G and C or by        non-Watson-Crick base pairing e.g. wobble base pairing, reverse        Watson-Crick base pairing, Hoogsteen base pairing, reverse        Hoogsteen base pairing or are capable of base pairing with each        other forming a partially reverse complementary sequence,        wherein an incomplete base pairing may occur between stem1 and        stem2, on the basis that one or more bases in one stem do not        have a complementary base in the reverse complementary sequence        of the other stem.

According to a further preferred embodiment of the first inventiveaspect, the inventive mRNA sequence may comprise at least one histonestem-loop sequence according to at least one of the following specificformulae (Ia) or (IIa):

-   -   formula (Ia) (stem-loop sequence without stem bordering        elements):

-   -   formula (IIa) (stem-loop sequence with stem bordering elements):

wherein N, C, G, T and U are as defined above.

According to a further more particularly preferred embodiment of thefirst aspect, the inventive mRNA sequence may comprise at least onehistone stem-loop sequence according to at least one of the followingspecific formulae (Ib) or (IIb):

-   -   formula (Ib) (stem-loop sequence without stem bordering        elements):

-   -   formula (IIb) (stem-loop sequence with stem bordering elements):

wherein N, C, G, T and U are as defined above.

In a preferred embodiment of the inventive mRNA sequence the histonestem-loop sequence is derived from a nucleic acid sequence according toSEQ ID NO: 3206 or from a corresponding RNA sequence (according to SEQID NO: 3207), a homolog, a fragment or a variant thereof.

In a particular preferred embodiment, the inventive mRNA sequencecomprises, additionally to the rotavirus protein coding region andpossibly further sequence sections, as described above, a poly(A)sequence, also called poly-A tail, preferably at the 3′ terminus of themRNA. When present, such a poly(A) sequence comprises a sequence ofabout 25 to about 400 adenosine nucleotides, preferably a sequence ofabout 50 to about 400 adenosine nucleotides, more preferably a sequenceof about 50 to about 300 adenosine nucleotides, even more preferably asequence of about 50 to about 250 adenosine nucleotides, most preferablya sequence of about 60 to about 250 adenosine nucleotides. In thiscontext the term “about” refers to a deviation of ±10% of the value(s)it is attached to. Mostly preferred is a poly-A tail of 64 adenosinenucleotide. The poly(A) sequence is preferably located 3′ of the codingregion comprised in the mRNA according to the invention.

According to a further preferred embodiment, the inventive mRNA sequencecan be modified by a sequence of at least 10 cytosines, preferably atleast 20 cytosines, more preferably at least 30 cytosines (so-called“poly(C) sequence”). Particularly, the mRNA may contain a poly(C)sequence of typically about 10 to 200 cytosine nucleotides, preferablyabout 10 to 100 cytosine nucleotides, more preferably about 10 to 70cytosine nucleotides or even more preferably about 20 to 50 or even 20to 30 cytosine nucleotides. Mostly preferred is a poly(C) sequence of 30cytosine nucleotides. The poly(C) sequence is preferably located 3′ ofthe coding region, more preferably 3′ of an optional poly(A) sequencecomprised in the mRNA according to the present invention.

For further improvement of the resistance to e.g. in vivo degradation(e.g. by an exo- or endonuclease), the inventive mRNA sequence isprovided as a stabilized nucleic acid, e.g. in the form of a modifiednucleic acid. In this context the G/C content is preferably increased asoutlined above. According to further preferred embodiments of theinvention the mRNA is further stabilized, preferably by backbonemodifications, sugar modifications and/or base modifications. All ofthese modifications may be introduced into the mRNA without impairingthe mRNA's function to be translated in the host cell.

A backbone modification in the context of the present invention ispreferably a modification in which phosphates of the backbone of thenucleotides contained in the mRNA are chemically modified, e.g. anionicinternucleoside linkage, N3′→P5′ modifications, replacement ofnon-bridging oxygen atoms by boranes, neutral internucleoside linkage,amide linkage of the nucleosides, methylene(methylimino) linkages,formacetal and thioformacetal linkages, introduction of sulfonyl groups,or the like.

A sugar modification in the context of the present invention ispreferably a chemical modification of the sugar of the nucleotides ofthe mRNA, e.g. methylation of the ribose residue or the like.

Further details about the chemical modification of the RNA, especiallythe mRNA, will be apparent from the following, wherein the term “RNAmodification” as used herein may refer to chemical modificationscomprising sugar modifications, backbone modifications as well as basemodifications or lipid modifications. In this context, a modified RNAmolecule as defined herein may contain nucleotideanalogues/modifications, e.g. backbone modifications, sugarmodifications or base modifications. A backbone modification inconnection with the present invention is a modification, in whichphosphates of the backbone of the nucleotides contained in an RNAmolecule as defined herein are chemically modified. A sugar modificationin connection with the present invention is a chemical modification ofthe sugar of the nucleotides of the RNA molecule as defined herein.Furthermore, a base modification in connection with the presentinvention is a chemical modification of the base moiety of thenucleotides of the RNA molecule. In this context, nucleotide analoguesor modifications are preferably selected from nucleotide analogues,which are applicable for transcription and/or translation.

The modified nucleosides and nucleotides, which may be incorporated intoa modified RNA molecule as described herein, can be modified in thesugar moiety. For example, the 2′ hydroxyl group (OH) can be modified orreplaced with a number of different “oxy” or “deoxy” substituents.Examples of “oxy”-2′ hydroxyl group modifications include, but are notlimited to, alkoxy or aryloxy (—OR, e.g., R═H, alkyl, cycloalkyl, aryl,aralkyl, heteroaryl or sugar); polyethyleneglycols (PEG),—O(CH₂CH₂O)nCH₂CH₂OR; “locked” nucleic acids (LNA) in which the 2′hydroxyl is connected, e.g., by a methylene bridge, to the 4′ carbon ofthe same ribose sugar; and amino groups (—O-amino, wherein the aminogroup, e.g., NRR, can be alkylamino, dialkylamino, heterocyclyl,arylamino, diarylamino, heteroarylamino, or diheteroaryl amino, ethylenediamine, polyamino) or aminoalkoxy.

“Deoxy” modifications include hydrogen, amino (e.g. NH₂; alkylamino,dialkylamino, heterocyclyl, arylamino, diaryl amino, heteroaryl amino,diheteroaryl amino, or amino acid); or the amino group can be attachedto the sugar through a linker, wherein the linker comprises one or moreof the atoms C, N, and O.

The sugar group can also contain one or more carbons that possess theopposite stereochemical configuration than that of the correspondingcarbon in ribose. Thus, a modified RNA molecule can include nucleotidescontaining, for instance, arabinose as the sugar.

The phosphate backbone may further be modified in the modifiednucleosides and nucleotides, which may be incorporated into a modifiedRNA molecule as described herein. The phosphate groups of the backbonecan be modified by replacing one or more of the oxygen atoms with adifferent substituent. Further, the modified nucleosides and nucleotidescan include the full replacement of an unmodified phosphate moiety witha modified phosphate as described herein. Examples of modified phosphategroups include, but are not limited to, phosphorothioate,phosphoroselenates, borano phosphates, borano phosphate esters, hydrogenphosphonates, phosphoroamidates, alkyl or aryl phosphonates andphosphotriesters. Phosphorodithioates have both non-linking oxygensreplaced by sulfur. The phosphate linker can also be modified by thereplacement of a linking oxygen with nitrogen (bridgedphosphoroamidates), sulfur (bridged phosphorothioates) and carbon(bridged methylene-phosphonates).

The modified nucleosides and nucleotides, which may be incorporated intoa modified RNA molecule as described herein, can further be modified inthe nucleobase moiety. Examples of nucleobases found in RNA include, butare not limited to, adenine, guanine, cytosine and uracil. For example,the nucleosides and nucleotides described herein can be chemicallymodified on the major groove face. In some embodiments, the major groovechemical modifications can include an amino group, a thiol group, analkyl group, or a halo group.

In particularly preferred embodiments of the present invention, thenucleotide analogues/modifications are selected from base modifications,which are preferably selected from2-amino-6-chloropurineriboside-5′-triphosphate,2-Aminopurine-riboside-5′-triphosphate;2-aminoadenosine-5′-triphosphate,2′-Amino-2′-deoxycytidine-triphosphate, 2-thiocytidine-5′-triphosphate,2-thiouridine-5′-triphosphate, 2′-Fluorothymidine-5′-triphosphate,2′-O-Methyl inosine-5′-triphosphate 4-thiouridine-5′-triphosphate,5-aminoallylcytidine-5′-triphosphate,5-aminoallyluridine-5′-triphosphate, 5-bromocytidine-5′-triphosphate,5-bromouridine-5′-triphosphate,5-Bromo-2′-deoxycytidine-5′-triphosphate,5-Bromo-2′-deoxyuridine-5′-triphosphate, 5-iodocytidine-5′-triphosphate,5-Iodo-2′-deoxycytidine-5′-triphosphate, 5-iodouridine-5′-triphosphate,5-Iodo-2′-deoxyuridine-5′-triphosphate,5-methylcytidine-5′-triphosphate, 5-methyluridine-5′-triphosphate,5-Propynyl-2′-deoxycytidine-5′-triphosphate,5-Propynyl-2′-deoxyuridine-5′-triphosphate,6-azacytidine-5′-triphosphate, 6-azauridine-5′-triphosphate,6-chloropurineriboside-5′-triphosphate,7-deazaadenosine-5′-triphosphate, 7-deazaguanosine-5′-triphosphate,8-azaadenosine-5′-triphosphate, 8-azidoadenosine-5′-triphosphate,benzimidazole-riboside-5′-triphosphate,N1-methyladenosine-5′-triphosphate, N1-methylguanosine-5′-triphosphate,N6-methyladenosine-5′-triphosphate, 06-methylguanosine-5′-triphosphate,pseudouridine-5′-triphosphate, or puromycin-5′-triphosphate,xanthosine-5′-triphosphate. Particular preference is given tonucleotides for base modifications selected from the group ofbase-modified nucleotides consisting of5-methylcytidine-5′-triphosphate, 7-deazaguanosine-5′-triphosphate,5-bromocytidine-5′-triphosphate, and pseudouridine-5′-triphosphate.

In some embodiments, modified nucleosides include pyridin-4-oneribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine,4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine,3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine,5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine,1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine,1-taurinomethyl-4-thio-uridine, 5-methyl-uridine,1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine,2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine,2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine,dihydropseudouridine, 2-thio-dihydrouridine,2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine,4-methoxy-pseudouridine, and 4-methoxy-2-thio-pseudouridine.

In some embodiments, modified nucleosides include 5-aza-cytidine,pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine,5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine,1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine,2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine,4-thio-1-methyl-pseudoisocytidine,4-thio-1-methyl-1-deaza-pseudoisocytidine,1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine,5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine,2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine,4-methoxy-pseudoisocytidine, and 4-methoxy-1-methyl-pseudoisocytidine.

In other embodiments, modified nucleosides include 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine,7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine,7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine,1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine,N6-(cis-hydroxyisopentenyl)adenosine,2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine,N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine,2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine,7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine.

In other embodiments, modified nucleosides include inosine,1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine,7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine,6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine,6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine,1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine,8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine,N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.

In some embodiments, the nucleotide can be modified on the major grooveface and can include replacing hydrogen on C-5 of uracil with a methylgroup or a halo group. In specific embodiments, a modified nucleoside is5′-O-(1-Thiophosphate)-Adenosine, 5′-O-(1-Thiophosphate)-Cytidine,5′-O-(1-Thiophosphate)-Guanosine, 5′-O-(1-Thiophosphate)-Uridine or5′-O-(1-Thiophosphate)-Pseudouridine.

In further specific embodiments, a modified RNA may comprise nucleosidemodifications selected from 6-aza-cytidine, 2-thio-cytidine,α-thio-cytidine, Pseudo-iso-cytidine, 5-aminoallyl-uridine,5-iodo-uridine, N1-methyl-pseudouridine, 5,6-dihydrouridine,α-thio-uridine, 4-thio-uridine, 6-aza-uridine, 5-hydroxy-uridine,deoxy-thymidine, 5-methyl-uridine, Pyrrolo-cytidine, inosine,α-thio-guanosine, 6-methyl-guanosine, 5-methyl-cytidine,8-oxo-guanosine, 7-deaza-guanosine, N1-methyl-adenosine,2-amino-6-Chloro-purine, N6-methyl-2-amino-purine, Pseudo-iso-cytidine,6-Chloro-purine, N6-methyl-adenosine, α-thio-adenosine,8-azido-adenosine, 7-deaza-adenosine.

Further nucleotide analogues are such as those disclosed inWO2013/052523, WO2014093924 WO2015051173, WO2015/051169 andWO2015/089511.

According to a further embodiment, a modified RNA molecule as definedherein can contain a lipid modification. Such a lipid-modified RNAmolecule typically comprises an RNA molecule as defined herein. Such alipid-modified RNA molecule as defined herein typically furthercomprises at least one linker covalently linked with that RNA molecule,and at least one lipid covalently linked with the respective linker.Alternatively, the lipid-modified RNA molecule comprises at least oneRNA molecule as defined herein and at least one (bifunctional) lipidcovalently linked (without a linker) with that RNA molecule. Accordingto a third alternative, the lipid-modified RNA molecule comprises an RNAmolecule as defined herein, at least one linker covalently linked withthat RNA molecule, and at least one lipid covalently linked with therespective linker, and also at least one (bifunctional) lipid covalentlylinked (without a linker) with that RNA molecule. In this context, it isparticularly preferred that the lipid modification is present at theterminal ends of a linear RNA sequence.

According to another preferred embodiment of the invention, a modifiedRNA molecule as defined herein, can be modified by the addition of aso-called “5′-CAP” structure, namely by modification of the 5′-end of aRNA molecule.

A 5′-cap is an entity, typically a modified nucleotide entity, whichgenerally “caps” the 5′-end of a mature mRNA. A 5′-cap may typically beformed by a modified nucleotide, particularly by a derivative of aguanine nucleotide. Preferably, the 5′-cap is linked to the 5′-terminusvia a 5′-5′-triphosphate linkage. A 5′-cap may be methylated, e.g.m7GpppN, wherein N is the terminal 5′ nucleotide of the nucleic acidcarrying the 5′-cap, typically the 5′-end of an RNA. m7GpppN is the5′-CAP structure which naturally occurs in mRNA transcribed bypolymerase II and is therefore not considered as modification comprisedin a modified RNA in this context. Accordingly, a modified RNA of thepresent invention may comprise a m7GpppN as 5′-CAP, but additionally themodified RNA comprises at least one further modification as definedherein.

Further examples of 5′-cap structures include glyceryl, inverted deoxyabasic residue (moiety), 4′,5′ methylene nucleotide,1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide, carbocyclicnucleotide, 1,5-anhydrohexitol nucleotide, L-nucleotides,alpha-nucleotide, modified base nucleotide, threo-pentofuranosylnucleotide, acyclic 3′,4′-seco nucleotide, acyclic 3,4-dihydroxybutylnucleotide, acyclic 3,5 dihydroxypentyl nucleotide, 3′-3′-invertednucleotide moiety, 3′-3′-inverted abasic moiety, 3′-2′-invertednucleotide moiety, 3′-2′-inverted abasic moiety, 1,4-butanediolphosphate, 3′-phosphoramidate, hexylphosphate, aminohexyl phosphate,3′-phosphate, 3′phosphorothioate, phosphorodithioate, or bridging ornon-bridging methylphosphonate moiety. These modified 5′-CAP structuresare regarded as at least one modification in this context.

Particularly preferred modified 5′-cap structures are CAP1 (methylationof the ribose of the adjacent nucleotide of m7G), CAP2 (methylation ofthe ribose of the 2nd nucleotide downstream of the m7G), CAP3(methylation of the ribose of the 3rd nucleotide downstream of the m7G),CAP4 (methylation of the ribose of the 4th nucleotide downstream of them7G), ARCA (anti-reverse CAP analogue, modified ARCA (e.g.phosphothioate modified ARCA), inosine, N1-methyl-guanosine,2′-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine,2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

According to a further preferred embodiment of the invention, theinventive mRNA sequence is optimized for translation, preferablyoptimized for translation by replacing codons for less frequent tRNAs ofa given amino acid by codons for more frequently occurring tRNAs of therespective amino acid. This is based on the finding that the translationefficiency is also determined by a different frequency in the occurrenceof tRNAs in cells. Thus, if so-called “less frequent codons” are presentin the inventive mRNA to an increased extent, the corresponding modifiedRNA is translated to a significantly poorer degree than in the casewhere codons coding for more frequent tRNAs are present. Preferably, thecoding region of the mRNA is modified compared to the correspondingregion of the wild type RNA or coding sequence such that at least onecodon of the wild type sequence which codes for a tRNA which isrelatively rare or less frequent in the cell is exchanged for a codonwhich codes for a tRNA which is more or most frequent in the cell andcarries the same amino acid as the relatively rare or less frequenttRNA. By this modification, the sequences of the mRNA can be modifiedsuch that codons for which more frequently occurring tRNAs are availableare inserted. In other words, according to the invention, by thismodification all codons of the wild type sequence which code for a tRNAwhich is relatively rare in the cell can in each case be exchanged for acodon which codes for a respective tRNA which is relatively frequent inthe cell and which, in each case, carries the same amino acid as therelatively rare tRNA. Furthermore, it is particularly preferable to linkthe sequential G/C content which is increased, in particular maximized,in the mRNA with the “frequent” codons without modifying the amino acidsequence of the protein encoded by the coding region of the mRNA or ofthe coding region. This preferred embodiment allows provision of aparticularly efficiently translated and stabilized (modified) mRNA.

Substitutions, additions or eliminations of bases are preferably carriedout using a DNA matrix for preparation of the nucleic acid molecule bytechniques of the well known site directed mutagenesis or with anoligonucleotide ligation. In such a process, for preparation of theinventive mRNA sequence as defined herein a corresponding DNA moleculemay be transcribed in vitro. This DNA matrix preferably comprises asuitable promoter, e.g. a T7 or SP6 promoter, for in vitrotranscription, which is followed by the desired nucleotide sequence forthe at least one RNA to be prepared and a termination signal for invitro transcription. The DNA molecule, which forms the matrix of theinventive mRNA sequence of interest, may be prepared by fermentativeproliferation and subsequent isolation as part of a plasmid which can bereplicated in bacteria. Plasmids which may be mentioned as suitable forthe present invention are e.g. the plasmids pT7 Ts (GenBank accessionnumber AB255037.1; Lai et al., Development 1995; 121:2349-2360), pGEM®series, e.g. pGEM®-1 (GenBank accession number X65300.1; from Promega)and pSP64 (GenBank accession number X65327.1); cf. also Mezei andStorts, Purification of PCR Products, in: Griffin and Griffin (ed.), PCRTechnology: Current Innovation, CRC Press, Boca Raton, F L, 2001.

The mRNA may be prepared using any method known in the art, includingsynthetic methods such as e.g. solid phase synthesis, as well as invitro methods, such as in vitro transcription reactions.

In summary, in the context of the present invention, an mRNA istypically an RNA, which is composed of several structural elements, e.g.an optional 5′-CAP structure, an optional 5′-UTR region, an upstreampositioned ribosomal binding site followed by a coding region, anoptional 3′-UTR region, which may be followed by a poly-A tail (and/or apoly-C-tail). An mRNA may occur as a mono-, di-, or even multicistronicRNA, i.e. a RNA which carries the VP8* coding region or repeats of theVP8* coding region, and optionally further sequence sections asdescribed above. Such coding sequences in di-, or even multicistronicmRNA may be separated by at least one IRES sequence as described herein.

In particularly preferred embodiments of the invention the inventivemRNA sequence has the following structure, wherein the mRNA sequencecomprises, preferably in 5′- to 3′-direction:

-   -   a 5′-CAP structure, preferably m7GpppN;    -   at least one coding region encoding at least one epitope of a        protein, or a fragment, variant or derivative thereof, of a        virus of the genus rotavirus;    -   optionally a 3′-UTR element preferably comprising or consisting        of a nucleic acid sequence which is derived from a α-globin        gene, preferably comprising the corresponding RNA sequence of        the nucleic acid sequence according to SEQ ID NO: 3205 or SEQ ID        NO: 3199 or a homolog, a fragment or a variant thereof;    -   a poly(A) sequence, preferably comprising 64 adenosines;    -   optionally a poly(C) sequence, preferably comprising 30        cytosines; and    -   optionally a histone-stem-loop, preferably comprising the        corresponding RNA sequence to the nucleic acid sequence        according to SEQ ID NO: 3207.

In a further particularly preferred embodiment of the invention theinventive mRNA sequence has the following structure, wherein the mRNAsequence comprises, preferably in 5′- to 3′-direction:

-   -   a 5′-CAP structure, preferably m7GpppN;    -   optionally a 5′-UTR element preferably comprising or consisting        of a nucleic acid sequence which is derived from the 5′-UTR of a        TOP gene, preferably comprising or consisting of the        corresponding RNA sequence of the nucleic acid sequence        according to SEQ ID NO: 3189 or a homolog, a fragment or a        variant thereof;    -   at least one coding region encoding at least one epitope of a        protein, or a fragment, variant or derivative thereof, of a        virus of the genus rotavirus;    -   optionally a 3′-UTR element preferably comprising or consisting        of a nucleic acid sequence which is derived from a gene        providing a stable mRNA, preferably comprising or consisting of        the corresponding RNA sequence of a nucleic acid sequence        according to SEQ ID NO: 3205 or SEQ ID NO: 3199 or a homolog, a        fragment or a variant thereof;    -   a poly(A) sequence preferably comprising 64 adenosines;    -   optionally a poly(C) sequence, preferably comprising 30        cytosines; and    -   optionally a histone-stem-loop, preferably comprising the        corresponding RNA sequence of the nucleic acid sequence        according to SEQ ID NO: 3207.

With respect to the at least one coding region encoding at least oneepitope of a rotavirus protein it is referred to the above description.Preferably, the at least one coding region encodes respectively the VP8*protein of one or more rotavirus strains/serotypes (or fragments orvariants thereof) and preferably further sequence sections as describedabove, especially at least one sequence section encoding a helperpeptide and/or at least one sequence section encoding a signal peptidefor co-translational transport and/or at least one sequence sectionencoding a factor for antigen clustering/VLP formation and/or at leastone sequence section encoding a transmembrane domain and/or a sequencesection encoding a linker peptide.

In especially preferred embodiments the at least one coding regionencoding the at least one epitope of a rotavirus protein encodes VP8*,wherein preferably the mRNA sequence comprises at least one sequenceaccording to any one of SEQ ID NOs: 828-3146 or 3306-3593 or a sequencethat is at least 60% identical, more preferably at least 70% identical,more preferably at least 80% identical, more preferably at least 90%identical, more preferably at least 95% identical, or most preferably atleast 99% identical to any one of the sequences according to SEQ ID NOs:828-3146 or 3306-3593.

According to a main aspect of the invention the mRNA sequence asdescribed above is prepared for use as a vaccine, wherein the vaccine isespecially advantageous for use in prophylaxis and/or treatment ofrotavirus infections.

Furthermore, the invention relates to a composition that comprises atleast one mRNA (one or more mRNAs) comprising at least one of the mRNAsequences as defined above and optionally a pharmaceutically acceptablecarrier. In this context a pharmaceutically acceptable carrier orvehicle is an agent which typically may be used within a pharmaceuticalcomposition for facilitating administering of the components of thepharmaceutical composition to an individual. A pharmaceuticallyacceptable carrier or vehicle typically includes a liquid or non-liquidmaterial, which is mixed with the component(s) of the inventivecomposition. If the components of the inventive composition are providedin liquid form, the carrier will typically be pyrogen-free water,isotonic saline or buffered aqueous solutions, e.g phosphate, citrateetc. buffered solutions. Ringer or Ringer-Lactate solution isparticularly preferred as a liquid basis. It may be preferred that atleast one of the components of the inventive composition is prepared forsustained and/or delayed release.

In a preferred embodiment of the composition according to the invention,the at least one mRNA according to the invention is complexed with oneor more cationic or polycationic compounds, preferably with cationic orpolycationic polymers, cationic or polycationic peptides or proteins,e.g. protamine, cationic or polycationic polysaccharides and/or cationicor polycationic lipids.

According to a preferred embodiment, the at least one mRNA of thecomposition according to the present invention may be complexed withlipids to form one or more liposomes, lipoplexes, or lipidnanoparticles. Therefore, in one embodiment, the inventive compositioncomprises liposomes, lipoplexes, and/or lipid nanoparticles comprisingthe at least one mRNA.

Lipid-based formulations have been increasingly recognized as one of themost promising delivery systems for RNA due to their biocompatibilityand their ease of large-scale production. Cationic lipids have beenwidely studied as synthetic materials for delivery of RNA. After mixingtogether, nucleic acids are condensed by cationic lipids to formlipid/nucleic acid complexes known as lipoplexes. These lipid complexesare able to protect genetic material from the action of nucleases anddeliver it into cells by interacting with the negatively charged cellmembrane. Lipoplexes can be prepared by directly mixing positivelycharged lipids at physiological pH with negatively charged nucleicacids.

Conventional liposomes consist of a lipid bilayer that can be composedof cationic, anionic, or neutral (phospho)lipids and cholesterol, whichencloses an aqueous core. Both the lipid bilayer and the aqueous spacecan incorporate hydrophobic or hydrophilic compounds, respectively.Liposome characteristics and behaviour in vivo can be modified byaddition of a hydrophilic polymer coating, e.g. polyethylene glycol(PEG), to the liposome surface to confer steric stabilization.Furthermore, liposomes can be used for specific targeting by attachingligands (e.g., antibodies, peptides, and carbohydrates) to its surfaceor to the terminal end of the attached PEG chains (Front Pharmacol. 2015Dec. 1; 6:286).

Liposomes are colloidal lipid-based and surfactant-based deliverysystems composed of a phospholipid bilayer surrounding an aqueouscompartment. They may present as spherical vesicles and can range insize from 20 nm to a few microns. Cationic lipid-based liposomes areable to complex with negatively charged nucleic acids via electrostaticinteractions, resulting in complexes that offer biocompatibility, lowtoxicity, and the possibility of the large-scale production required forin vivo clinical applications. Liposomes can fuse with the plasmamembrane for uptake; once inside the cell, the liposomes are processedvia the endocytic pathway and the genetic material is then released fromthe endosome/carrier into the cytoplasm. Liposomes have long beenperceived as drug delivery vehicles because of their superiorbiocompatibility, given that liposomes are basically analogs ofbiological membranes, and can be prepared from both natural andsynthetic phospholipids (Int J Nanomedicine. 2014; 9: 1833-1843).

Cationic liposomes have been traditionally the most commonly usednon-viral delivery systems for oligonucleotides, including plasmid DNA,antisense oligos, and siRNA/small hairpin RNA-shRNA). Cationic lipids,such as DOTAP, (1,2-dioleoyl-3-trimethylammonium-propane) and DOTMA(N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl-ammonium methyl sulfate)can form complexes or lipoplexes with negatively charged nucleic acidsto form nanoparticles by electrostatic interaction, providing high invitro transfection efficiency. Furthermore, neutral lipid-basednanoliposomes for RNA delivery as e.g. neutral1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC)-based nanoliposomeswere developed. (Adv Drug Deliv Rev. 2014 February; 66: 110-116.).

Therefore, in one embodiment the at least one mRNA of the compositionaccording to the present invention is complexed with cationic lipidsand/or neutral lipids and thereby forms liposomes, lipid nanoparticles,lipoplexes or neutral lipid-based nanoliposomes.

In a preferred embodiment, the composition according to the inventioncomprises the mRNA comprising at least one mRNA sequence according tothe invention that is formulated together with a cationic orpolycationic compound and/or with a polymeric carrier. Accordingly, in afurther embodiment of the invention, it is preferred that the mRNA asdefined herein or any other nucleic acid comprised in the inventive(pharmaceutical) composition or vaccine is associated with or complexedwith a cationic or polycationic compound or a polymeric carrier,optionally in a weight ratio selected from a range of about 6:1 (w/w) toabout 0.25:1 (w/w), more preferably from about 5:1 (w/w) to about 0.5:1(w/w), even more preferably of about 4:1 (w/w) to about 1:1 (w/w) or ofabout 3:1 (w/w) to about 1:1 (w/w), and most preferably a ratio of about3:1 (w/w) to about 2:1 (w/w) of mRNA or nucleic acid to cationic orpolycationic compound and/or with a polymeric carrier; or optionally ina nitrogen/phosphate (N/P) ratio of mRNA or nucleic acid to cationic orpolycationic compound and/or polymeric carrier in the range of about0.1-10, preferably in a range of about 0.3-4 or 0.3-1, and mostpreferably in a range of about 0.5-1 or 0.7-1, and even most preferablyin a range of about 0.3-0.9 or 0.5-0.9. More preferably, the N/P ratioof the at least one mRNA to the one or more polycations is in the rangeof about 0.1 to 10, including a range of about 0.3 to 4, of about 0.5 to2, of about 0.7 to 2 and of about 0.7 to 1.5.

Therein, the mRNA as defined herein or any other nucleic acid comprisedin the (pharmaceutical) composition or vaccine according to theinvention can also be associated with a vehicle, transfection orcomplexation agent for increasing the transfection efficiency and/or theimmunostimulatory properties of the mRNA according to the invention orof optionally comprised further included nucleic acids.

In a particularly preferred embodiment of the composition the at leastone mRNA is at least partially associated with or complexed (formulated)with a cationic or polycationic compound and/or a polymeric carrier.Cationic compounds being particularly preferred agents in this contextinclude protamine, nucleoline, spermine or spermidine, or other cationicpeptides or proteins, such as poly-L-lysine (PLL), poly-arginine, basicpolypeptides, cell penetrating peptides (CPPs), including HIV-bindingpeptides, HIV-1 Tat (HIV), Tat-derived peptides, Penetratin, VP22derived or analog peptides, HSV VP22 (Herpes simplex), MAP, KALA orprotein transduction domains (PTDs), PpT620, proline-rich peptides,arginine-rich peptides, lysine-rich peptides, MPG-peptide(s), Pep-1,L-oligomers, Calcitonin peptide(s), Antennapedia-derived peptides(particularly from Drosophila antennapedia), pAntp, plsl, FGF,Lactoferrin, Transportan, Buforin-2, Bac715-24, SynB, SynB(1), pVEC,hCT-derived peptides, SAP, or histones. Protamine is particularlypreferred. Nevertheless, it is also possible that the mRNA of theinventive composition is naked or the composition comprises a mixture ofnaked and complexed mRNA.

Additionally, preferred cationic or polycationic proteins or peptidesmay be selected from the following proteins or peptides having thefollowing total formula (III):

(Arg)_(l);(Lys)_(m);(His)_(n);(Orn)_(o);(Xaa)_(x),  (formula (III))

wherein l+m+n+o+x=8-15, and l, m, n or o independently of each other maybe any number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14 or 15, provided that the overall content of Arg, Lys, His and Ornrepresents at least 50% of all amino acids of the oligopeptide; and Xaamay be any amino acid selected from native (=naturally occurring) ornon-native amino acids except of Arg, Lys, His or Orn; and x may be anynumber selected from 0, 1, 2, 3 or 4, provided, that the overall contentof Xaa does not exceed 50% of all amino acids of the oligopeptide.Particularly preferred cationic peptides in this context are e.g. Arg7,Arg8, Arg9, H3R9, R9H3, H3R9H3, YSSR9SSY, (RKH)4, Y(RKH)2R, etc. In thiscontext the disclosure of WO 2009/030481 is incorporated herewith byreference.

Further preferred cationic or polycationic compounds, which can be usedas transfection or complexation agent may include cationicpolysaccharides, for example chitosan, polybrene, cationic polymers,e.g. polyethyleneimine (PEI), cationic lipids, e.g. DOTMA:[1-(2,3-sioleyloxy)propyl)]-N,N,N-trimethylammonium chloride, DMRIE,di-C14-amidine, DOTIM, SAINT, DC-Chol, BGTC, CTAP, DOPC, DODAP, DOPE:Dioleyl phosphatidylethanol-amine, DOSPA, DODAB, DOIC, DMEPC, DOGS:Dioctadecylamidoglicylspermin, DIMRI: Dimyristo-oxypropyl dimethylhydroxyethyl ammonium bromide, DOTAP:dioleoyloxy-3-(trimethylammonio)propane, DC-6-14:O,O-ditetradecanoyl-N-(α-trimethylammonioacetyl)diethanolamine chloride,CLIP1: rac-[(2,3-dioctadecyloxypropyl)(2-hydroxyethyl)]-dimethylammoniumchloride, CLIP6:rac-[2(2,3-dihexadecyloxypropyl-oxymethyloxy)ethyl]trimethylammonium,CLIP9:rac-[2(2,3-dihexadecyloxypropyl-oxysuccinyloxy)ethyl]-trimethylammonium,oligofectamine, or cationic or polycationic polymers, e.g. modifiedpolyaminoacids, such as β-aminoacid-polymers or reversed polyamides,etc., modified polyethylenes, such as PVP(poly(N-ethyl-4-vinylpyridinium bromide)), etc., modified acrylates,such as pDMAEMA (poly(dimethylaminoethyl methylacrylate)), etc.,modified amidoamines such as pAMAM (poly(amidoamine)), etc., modifiedpolybetaaminoester (PBAE), such as diamine end modified 1,4 butanedioldiacrylate-co-5-amino-1-pentanol polymers, etc., dendrimers, such aspolypropylamine dendrimers or pAMAM based dendrimers, etc.,polyimine(s), such as PEI: poly(ethyleneimine), poly(propyleneimine),etc., polyallylamine, sugar backbone based polymers, such ascyclodextrin based polymers, dextran based polymers, chitosan, etc.,silan backbone based polymers, such as PMOXA-PDMS copolymers, etc.,blockpolymers consisting of a combination of one or more cationic blocks(e.g. selected from a cationic polymer as mentioned above) and of one ormore hydrophilic or hydrophobic blocks (e.g. polyethyleneglycole); etc.

According to a preferred embodiment, the composition of the presentinvention comprises the mRNA as defined herein and a polymeric carrier.A polymeric carrier used according to the invention might be a polymericcarrier formed by disulfide-crosslinked cationic components. Thedisulfide-crosslinked cationic components may be the same or differentfrom each other. The polymeric carrier can also contain furthercomponents. It is also particularly preferred that the polymeric carrierused according to the present invention comprises mixtures of cationicpeptides, proteins or polymers and optionally further components asdefined herein, which are crosslinked by disulfide bonds as describedherein. In this context, the disclosure of WO 2012/013326 isincorporated herewith by reference.

In this context, the cationic components, which form basis for thepolymeric carrier by disulfide-crosslinkage, are typically selected fromany suitable cationic or polycationic peptide, protein or polymersuitable for this purpose, particular any cationic or polycationicpeptide, protein or polymer capable of complexing the mRNA as definedherein or a further nucleic acid comprised in the composition, andthereby preferably condensing the mRNA or the nucleic acid. The cationicor polycationic peptide, protein or polymer, is preferably a linearmolecule, however, branched cationic or polycationic peptides, proteinsor polymers may also be used.

Every disulfide-crosslinking cationic or polycationic protein, peptideor polymer of the polymeric carrier, which may be used to complex themRNA according to the invention or any further nucleic acid comprised inthe (pharmaceutical) composition or vaccine of the present inventioncontains at least one —SH moiety, most preferably at least one cysteineresidue or any further chemical group exhibiting an —SH moiety, capableof forming a disulfide linkage upon condensation with at least onefurther cationic or polycationic protein, peptide or polymer as cationiccomponent of the polymeric carrier as mentioned herein.

As defined above, the polymeric carrier, which may be used to complexthe mRNA of the present invention or any further nucleic acid comprisedin the (pharmaceutical) composition or vaccine according to theinvention may be formed by disulfide-crosslinked cationic (orpolycationic) components. Preferably, such cationic or polycationicpeptides or proteins or polymers of the polymeric carrier, whichcomprise or are additionally modified to comprise at least one —SHmoiety, are selected from, proteins, peptides and polymers as definedherein for complexation agent.

In a further particular embodiment, the polymeric carrier which may beused to complex the RNA as defined herein or any further nucleic acidcomprised in the (pharmaceutical) composition or vaccine according tothe invention may be selected from a polymeric carrier moleculeaccording to generic formula (IV):

L-P¹—S—[S—P²—S]_(n)—S—P³-L  formula (IV)

wherein,

-   -   P¹ and P³ are different or identical to each other and represent        a linear or branched hydrophilic polymer chain, each P¹ and P³        exhibiting at least one —SH-moiety, capable to form a disulfide        linkage upon condensation with component P², or alternatively        with (AA), (AA)_(x), or [(AA)_(x)]_(z) if such components are        used as a linker between P¹ and P² or P³ and P²) and/or with        further components (e.g. (AA), (AA)_(x), [(AA)_(x)]_(z) or L),        the linear or branched hydrophilic polymer chain selected        independent from each other from polyethylene glycol (PEG),        poly-N-(2-hydroxypropyl)methacrylamide,        poly-2-(methacryloyloxy)ethyl phosphorylcholines,        poly(hydroxyalkyl L-asparagine), poly(2-(methacryloyloxy)ethyl        phosphorylcholine), hydroxyethylstarch or poly(hydroxyalkyl        L-glutamine), wherein the hydrophilic polymer chain exhibits a        molecular weight of about 1 kDa to about 100 kDa, preferably of        about 2 kDa to about 25 kDa; or more preferably of about 2 kDa        to about 10 kDa, e.g. about 5 kDa to about 25 kDa or 5 kDa to        about 10 kDa;    -   P² is a cationic or polycationic peptide or protein, e.g. as        defined above for the polymeric carrier formed by        disulfide-crosslinked cationic components, and preferably having        a length of about 3 to about 100 amino acids, more preferably        having a length of about 3 to about 50 amino acids, even more        preferably having a length of about 3 to about 25 amino acids,        e.g. a length of about 3 to 10, 5 to 15, 10 to 20 or 15 to 25        amino acids, more preferably a length of about 5 to about 20 and        even more preferably a length of about 10 to about 20; or        -   is a cationic or polycationic polymer, e.g. as defined above            for the polymeric carrier formed by disulfide-crosslinked            cationic components, typically having a molecular weight of            about 0.5 kDa to about 30 kDa, including a molecular weight            of about 1 kDa to about 20 kDa, even more preferably of            about 1.5 kDa to about 10 kDa, or having a molecular weight            of about 0.5 kDa to about 100 kDa, including a molecular            weight of about 10 kDa to about 50 kDa, even more preferably            of about 10 kDa to about 30 kDa;        -   each P² exhibiting at least two —SH-moieties, capable to            form a disulfide linkage upon condensation with further            components P² or component(s) P¹ and/or P³ or alternatively            with further components (e.g. (AA), (AA)_(x), or            [(AA)_(x)]_(z));    -   —S—S— is a (reversible) disulfide bond (the brackets are omitted        for better readability), wherein S preferably represents sulphur        or a —SH carrying moiety, which has formed a (reversible)        disulfide bond. The (reversible) disulfide bond is preferably        formed by condensation of —SH-moieties of either components P¹        and P², P² and P², or P² and P³, or optionally of further        components as defined herein (e.g. L, (AA), (AA)_(x),        [(AA)_(x)]z, etc); The —SH-moiety may be part of the structure        of these components or added by a modification as defined below;    -   L is an optional ligand, which may be present or not, and may be        selected independent from the other from RGD, Transferrin,        Folate, a signal peptide or signal sequence, a localization        signal or sequence, a nuclear localization signal or sequence        (NLS), an antibody, a cell penetrating peptide, (e.g. TAT or        KALA), a ligand of a receptor (e.g. cytokines, hormones, growth        factors etc), small molecules (e.g. carbohydrates like mannose        or galactose or synthetic ligands), small molecule agonists,        inhibitors or antagonists of receptors (e.g. RGD peptidomimetic        analogues), or any further protein as defined herein, etc.;    -   n is an integer, typically selected from a range of about 1 to        50, preferably from a range of about 1, 2 or 3 to 30, more        preferably from a range of about 1, 2, 3, 4, or 5 to 25, or a        range of about 1, 2, 3, 4, or 5 to 20, or a range of about 1, 2,        3, 4, or 5 to 15, or a range of about 1, 2, 3, 4, or 5 to 10,        including e.g. a range of about 4 to 9, 4 to 10, 3 to 20, 4 to        20, 5 to 20, or 10 to 20, or a range of about 3 to 15, 4 to 15,        5 to 15, or 10 to 15, or a range of about 6 to 11 or 7 to 10.        Most preferably, n is in a range of about 1, 2, 3, 4, or 5 to        10, more preferably in a range of about 1, 2, 3, or 4 to 9, in a        range of about 1, 2, 3, or 4 to 8, or in a range of about 1, 2,        or 3 to 7.

In this context, the disclosure of WO 2011/026641 is incorporatedherewith by reference. Each of hydrophilic polymers P1 and P3 typicallyexhibits at least one —SH-moiety, wherein the at least one —SH-moiety iscapable to form a disulfide linkage upon reaction with component P2 orwith component (AA) or (AA)_(x), if used as linker between P1 and P2 orP3 and P2 as defined below and optionally with a further component, e.g.L and/or (AA) or (AA)_(x), e.g. if two or more —SH-moieties arecontained. The following subformulae “P1-S—S—P2” and “P2-S—S—P3” withingeneric formula (IV) above (the brackets are omitted for betterreadability), wherein any of S, P1 and P3 are as defined herein,typically represent a situation, wherein one-SH-moiety of hydrophilicpolymers P1 and P3 was condensed with one —SH-moiety of component P2 ofgeneric formula (IV) above, wherein both sulphurs of these —SH-moietiesform a disulfide bond —S—S— as defined herein in formula (IV). These—SH-moieties are typically provided by each of the hydrophilic polymersP1 and P3, e.g. via an internal cysteine or any further (modified) aminoacid or compound which carries a —SH moiety. Accordingly, thesubformulae “P1-S—S—P2” and “P2-S—S—P3” may also be written as“P1-Cys-Cys-P2” and “P2-Cys-Cys-P3”, if the —SH-moiety is provided by acysteine, wherein the term Cys-Cys represents two cysteines coupled viaa disulfide bond, not via a peptide bond. In this case, the term “—S—S—”in these formulae may also be written as “—S-Cys”, as “-Cys-S” or as“-Cys-Cys-”. In this context, the term “-Cys-Cys-” does not represent apeptide bond but a linkage of two cysteines via their —SH-moieties toform a disulfide bond. Accordingly, the term “-Cys-Cys-”also may beunderstood generally as “-(Cys-S)—(S-Cys)-”, wherein in this specificcase S indicates the sulphur of the —SH-moiety of cysteine. Likewise,the terms “—S-Cys” and “—Cys-S” indicate a disulfide bond between a —SHcontaining moiety and a cysteine, which may also be written as“—S—(S-Cys)” and “-(Cys-S)—S”. Alternatively, the hydrophilic polymersP1 and P3 may be modified with a —SH moiety, preferably via a chemicalreaction with a compound carrying a —SH moiety, such that each of thehydrophilic polymers P1 and P3 carries at least one such —SH moiety.Such a compound carrying a —SH moiety may be e.g. an (additional)cysteine or any further (modified) amino acid, which carries a —SHmoiety. Such a compound may also be any non-amino compound or moiety,which contains or allows to introduce a —SH moiety into hydrophilicpolymers P1 and P3 as defined herein. Such non-amino compounds may beattached to the hydrophilic polymers P1 and P3 of formula (IV) of thepolymeric carrier according to the present invention via chemicalreactions or binding of compounds, e.g. by binding of a 3-thio propionicacid or thioimolane, by amide formation (e.g. carboxylic acids,sulphonic acids, amines, etc), by Michael addition (e.g maleinimidemoieties, α,β-unsatured carbonyls, etc), by click chemistry (e.g. azidesor alkines), by alkene/alkine methatesis (e.g. alkenes or alkines),imine or hydrozone formation (aldehydes or ketons, hydrazins,hydroxylamins, amines), complexation reactions (avidin, biotin, proteinG) or components which allow Sn-type substitution reactions (e.ghalogenalkans, thiols, alcohols, amines, hydrazines, hydrazides,sulphonic acid esters, oxyphosphonium salts) or other chemical moietieswhich can be utilized in the attachment of further components. Aparticularly preferred PEG derivate in this context isalpha-Methoxy-omega-mercapto poly(ethylene glycol). In each case, theSH-moiety, e.g. of a cysteine or of any further (modified) amino acid orcompound, may be present at the terminal ends or internally at anyposition of hydrophilic polymers P1 and P3. As defined herein, each ofhydrophilic polymers P1 and P3 typically exhibits at least one—SH-moiety preferably at one terminal end, but may also contain two oreven more —SH-moieties, which may be used to additionally attach furthercomponents as defined herein, preferably further functional peptides orproteins e.g. a ligand, an amino acid component (AA) or (AA)x,antibodies, cell penetrating peptides or enhancer peptides (e.g. TAT,KALA), etc.

In this context it is particularly preferred to select the peptidesequence according to SEQ ID No. 3594 as P2.

Preferably, the inventive composition comprises at least one mRNA asdefined herein, which is complexed with one or more polycations, and atleast one free mRNA, wherein the at least one complexed mRNA ispreferably identical to the at least one free mRNA. In this context, itis particularly preferred that the composition of the present inventioncomprises the mRNA according to the invention that is complexed at leastpartially with a cationic or polycationic compound and/or a polymericcarrier, preferably cationic proteins or peptides. In this context, thedisclosure of WO 2010/037539 and WO 2012/113513 is incorporated herewithby reference. Partially means that only a part of the mRNA as definedherein is complexed in the composition according to the invention with acationic compound and that the rest of the mRNA as defined herein is(comprised in the inventive (pharmaceutical) composition or vaccine) inuncomplexed form (“free”). Preferably, the molar ratio of the complexedmRNA to the free mRNA is selected from a molar ratio of about 0.001:1 toabout 1:0.001, including a ratio of about 1:1. More preferably the ratioof complexed mRNA to free mRNA (in the (pharmaceutical) composition orvaccine of the present invention) is selected from a range of about 5:1(w/w) to about 1:10 (w/w), more preferably from a range of about 4:1(w/w) to about 1:8 (w/w), even more preferably from a range of about 3:1(w/w) to about 1:5 (w/w) or 1:3 (w/w), and most preferably the ratio ofcomplexed mRNA to free mRNA in the inventive pharmaceutical compositionor vaccine is selected from a ratio of about 1:1 (w/w).

The complexed mRNA in the (pharmaceutical) composition or vaccineaccording to the present invention, is preferably prepared according toa first step by complexing the mRNA according to the invention with acationic or polycationic compound and/or with a polymeric carrier,preferably as defined herein, in a specific ratio to form a stablecomplex. In this context, it is highly preferable, that no free cationicor polycationic compound or polymeric carrier or only a negligibly smallamount thereof remains in the component of the complexed mRNA aftercomplexing the mRNA. Accordingly, the ratio of the mRNA and the cationicor polycationic compound and/or the polymeric carrier in the componentof the complexed RNA is typically selected in a range so that the mRNAis entirely complexed and no free cationic or polycationic compound orpolymeric carrier or only a negligibly small amount thereof remains inthe composition.

In other embodiments, the composition according to the inventioncomprising the mRNA as defined herein may be administered naked withoutbeing associated with any further vehicle, transfection or complexationagent.

It has to be understood and recognized, that according to the presentinvention, the inventive composition may comprise at least one nakedmRNA as defined herein and/or at least one formulated/complexed mRNA asdefined herein, wherein every formulation and/or complexation asdisclosed above may be used.

In an especially preferred embodiment of the inventive composition themRNA sequence encoding a rotavirus protein is combined with at least oneVLP (virus like particle) forming protein or peptide or a fragment,variant or derivative thereof. Additionally or alternatively the mRNAsequence encoding a rotavirus protein is combined with a nucleic acidmolecule, preferably an mRNA sequence, encoding a VLP forming protein orpeptide or a fragment, variant or derivative thereof. In this context itis preferred that the mRNA sequence encoding at least one epitope of arotavirus protein (e.g. VP8*) is fused to a transmembrane domain of aprotein, or a fragment, variant or derivative thereof (e.g.transmembrane domain of Influenza HA) resulting in a membrane-bound formof the rotavirus protein. More preferably the mRNA sequence encoding therotavirus protein additionally comprises a sequence section encoding asignal peptide as described above. A preferred construct may comprise in5′-3′ direction sequence sections coding for a signal peptide, VP8* anda transmembrane domain. This embodiment of the inventive composition,namely a combination of an mRNA construct encoding the rotavirus proteinand at least one mRNA construct encoding a VLP forming protein orpeptide, leads to co-expression of the membrane-bound rotavirus proteinand the at least one VLP forming protein or peptide allowing formationof virus like particles thereby further increasing immune responses byantigen clustering.

The co-expression may be implemented in one single multicistronic mRNAconstruct or in at least two separated mRNA constructs.

In an especially preferred embodiment of this aspect of the inventionthe VLP forming protein or peptide is a viral matrix protein, or afragment or derivative thereof, derived from an enveloped virus. Theco-expression of such VLP forming proteins or peptides with themembrane-bound rotavirus protein advantageously results in the formationof VLPs with a lipid envelope. In preferred embodiments the matrixprotein is a gag protein derived from an enveloped virus selected fromHIV-1, EIAV, and MLV. In further preferred embodiments, the matrixprotein is the matrix protein of vesiclular stomatitis virus (VSV),Rabies virus or the VP40 protein derived from an Ebola virus. Preferablythe VLP forming protein is selected from any of the sequences accordingto SEQ ID Nos. 3172-3173.

Moreover, the invention relates to a pharmaceutical composition thatcomprises the composition as defined above, preferably in combinationwith a pharmaceutically acceptable carrier and/or vehicle.

The inventive pharmaceutical composition may be administered in variousways. Generally, the inventive pharmaceutical composition may beadministered orally, parenterally, by inhalation spray, topically,rectally, nasally, buccally, vaginally or via an implanted reservoir.The term parenteral as used herein includes subcutaneous, intravenous,intramuscular, intraarticular, intranodal, intrasynovial, intrasternal,intrathecal, intrahepatic, intralesional, intracranial, transdermal,intradermal, intrapulmonal, intraperitoneal, intracardial,intraarterial, and sublingual injection or infusion techniques.

Preferably, the inventive pharmaceutical composition may be administeredby parenteral injection, more preferably by subcutaneous, intravenous,intramuscular, intraarticular, intranodal, intrasynovial, intrasternal,intrathecal, intrahepatic, intralesional, intracranial, transdermal,intradermal, intrapulmonal, intraperitoneal, intracardial,intraarterial, and sublingual injection or via infusion techniques.Particularly preferred is intradermal and intramuscular injection. Inone particularly preferred embodiment, the pharmaceutical composition isadministered intramuscularly.

Methods for intramuscular administration are known in the art.Typically, a liquid is injected into a skeletal muscle (such as M.gluteus, M. deltoideus or M. vastus lateralis) using, for example, asyringe or a needle-free injection system, such as a jet injectionsystem. Jet injection refers to a needle-free injection method, whereina fluid comprising the inventive composition and, optionally, furthersuitable excipients is forced through an orifice, thus generating anultra-fine liquid stream of high pressure that is capable of penetratingmammalian skin. In principle, the liquid stream forms a hole in theskin, through which the liquid stream is pushed into the target tissue.

Sterile injectable forms of the inventive pharmaceutical composition maybe aqueous or oleaginous suspension. These suspensions may be formulatedaccording to techniques known in the art using suitable dispersing orwetting agents and suspending agents. The sterile injectable preparationmay also be a sterile injectable solution or suspension in a non-toxicparenterally-acceptable diluent or solvent, for example as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that may beemployed are water, Ringer's solution and isotonic sodium chloridesolution. In addition, sterile, fixed oils are conventionally employedas a solvent or suspending medium. For this purpose, any bland fixed oilmay be employed including synthetic mono- or di-glycerides. Fatty acids,such as oleic acid and its glyceride derivatives are useful in thepreparation of injectables, as are natural pharmaceutically-acceptableoils, such as olive oil or castor oil, especially in theirpolyoxyethylated versions. These oil solutions or suspensions may alsocontain a long-chain alcohol diluent or dispersant, such ascarboxymethyl cellulose or similar dispersing agents that are commonlyused in the formulation of pharmaceutically acceptable dosage formsincluding emulsions and suspensions. Other commonly used surfactants,such as Tweens, Spans and other emulsifying agents or bioavailabilityenhancers which are commonly used in the manufacture of pharmaceuticallyacceptable solid, liquid, or other dosage forms may also be used for thepurposes of formulation of the inventive pharmaceutical composition.

Moreover, the inventive pharmaceutical composition as defined herein mayalso be administered orally in any orally acceptable dosage formincluding, but not limited to, capsules, tablets, aqueous suspensions orsolutions. In the case of tablets for oral use, carriers commonly usedinclude lactose and corn starch. Lubricating agents, such as magnesiumstearate, are also typically added. For oral administration in a capsuleform, useful diluents include lactose and dried cornstarch. When aqueoussuspensions are required for oral use, the active ingredients arecombined with emulsifying and suspending agents. If desired, certainsweetening, flavoring or coloring agents may also be added.

In a particularly preferred embodiment the inventive pharmaceuticalcomposition is administered topically. For topical applications, theinventive pharmaceutical composition may be formulated in a suitableointment, containing the component(s) of the inventive compositionsuspended or dissolved in one or more carriers. Carriers for topicaladministration include, but are not limited to, mineral oil, liquidpetrolatum, white petrolatum, propylene glycol, polyoxyethylene,polyoxypropylene compound, emulsifying wax and water. Alternatively, theinventive pharmaceutical composition can be formulated in a suitablelotion or cream. In the context of the present invention, suitablecarriers include, but are not limited to, mineral oil, sorbitanmonostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol,2-octyldodecanol, benzyl alcohol and water. In especially preferredembodiments of the inventive composition enhancers for topicaladministration may be added to the composition, particularly substanceswhich enhance skin permeability.

Moreover, transdermal administration may be preferred. In an especiallypreferred embodiment the pharmaceutical composition is prepared in theform of a transdermal patch, e.g. a microneedle patch (solid, hollow ordissolving), and the composition optionally comprises enhancers fortransdermal delivery. Dermal or transdermal patches are particularlyadvantageous for slow release of the component(s) of the inventivecomposition.

In an especially preferred embodiment of the invention the inventivecomposition or the inventive pharmaceutical composition is provided orused as a vaccine. Therefore, the invention also relates to a vaccinecomprising or consisting of a composition or pharmaceutical compositionas defined above. Typically, such a vaccine is as defined above forpharmaceutical compositions. In the specific context of the inventivevaccine, the choice of a pharmaceutically acceptable carrier isdetermined in principle by the manner in which the inventive vaccine isadministered. Routes for local administration in general include, forexample, topical administration routes but also intradermal,transdermal, subcutaneous, or intramuscular injections or intralesional,intracranial, intrapulmonal, intracardial, and sublingual injection.Inventive vaccines are therefore preferably formulated in liquid (orsometimes in solid) form. Preferably, the inventive vaccine may beadministered by conventional needle injection or needle-free jetinjection. In a preferred embodiment the inventive vaccine may beadministered by topical or transdermal routes.

According to another embodiment, the (pharmaceutical) composition orvaccine according to the invention may comprise an adjuvant, which ispreferably added in order to enhance the immunostimulatory properties ofthe composition. In this context, an adjuvant may be understood as anycompound, which is suitable to support administration and delivery ofthe composition according to the invention. Furthermore, such anadjuvant may, without being bound thereto, initiate or increase animmune response of the innate immune system, i.e. a non-specific immuneresponse. In other words, when administered, the composition accordingto the invention typically initiates an adaptive immune response due toan antigen as defined herein or a fragment or variant thereof, which isencoded by the at least one coding region of the inventive mRNAcontained in the composition of the present invention. Additionally, thecomposition according to the invention may generate an (supportive)innate immune response due to addition of an adjuvant as defined hereinto the composition according to the invention.

Such an adjuvant may be selected from any adjuvant known to a skilledperson and suitable for the present case, i.e. supporting the inductionof an immune response in a mammal. Preferably, the adjuvant may beselected from the group consisting of, without being limited thereto,TDM, MDP, muramyl dipeptide, pluronics, alum solution, aluminiumhydroxide, ADJUMER™ (polyphosphazene); aluminium phosphate gel; glucansfrom algae; algammulin; aluminium hydroxide gel (alum); highlyprotein-adsorbing aluminium hydroxide gel; low viscosity aluminiumhydroxide gel; AF or SPT (emulsion of squalane (5%), Tween 80 (0.2%),Pluronic L121 (1.25%), phosphate-buffered saline, pH 7.4); AVRIDINE™(propanediamine); BAY R1005™((N-(2-deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyl-dodecanoyl-amidehydroacetate); CALCITRIOL™ (1-alpha,25-dihydroxy-vitamin D3); calciumphosphate gel; CAP™ (calcium phosphate nanoparticles); choleraholotoxin, cholera-toxin-A1-protein-A-D-fragment fusion protein,sub-unit B of the cholera toxin; CRL 1005 (block copolymer P1205);cytokine-containing liposomes; DDA (dimethyldioctadecylammoniumbromide); DHEA (dehydroepiandrosterone); DMPC(dimyristoylphosphatidylcholine); DMPG(dimyristoylphosphatidylglycerol); DOC/alum complex (deoxycholic acidsodium salt); Freund's complete adjuvant; Freund's incomplete adjuvant;gamma inulin; Gerbu adjuvant (mixture of:i)N-acetylglucosaminyl-(P1-4)-N-acetylmuramyl-L-alanyl-D-glutamine(GMDP), ii) dimethyldioctadecylammonium chloride (DDA), iii)zinc-L-proline salt complex (ZnPro-8); GM-CSF); GMDP(N-acetylglucosaminyl-(b1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine);imiquimod (1-(2-methypropyl)-1H-imidazo[4,5-c]quinoline-4-amine);ImmTher^(T)M(N-acetylglucosaminyl-N-acetylmuramyl-L-Ala-D-isoGlu-L-Ala-glyceroldipalmitate); DRVs (immunoliposomes prepared fromdehydration-rehydration vesicles); interferon-gamma; interleukin-1beta;interleukin-2; interleukin-7; interleukin-12; ISCOMS™; ISCOPREP 7.0.3.™;liposomes; LOXORIBINE™ (7-allyl-8-oxoguanosine); LT oral adjuvant (E.coli labile enterotoxin-protoxin); microspheres and microparticles ofany composition; MF59™; (squalene-water emulsion); MONTANIDE ISA 51™(purified incomplete Freund's adjuvant); MONTANIDE ISA 720™(metabolisable oil adjuvant); MPL™ (3-Q-desacyl-4′-monophosphoryl lipidA); MTP-PE and MTP-PE liposomes((N-acetyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-glycero-3-(hydroxyphosphoryloxy))-ethylamide,monosodium salt); MURAMETIDE™ (Nac-Mur-L-Ala-D-Gln-OCH3); MURAPALMITINE™and D-MURAPALMITINE™ (Nac-Mur-L-Thr-D-isoGln-sn-glyceroldipalmitoyl);NAGO (neuraminidase-galactose oxidase); nanospheres or nanoparticles ofany composition; NISVs (non-ionic surfactant vesicles); PLEURAN™(@3-glucan); PLGA, PGA and PLA (homo- and co-polymers of lactic acid andglycolic acid; microspheres/nanospheres); PLURONIC L121™; PMMA(polymethyl methacrylate); PODDS™ (proteinoid microspheres);polyethylene carbamate derivatives; poly-rA: poly-rU (polyadenylicacid-polyuridylic acid complex); polysorbate 80 (Tween 80); proteincochleates (Avanti Polar Lipids, Inc., Alabaster, AL); STIMULON™(QS-21); Quil-A (Quil-A saponin); S-28463(4-amino-otec-dimethyl-2-ethoxymethyl-1H-imidazo[4,5c]quinoline-1-ethanol); SAF-1™ (“Syntex adjuvant formulation”); Sendaiproteoliposomes and Sendai-containing lipid matrices; Span-85 (sorbitantrioleate); Specol (emulsion of Marcol 52, Span 85 and Tween 85);squalene or Robane® (2,6,10,15,19,23-hexamethyltetracosan and2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexane);stearyltyrosine (octadecyltyrosine hydrochloride); Theramid®(N-acetylglucosaminyl-N-acetylmuramyl-L-Ala-D-isoGlu-L-Ala-dipalmitoxypropylamide);Theronyl-MDP (Termurtide™ or [thr 1]-MDP;N-acetylmuramyl-L-threonyl-D-isoglutamine); Ty particles (Ty-VLPs orvirus-like particles); Walter-Reed liposomes (liposomes containing lipidA adsorbed on aluminium hydroxide), and lipopeptides, including Pam3Cys,in particular aluminium salts, such as Adju-phos, Alhydrogel,Rehydragel; emulsions, including CFA, SAF, IFA, MF59, Provax, TiterMax,Montanide, Vaxfectin; copolymers, including Optivax (CRL1005), L121,Poloaxmer4010), etc.; liposomes, including Stealth, cochleates,including BIORAL; plant derived adjuvants, including QS21, Quil A,Iscomatrix, ISCOM; adjuvants suitable for costimulation includingTomatine, biopolymers, including PLG, PMM, Inulin; microbe derivedadjuvants, including Romurtide, DETOX, MPL, CWS, Mannose, CpG nucleicacid sequences, CpG7909, ligands of human TLR 1-10, ligands of murineTLR 1-13, ISS-1018, IC31, Imidazoquinolines, Ampligen, Ribi529, IMOxine,IRIVs, VLPs, cholera toxin, heat-labile toxin, Pam3Cys, Flagellin, GPIanchor, LNFPIII/Lewis X, antimicrobial peptides, UC-1V150, RSV fusionprotein, cdiGMP; and adjuvants suitable as antagonists including CGRPneuropeptide.

Particularly preferred, an adjuvant may be selected from adjuvants,which support induction of a Th1-immune response or maturation of naïveT-cells, such as GM-CSF, IL-12, IFNγ, any immunostimulatory nucleic acidas defined herein, preferably an immunostimulatory RNA, CpG DNA, etc.

In a further preferred embodiment it is also possible that the inventivecomposition contains besides the antigen-providing mRNA furthercomponents which are selected from the group comprising: furtherantigens (e.g. in the form of a peptide or protein) or furtherantigen-encoding nucleic acids; a further immunotherapeutic agent; oneor more auxiliary substances; or any further compound, which is known tobe immunostimulating due to its binding affinity (as ligands) to humanToll-like receptors; and/or an adjuvant nucleic acid, preferably animmunostimulatory RNA (isRNA).

The composition of the present invention can additionally contain one ormore auxiliary substances in order to increase its immunogenicity orimmunostimulatory capacity, if desired. A synergistic action of the mRNAas defined herein and of an auxiliary substance, which may be optionallycontained in the inventive composition, is preferably achieved thereby.Depending on the various types of auxiliary substances, variousmechanisms can come into consideration in this respect. For example,compounds that permit the maturation of dendritic cells (DCs), forexample lipopolysaccharides, TNF-alpha or CD40 ligand, form a firstclass of suitable auxiliary substances. In general, it is possible touse as auxiliary substance any agent that influences the immune systemin the manner of a “danger signal” (LPS, GP96, etc.) or cytokines, suchas GM-CFS, which allow an immune response to be enhanced and/orinfluenced in a targeted manner. Particularly preferred auxiliarysubstances are cytokines, such as monokines, lymphokines, interleukinsor chemokines, that further promote the innate immune response, such asIL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12,IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL- 20, IL-21, IL-22,IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32,IL-33, IFN-alpha, IFN-beta, IFN-gamma, GM-CSF, G-CSF, M-CSF, LT-beta orTNF-alpha, growth factors, such as hGH. A synergistic action of the mRNAcontained in the inventive composition and of an auxiliary substance,which may be optionally be co-formulated (or separately formulated) withthe inventive vaccine or composition as described above, is preferablyachieved thereby. Preferably, such immunogenicity increasing agents orcompounds are provided separately (not co-formulated with the inventivevaccine or composition) and administered individually.

Suitable adjuvants may also be selected from cationic or polycationiccompounds wherein the adjuvant is preferably prepared upon complexingthe mRNA of the composition according to the invention with the cationicor polycationic compound as disclosed above.

The inventive vaccine or composition can also additionally contain anyfurther compound, which is known to be immune-stimulating due to itsbinding affinity (as ligands) to human Toll-like receptors TLR1, TLR2,TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, or due to its bindingaffinity (as ligands) to murine Toll-like receptors TLR1, TLR2, TLR3,TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12 or TLR13.

Another class of compounds, which may be added to an inventive vaccineor composition in this context, may be CpG nucleic acids, in particularCpG-RNA or CpG-DNA. A CpG-RNA or CpG-DNA can be a single-strandedCpG-DNA (ss CpG-DNA), a double-stranded CpG-DNA (dsDNA), asingle-stranded CpG-RNA (ss CpG-RNA) or a double-stranded CpG-RNA (dsCpG-RNA). The CpG nucleic acid is preferably in the form of CpG-RNA,more preferably in the form of single-stranded CpG-RNA (ss CpG-RNA). TheCpG nucleic acid preferably contains at least one or more (mitogenic)cytosine/guanine dinucleotide sequence(s) (CpG motif(s)). According to afirst preferred alternative, at least one CpG motif contained in thesesequences, that is to say the C (cytosine) and the G (guanine) of theCpG motif, is unmethylated. All further cytosines or guanines optionallycontained in these sequences can be either methylated or unmethylated.According to a further preferred alternative, however, the C (cytosine)and the G (guanine) of the CpG motif can also be present in methylatedform.

Suitable adjuvants may furthermore be selected from nucleic acids havingthe formula (Va): G_(l)X_(m)G_(n), wherein: G is guanosine (guanine),uridine (uracil) or an analogue of guanosine (guanine) or uridine(uracil); X is guanosine (guanine), uridine (uracil), adenosine(adenine), thymidine (thymine), cytidine (cytosine) or an analogue ofthe above-mentioned nucleotides (nucleosides); l is an integer from 1 to40, wherein when l=1 G is guanosine (guanine) or an analogue thereof,when l>1 at least 50% of the nucleotides are guanosine (guanine) or ananalogue thereof; m is an integer and is at least 3; wherein when m=3 Xis uridine (uracil) or an analogue thereof, when m>3 at least 3successive uridines (uracils) or analogues of uridine (uracil) occur; nis an integer from 1 to 40, wherein when n=1 G is guanosine (guanine) oran analogue thereof, when n>1 at least 50% of the nucleotides(nucleosides) are guanosine (guanine) or an analogue thereof, or formula(Vb): (N_(u)G_(l)X_(m)G_(n)N_(v))_(a), wherein: G is guanosine(guanine), uridine (uracil) or an analogue of guanosine (guanine) oruridine (uracil), preferably guanosine (guanine) or an analogue thereof;X is guanosine (guanine), uridine (uracil), adenosine (adenine),thymidine (thymine), cytidine (cytosine), or an analogue of thesenucleotides (nucleosides), preferably uridine (uracil) or an analoguethereof; N is a nucleic acid sequence having a length of about 4 to 50,preferably of about 4 to 40, more preferably of about 4 to 30 or 4 to 20nucleic acids, each N independently being selected from guanosine(guanine), uridine (uracil), adenosine (adenine), thymidine (thymine),cytidine (cytosine) or an analogue of these nucleotides (nucleosides); ais an integer from 1 to 20, preferably from 1 to 15, most preferablyfrom 1 to 10; l is an integer from 1 to 40, wherein when I=1, G isguanosine (guanine) or an analogue thereof, when l>1, at least 50% ofthese nucleotides (nucleosides) are guanosine (guanine) or an analoguethereof; m is an integer and is at least 3; wherein when m=3, X isuridine (uracil) or an analogue thereof, and when m>3, at least 3successive uridines (uracils) or analogues of uridine (uracil) occur; nis an integer from 1 to 40, wherein when n=1, G is guanosine (guanine)or an analogue thereof, when n>1, at least 50% of these nucleotides(nucleosides) are guanosine (guanine) or an analogue thereof; u,v may beindependently from each other an integer from 0 to 50, preferablywherein when u=0, v≥1, or when v=0, u≥1; wherein the nucleic acidmolecule of formula (Vb) has a length of at least 50 nucleotides,preferably of at least 100 nucleotides, more preferably of at least 150nucleotides, even more preferably of at least 200 nucleotides and mostpreferably of at least 250 nucleotides.

Other suitable adjuvants may furthermore be selected from nucleic acidshaving the formula (VI): C_(l)X_(m)C_(n), wherein: C is cytidine(cytosine), uridine (uracil) or an analogue of cytidine (cytosine) oruridine (uracil); X is guanosine (guanine), uridine (uracil), adenosine(adenine), thymidine (thymine), cytidine (cytosine) or an analogue ofthe above-mentioned nucleotides (nucleosides); l is an integer from 1 to40, wherein when l=1 C is cytidine (cytosine) or an analogue thereof,when l>1 at least 50% of the nucleotides are cytidine (cytosine) or ananalogue thereof; m is an integer and is at least 3; wherein when m=3 Xis uridine (uracil) or an analogue thereof, when m>3 at least 3successive uridines (uracils) or analogues of uridine (uracil) occur; nis an integer from 1 to 40, wherein when n=1 C is cytidine (cytosine) oran analogue thereof, when n>1 at least 50% of the nucleotides(nucleosides) are cytidine (cytosine) or an analogue thereof.

In this context the disclosure of WO002008014979 and WO2009095226 isalso incorporated herein by reference.

Further additives which may be included in the inventive vaccine orcomposition are emulsifiers, such as, for example, Tween; wettingagents, such as, for example, sodium lauryl sulfate; colouring agents;taste-imparting agents, pharmaceutical carriers; tablet-forming agents;stabilizers; antioxidants; preservatives.

In a further aspect, the present invention provides a vaccine, which isbased on the mRNA sequence according to the invention comprising atleast one coding region as defined herein. The vaccine according to theinvention is preferably a (pharmaceutical) composition as definedherein.

Accordingly, the vaccine according to the invention is based on the samecomponents as the (pharmaceutical) composition described herein.Insofar, it may be referred to the description of the (pharmaceutical)composition as provided herein. Preferably, the vaccine according to theinvention comprises at least one mRNA comprising at least one mRNAsequence as defined herein and a pharmaceutically acceptable carrier. Inembodiments, where the vaccine comprises more than one mRNA sequence(such as a plurality of RNA sequences according to the invention,wherein each preferably encodes a distinct antigenic peptide orprotein), the vaccine may be provided in physically separate form andmay be administered by separate administration steps. The vaccineaccording to the invention may correspond to the (pharmaceutical)composition as described herein, especially where the mRNA sequences areprovided by one single composition. However, the inventive vaccine mayalso be provided physically separated. For instance, in embodiments,wherein the vaccine comprises more than one mRNA sequences/species,these RNA species may be provided such that, for example, two, three,four, five or six separate compositions, which may contain at least onemRNA species/sequence each (e.g. three distinct mRNA species/sequences),each encoding distinct antigenic peptides or proteins, are provided,which may or may not be combined. Also, the inventive vaccine may be acombination of at least two distinct compositions, each compositioncomprising at least one mRNA encoding at least one of the antigenicpeptides or proteins defined herein. Alternatively, the vaccine may beprovided as a combination of at least one mRNA, preferably at least two,three, four, five, six or more mRNAs, each encoding one of the antigenicpeptides or proteins defined herein. The vaccine may be combined toprovide one single composition prior to its use or it may be used suchthat more than one administration is required to administer the distinctmRNA sequences/species encoding any of the antigenic peptides orproteins as defined herein. If the vaccine contains at least one mRNAsequence, typically at least two mRNA sequences, encoding the antigencombinations defined herein, it may e.g. be administered by one singleadministration (combining all mRNA species/sequences), by at least twoseparate administrations. Accordingly; any combination of mono-, bi- ormulticistronic mRNAs encoding the at least one antigenic peptide orprotein or any combination of antigens as defined herein (and optionallyfurther antigens), provided as separate entities (containing one mRNAspecies) or as combined entity (containing more than one mRNA species),is understood as a vaccine according to the present invention. Accordingto a particularly preferred embodiment of the inventive vaccine, the atleast one antigen, preferably a combination as defined herein of atleast two, three, four, five, six or more antigens encoded by theinventive composition as a whole, is provided as an individual(monocistronic) mRNA, which is administered separately.

As with the (pharmaceutical) composition according to the presentinvention, the entities of the vaccine may be provided in liquid and orin dry (e.g. lyophilized) form. They may contain further components, inparticular further components allowing for its pharmaceutical use. Thevaccine or the (pharmaceutical) composition may, e.g., additionallycontain a pharmaceutically acceptable carrier and/or further auxiliarysubstances and additives and/or adjuvants.

The vaccine or (pharmaceutical) composition typically comprises a safeand effective amount of the mRNA according to the invention as definedherein, encoding an antigenic peptide or protein as defined herein or afragment or variant thereof or a combination of antigens, preferably asdefined herein. As used herein, “safe and effective amount” means anamount of the mRNA that is sufficient to significantly induce a positivemodification of cancer or a disease or disorder related to cancer. Atthe same time, however, a “safe and effective amount” is small enough toavoid serious side-effects, that is to say to permit a sensiblerelationship between advantage and risk. The determination of theselimits typically lies within the scope of sensible medical judgment. Inrelation to the vaccine or (pharmaceutical) composition of the presentinvention, the expression “safe and effective amount” preferably meansan amount of the mRNA (and thus of the encoded antigen) that is suitablefor stimulating the adaptive immune system in such a manner that noexcessive or damaging immune reactions are achieved but, preferably,also no such immune reactions below a measurable level. Such a “safe andeffective amount” of the mRNA of the (pharmaceutical) composition orvaccine as defined herein may furthermore be selected in dependence ofthe type of mRNA, e.g. monocistronic, bi- or even multicistronic mRNA,since a bi- or even multicistronic mRNA may lead to a significantlyhigher expression of the encoded antigen(s) than the use of an equalamount of a monocistronic mRNA. A “safe and effective amount” of themRNA of the (pharmaceutical) composition or vaccine as defined abovewill furthermore vary in connection with the particular condition to betreated and also with the age and physical condition of the patient tobe treated, the severity of the condition, the duration of thetreatment, the nature of the accompanying therapy, of the particularpharmaceutically acceptable carrier used, and similar factors, withinthe knowledge and experience of the accompanying doctor. The vaccine orcomposition according to the invention can be used according to theinvention for human and also for veterinary medical purposes, as apharmaceutical composition or as a vaccine.

In a preferred embodiment, the mRNA of the (pharmaceutical) composition,vaccine or kit of parts according to the invention is provided inlyophilized form. Preferably, the lyophilized mRNA is reconstituted in asuitable buffer, advantageously based on an aqueous carrier, prior toadministration, e.g. Ringer-Lactate solution, which is preferred, Ringersolution, a phosphate buffer solution. In a preferred embodiment, the(pharmaceutical) composition, the vaccine or the kit of parts accordingto the invention contains at least one, two, three, four, five, six ormore mRNAs, preferably mRNAs which are provided separately inlyophilized form (optionally together with at least one furtheradditive) and which are preferably reconstituted separately in asuitable buffer (such as Ringer-Lactate solution) prior to their use soas to allow individual administration of each of the (monocistronic)mRNAs.

The vaccine or (pharmaceutical) composition according to the inventionmay typically contain a pharmaceutically acceptable carrier. Theexpression “pharmaceutically acceptable carrier” as used hereinpreferably includes the liquid or non-liquid basis of the inventivevaccine. If the inventive vaccine is provided in liquid form, thecarrier will be water, typically pyrogen-free water; isotonic saline orbuffered (aqueous) solutions, e.g phosphate, citrate etc. bufferedsolutions. Particularly for injection of the inventive vaccine, water orpreferably a buffer, more preferably an aqueous buffer, may be used,containing a sodium salt, preferably at least 50 mM of a sodium salt, acalcium salt, preferably at least 0.01 mM of a calcium salt, andoptionally a potassium salt, preferably at least 3 mM of a potassiumsalt. According to a preferred embodiment, the sodium, calcium and,optionally, potassium salts may occur in the form of their halogenides,e.g. chlorides, iodides, or bromides, in the form of their hydroxides,carbonates, hydrogen carbonates, or sulfates, etc. Without being limitedthereto, examples of sodium salts include e.g. NaCl, NaI, NaBr, Na₂CO₃,NaHCO₃, Na₂SO₄, examples of the optional potassium salts include e.g.KCl, KI, KBr, K₂CO₃, KHCO₃, K₂SO₄, and examples of calcium salts includee.g. CaCl₂, CaI₂, CaBr₂, CaCO₃, CaSO₄, Ca(OH)₂. Furthermore, organicanions of the aforementioned cations may be contained in the buffer.According to a more preferred embodiment, the buffer suitable forinjection purposes as defined above, may contain salts selected fromsodium chloride (NaCl), calcium chloride (CaCl₂) and optionallypotassium chloride (KCl), wherein further anions may be presentadditional to the chlorides. CaCl₂ can also be replaced by another saltlike KCl. Typically, the salts in the injection buffer are present in aconcentration of at least 50 mM sodium chloride (NaCl), at least 3 mMpotassium chloride (KCl) and at least 0.01 mM calcium chloride (CaCl₂).The injection buffer may be hypertonic, isotonic or hypotonic withreference to the specific reference medium, i.e. the buffer may have ahigher, identical or lower salt content with reference to the specificreference medium, wherein preferably such concentrations of the aforementioned salts may be used, which do not lead to damage of cells due toosmosis or other concentration effects. Reference media are e.g. in “invivo” methods occurring liquids such as blood, lymph, cytosolic liquids,or other body liquids, or e.g. liquids, which may be used as referencemedia in “in vitro” methods, such as common buffers or liquids. Suchcommon buffers or liquids are known to a skilled person. Ringer-Lactatesolution is particularly preferred as a liquid basis.

However, one or more compatible solid or liquid fillers or diluents orencapsulating compounds may be used as well, which are suitable foradministration to a person. The term “compatible” as used herein meansthat the constituents of the inventive vaccine are capable of beingmixed with the mRNA according to the invention as defined herein, insuch a manner that no interaction occurs, which would substantiallyreduce the pharmaceutical effectiveness of the inventive vaccine undertypical use conditions. Pharmaceutically acceptable carriers, fillersand diluents must, of course, have sufficiently high purity andsufficiently low toxicity to make them suitable for administration to aperson to be treated. Some examples of compounds which can be used aspharmaceutically acceptable carriers, fillers or constituents thereofare sugars, such as, for example, lactose, glucose, trehalose andsucrose; starches, such as, for example, corn starch or potato starch;dextrose; cellulose and its derivatives, such as, for example, sodiumcarboxymethylcellulose, ethylcellulose, cellulose acetate; powderedtragacanth; malt; gelatin; tallow; solid glidants, such as, for example,stearic acid, magnesium stearate; calcium sulfate; vegetable oils, suchas, for example, groundnut oil, cottonseed oil, sesame oil, olive oil,corn oil and oil from theobroma; polyols, such as, for example,polypropylene glycol, glycerol, sorbitol, mannitol and polyethyleneglycol; alginic acid.

The choice of a pharmaceutically acceptable carrier is determined, inprinciple, by the manner, in which the pharmaceutical composition orvaccine according to the invention is administered. The composition orvaccine can be administered, for example, systemically or locally.Routes for systemic administration in general include, for example,transdermal, oral, parenteral routes, including subcutaneous,intravenous, intramuscular, intraarterial, intradermal andintraperitoneal injections and/or intranasal administration routes.Routes for local administration in general include, for example, topicaladministration routes but also intradermal, transdermal, subcutaneous,or intramuscular injections or intralesional, intracranial,intrapulmonal, intracardial, and sublingual injections. More preferably,composition or vaccines according to the present invention may beadministered by an intradermal, subcutaneous, or intramuscular route,preferably by injection, which may be needle-free and/or needleinjection. Compositions/vaccines are therefore preferably formulated inliquid or solid form. The suitable amount of the vaccine or compositionaccording to the invention to be administered can be determined byroutine experiments, e.g. by using animal models. Such models include,without implying any limitation, rabbit, sheep, mouse, rat, dog andnon-human primate models. Preferred unit dose forms for injectioninclude sterile solutions of water, physiological saline or mixturesthereof. The pH of such solutions should be adjusted to about 7.4.Suitable carriers for injection include hydrogels, devices forcontrolled or delayed release, polylactic acid and collagen matrices.Suitable pharmaceutically acceptable carriers for topical applicationinclude those which are suitable for use in lotions, creams, gels andthe like. If the inventive composition or vaccine is to be administeredperorally, tablets, capsules and the like are the preferred unit doseform. The pharmaceutically acceptable carriers for the preparation ofunit dose forms which can be used for oral administration are well knownin the prior art. The choice thereof will depend on secondaryconsiderations such as taste, costs and storability, which are notcritical for the purposes of the present invention, and can be madewithout difficulty by a person skilled in the art.

Despite, the inventive composition may comprise further components forfacilitating administration and uptake of components of thepharmaceutical composition. Such further components may be anappropriate carrier or vehicle, additional adjuvants for supporting anyimmune response, antibacterial and/or antiviral agents.

A further component of the inventive pharmaceutical composition may bean immunotherapeutic agent that can be selected from immunoglobulins,preferably IgGs, monoclonal or polyclonal antibodies, polyclonal serumor sera, etc. Preferably, such a further immunotherapeutic agent may beprovided as a peptide/protein or may be encoded by a nucleic acid,preferably by a DNA or an RNA, more preferably an mRNA.

Further additives which may be included in the inventive composition areemulsifiers, such as, for example, Tween®; wetting agents, such as, forexample, sodium lauryl sulfate; colouring agents; taste-impartingagents, pharmaceutical carriers; tablet-forming agents; stabilizers;antioxidants; preservatives.

The inventive composition and especially the pharmaceutical compositionor vaccine typically comprises a “safe and effective amount” of thecomponents of the composition, particularly of the mRNA sequencemolecule(s) as defined herein. As used herein, a “safe and effectiveamount” means an amount of the mRNA molecule(s) as defined herein assuch that is sufficient to significantly induce a positive protection ortreatment of rotavirus disease. At the same time, however, a “safe andeffective amount” is small enough to avoid serious side-effects and topermit a sensible relationship between advantage and risk. Thedetermination of these limits typically lies within the scope ofsensible medical judgment. A “safe and effective amount” of thecomponents of the inventive pharmaceutical composition will furthermorevary in connection with the particular condition to be treated and alsowith the age and physical condition of the patient to be treated, thebody weight, general health, sex, diet, time of administration, rate ofexcretion, drug combination, the severity of the condition, the durationof the treatment, the nature of the accompanying therapy, of theparticular pharmaceutically acceptable carrier used, and similarfactors, within the knowledge and experience of the accompanying doctor.

The inventive pharmaceutical composition may be used for human and alsofor veterinary medical purposes, preferably for human medical purposes,as a pharmaceutical composition in general or preferably as a vaccine orimmunostimulating agent for prophylaxis and/or treatment of rotavirusinfections.

Moreover, one or more compatible solid or liquid fillers or diluents orencapsulating compounds, which are suitable for administration to apatient to be treated, may be used as well for the pharmaceuticalcomposition or vaccine according to the invention. The term “compatible”as used here means that these constituents of the inventivepharmaceutical composition or vaccine are capable of being mixed withthe components of the inventive pharmaceutical composition or vaccine insuch a manner that no interaction occurs which would substantiallyreduce the pharmaceutical effectiveness of the pharmaceuticalcomposition or vaccine under typical use conditions.

Furthermore, the inventive pharmaceutical composition or vaccine maycomprise at least one additional pharmaceutically active component. Apharmaceutically active component in this connection is a compound thathas a therapeutic effect to heal, ameliorate or prevent a particularindication or disease. Such compounds include, without implying anylimitation, peptides or proteins, preferably as defined herein, nucleicacids, preferably as defined herein, (therapeutically active) lowmolecular weight organic or inorganic compounds (molecular weight lessthan 5000, preferably less than 1000), sugars, antigens or antibodies,preferably as defined herein, therapeutic agents already known in theprior art, antigenic cells, antigenic cellular fragments, cellularfractions, cell wall components (e.g. polysaccharides), modified,attenuated or de-activated (e.g. chemically or by irradiation) pathogens(virus, bacteria etc.), antibacterial agents etc.

In a further aspect, the invention relates to a kit, preferably a kit ofparts comprising one or more of the inventive mRNA sequence or the mRNAcontaining (pharmaceutical) composition or vaccine as described above,optionally a liquid vehicle for solubilising, and optionally technicalinstructions with information on the administration and dosage of thecomponents respectively the composition or the pharmaceuticalcomposition or the vaccine. Preferably, the mRNA component of thecomposition and possibly further components are provided in lyophilizedform as a separate part. Preferably, the kit contains as a partRinger-Lactate solution.

Beside the components of the inventive mRNA containing composition, thekit may additionally contain a pharmaceutically acceptable vehicleand/or one or more adjuvant components and optionally further componentsas described below, as well as means for administration and technicalinstructions. In a preferred embodiment, prior to use of the kit, theprovided vehicle is than added to the lyophilized components in apredetermined amount as written e.g. in the provided technicalinstructions.

Moreover, the invention relates to the composition as defined above, orthe pharmaceutical composition as defined above, or the vaccine asdefined above, or the kit as defined above for use as a medicament andespecially for use for the preparation of a medicament.

Moreover, the invention relates to a use of the composition as definedabove, or the pharmaceutical composition as defined above, or thevaccine as defined above, or the kit as defined above for use in thetreatment or prophylaxis of rotavirus infections. It is especiallypreferred to use the composition or the pharmaceutical composition orthe vaccine or the kit in prophylaxis of rotavirus infections. It isespecially preferred to use it as a prophylactic vaccine because theinventive vaccine is very efficient and safe and also cheap inproduction.

Preferably the composition as defined above, or the pharmaceuticalcomposition as defined above, or the vaccine as defined above, or thekit as defined above is prepared for parenteral administration, morepreferably for administration by subcutaneous or intramuscular orintradermal or topical or transdermal application. Compared to oraladministration parenteral administration is particularly preferredbecause the efficiency or oral vaccination is significantly reduced indeveloping countries as already described above. Preferably, theadministration is done by conventional needle injection orjet injection,preferably by using jet injection. For practical reasons in developingcountries particularly conventional needle injection may be preferred,whereas also jet injection may be preferred, because it is an especiallyeffective administration route. Nevertheless, other administrationroutes may also be applied, especially topical or transdermaladministration may be applied, wherein the pharmaceutical composition orvaccine may be prepared in the form of a transdermal patch. Theefficiency of the transdermal application may be enhanced by addition ofenhancers for transdermal delivery.

Moreover, the invention relates to a method of treatment or prophylaxisof rotavirus infections, wherein one or more mRNA sequences or thecomposition or the pharmaceutical composition or the vaccine or the kitor kit of parts as defined above is provided and applied or administeredto a tissue or an organism. Preferably, a therapeutically effectiveamount thereof is applied or administered to a subject in need thereof.In preferred embodiments the mRNA sequence(s) or the composition or thepharmaceutical composition or the vaccine or the kit or kit of parts isadministered by subcutaneous or intramuscular or intradermal or topicalor transdermal application, e. g. by conventional needle injection orjet injection.

Moreover, topical or transdermal administration may be especiallypreferred, for example by iontophoresis or by non-cavitationalultrasound or by cavitational ultrasound or by electroporation of bymicroneedles or by thermal ablation or by microdermabrasion. In thiscontext it is referred to the article of Prausnitz M. R. and Langer R.(Prausnitz M. R. and Langer R. (2008), Nat Biotechnol November26(11):1261-1268) generally describing methods for transdermal drugdelivery, which may be used for the inventive composition. It may beespecially preferred to use transdermal patches for administration, asdescribed above. Moreover, patches with microneedles may be used,especially for slow release. Moreover, in especially preferredembodiments, creams, lotions or gels containing the inventivecomposition may be used.

According to a specific embodiment, the inventive mRNA sequence(s), orthe inventive (pharmaceutical) composition or vaccine may beadministered to the patient as a single dose or as at least one singledose, respectively. In certain embodiments, the inventive mRNAsequence(s) or the inventive (pharmaceutical) composition or vaccine maybe administered to a patient as a single dose followed by a second doselater and optionally even a third, fourth (or more) dose subsequentthereto etc. In accordance with this embodiment, booster inoculationswith the inventive mRNA sequence(s) or the inventive (pharmaceutical)composition or vaccine may be administered to a patient at specific timeintervals, preferably as defined below, following the second (or third,fourth, etc.) inoculation. Preferably, at least one dose of theinventive mRNA sequence, pharmaceutical composition or vaccine isadministered, preferably from 1 to 10 doses, more preferably from 2 to 7doses, even more preferably from 2 to 5 doses and most preferably from 3to 5 doses. In a particularly preferred embodiment, 3 doses areadministered. In another embodiment 5 doses are administered. In thatembodiment, the doses are given in a specific time period, e.g. 20-30 or20-60 days. The interval between the administration of two or more dosesis preferably from 5 to 120 days, more preferably from 7 to 15 days or15 to 30 days. In a preferred embodiment, the interval between theadministration of two or more doses is at least 7 days, more preferably28 days.

In a preferred embodiment, a single dose of the inventive mRNAsequence(s), composition or vaccine comprises a specific amount of themRNA according to the invention. Preferably, the inventive mRNAsequence(s) is provided in an amount of at least 40 μg per dose,preferably in an amount of from 40 to 700 μg per dose, more preferablyin an amount of from 80 to 400 μg per dose. More specifically, in thecase of intradermal injection, which is preferably carried out by usinga conventional needle, the amount of the inventive mRNA sequence(s)comprised in a single dose is typically at least 200 μg, preferably from200 μg to 1.000 μg, more preferably from 300 μg to 850 μg, even morepreferably from 300 μg to 700 μg. In the case of intradermal injection,which is preferably carried out via jet injection (e.g. using a Tropisdevice), the amount of the inventive mRNA sequence(s) comprised in asingle dose is typically at least 80 μg, preferably from 80 μg to 700μg, more preferably from 80 μg to 400 μg. Moreover, in the case ofintramuscular injection, which is preferably carried out by using aconventional needle or via jet injection, the amount of the inventivemRNA sequence(s) comprised in a single dose is typically at least 80 μg,preferably from 80 μg to 1.000 μg, more preferably from 80 μg to 850 μg,even more preferably from 80 μg to 700 μg.

More specifically, the following specific embodiments are particularlypreferred:

-   -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intradermally, in three doses (40 μg/dose),        preferably within 20-60 days, e.g. on day 0, 7 and 28 or on day        0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intradermally, in three doses (80 μg/dose),        preferably within 20-60 days, e.g. on day 0, 7 and 28 or on day        0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intradermally, in three doses (160 μg/dose),        preferably within 20-60 days, e.g. on day 0, 7 and 28 or on day        0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intradermally, in three doses (320 μg/dose),        preferably within 20-60 days, e.g. on day 0, 7 and 28 or on day        0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intradermally by jet injection, in three        doses (40 μg/dose), preferably within 20-60 days, e.g. on day 0,        7 and 28 or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intradermally by jet injection, in three        doses (80 μg/dose), preferably within 20-60 days, e.g. on day 0,        7 and 28 or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intradermally by jet injection, in three        doses (160 μg/dose), preferably within 20-60 days, e.g. on day        0, 7 and 28 or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intradermally by jet injection, in three        doses (320 μg/dose), preferably within 20-60 days, e.g. on day        0, 7 and 28 or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intramuscularly, in three doses (40        μg/dose), preferably within 20-60 days, e.g. on day 0, 7 and 28        or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intramuscularly in three doses (80 μg/dose),        preferably within 20-60 days, e.g. on day 0, 7 and 28 or on day        0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intramuscularly, in three doses (160        μg/dose), preferably within 20-60 days, e.g. on day 0, 7 and 28        or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intramuscularly, in three doses (320        μg/dose), preferably within 20-60 days, e.g. on day 0, 7 and 28        or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intramuscularly, in three doses (640        μg/dose), preferably within 20-60 days, e.g. on day 0, 7 and 28        or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intramuscularly by jet injection, in three        doses (40 μg/dose), preferably within 20-60 days, e.g. on day 0,        7 and 28 or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intramuscularly by jet injection, in three        doses (80 μg/dose), preferably within 20-60 days, e.g. on day 0,        7 and 28 or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intramuscularly by jet injection, in three        doses (160 μg/dose), preferably within 20-60 days, e.g. on day        0, 7 and 28 or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intramuscularly by jet injection, in three        doses (320 μg/dose), preferably within 20-60 days, e.g. on day        0, 7 and 28 or on day 0, 28 and 56 of the treatment.    -   the inventive mRNA sequence(s), or the inventive        (pharmaceutical) composition or vaccine is administered to the        patient, preferably intramuscularly by jet injection, in three        doses (640 μg/dose), preferably within 20-60 days, e.g. on day        0, 7 and 28 or on day 0, 28 and 56 of the treatment.

In certain embodiments, such booster inoculations with the inventivemRNA sequence(s) or inventive (pharmaceutical) composition or vaccine asdisclosed above (second, third etc. vaccination) may utilize anadditional compound or component as defined for the inventive mRNAsequence(s) or inventive (pharmaceutical) composition or vaccine asdefined herein.

In the present invention, if not otherwise indicated, different featuresof alternatives and embodiments may be combined with each other, wheresuitable. Furthermore, the term “comprising” shall not be narrowlyconstrued as being limited to “consisting of” only, if not specificallymentioned. Rather, in the context of the present invention, “consistingof” is an embodiment specifically contemplated by the inventors to fallunder the scope of “comprising”, wherever “comprising” is used herein.

All publications, patents and patent applications cited in thisspecification are herein incorporated by reference as if each individualpublication or patent application were specifically and individuallyindicated to be incorporated by reference. Although the foregoinginvention has been described in some detail by way of illustration andexample for purposes of clarity of understanding, it will be readilyapparent to those of ordinary skill in the art in light of the teachingsof this invention that certain changes and modifications may be madethereto without departing from the spirit or scope of the appendedclaims.

The examples and figures shown in the following are merely illustrativeand shall describe the present invention in a further way. These figuresand examples shall not be construed to limit the present inventionthereto.

SHORT DESCRIPTION OF THE FIGURES

FIG. 1 Schematic drawings of preferred VP8* constructs. P2: P2 helperpeptide from Tetanus toxin; VP8*: Virus protein 8* (cleavage product ofrotavirus VP4 protein); SP: signal peptide; WhcAg: Wodchuck Hepatitisvirus core antigen; L: linker; TM: transmembrane domain

FIG. 2 Humoral responses upon vaccination with the preferred constructsencoding the P2 VP8* protein.

-   -   A: IgG1 and IgG2a antibody titers assessed by ELISA using P2        VP8* P[6] protein as a coating reagent. The experiment was        performed as described in Example 2. Statistically significant        IgG1 and IgG2a responses were detectable for most groups        vaccinated with the mRNA vaccine encoding P2 VP8*. The best        antibody responses were detectable in secreted and VLP designs.        Each dot represents an individual animal and horizontal lines        represent median values.    -   B: IgG1 and IgG2a antibody titers assessed by ELISA using P2        VP8* P[4] protein as a coating reagent. The experiment was        performed as described in Example 2. This figure shows        cross-reactive responses in mice vaccinated with P[6] designs        with P[4] serotype protein. Comparison of the different groups        shows that the trend seen for P[6] coating remains unaltered.        Each dot represents an individual animal and horizontal lines        represent median values.    -   C: IgG1 and IgG2a antibody titers assessed by ELISA using P2        VP8* P[8] protein as a coating reagent. The experiment was        performed as described in Example 2. This figure shows        cross-reactive responses in mice vaccinated with P[6] designs        with P[8] serotype protein. Comparison of the different groups        shows that the trend seen for P[6] and P[4] coating remains        unaltered. Each dot represents an individual animal and        horizontal lines represent median values.

EXAMPLES

The examples shown in the following are merely illustrative and shalldescribe the present invention in a further way. These examples shallnot be construed to limit the present invention thereto.

Example 1: Preparation of the Rotavirus mRNA Vaccine

1. Preparation of DNA and mRNA Constructs

For the present examples DNA sequences encoding the VP8* protein ofdifferent serotypes of rotavirus were prepared and used for subsequentin vitro transcription. Schematics of the constructs are shown in FIG. 1.

2. In Vitro Transcription

The respective DNA plasmids prepared according to paragraph 1 weretranscribed in vitro using T7 RNA polymerase in the presence of a CAPanalogue (m7GpppG). Subsequently the mRNA was purified usingPureMessenger® (CureVac, Tübingen, Germany; WO2008/077592A1).

The following mRNA sequences were prepared:

TABLE 21 SEQ N glycos- Trans- R ID Sero- AA in Helper Signal ylationmembrane VLP number NO. type VP4 peptide peptide sites domain domain 1.R3718 3114 P[6] +P2 N -> Q 2. R3720 3135 P[6] +P2 N -> Q 3. R3722 3121P[6] +P2 N -> Q 4. R3724 3128 P[6] +P2 N -> Q WhcAg 5. R5471 2968 P[8]65-223 +P2 — wt 6. R5473 2872 P[8] 40-223 +P2 — wt 7. R5475 2488 P[8] 2-230 +P2 — wt 8. R5479 2484 P[8]  1-230 — — wt 9. R5481 2496 P[8] 2-230 — +HSA wt 10. R5483 2592 P[8] 10-223 — +HSA wt 11. R5485 2880P[8] 40-223 — +HSA wt 12. R5487 2900 P[8] 40-223 +P2 +HSA wt 13. R54892904 P[8] 40-223 +P2 +IgE  wt 14. R5491 2736 P[8] 10-240 — +HSA N -> Q15. R5493 2928 P[8] 40-223 — +HSA N -> Q 16. R5594 2875 P[6] 40-223 —+HSA wt 17. R5595 2895 P[6] 40-223 +P2 +TPA wt 18. R5596 2491 P[6] 2-230 — +TPA wt 19. R5597 2827 P[6] 20-240 — +TPA N -> Q

The mRNA sequences comprise in 5′- to 3′-direction:

-   -   a) a 5′-CAP structure, consisting of m7GpppN;    -   b) a 5′-UTR element comprising the corresponding RNA sequence of        the nucleic acid sequence according to SEQ ID NO: 3189;    -   c) at least one sequence encoding a signal peptide    -   d) optionally at least one sequence encoding at least one helper        peptide (e.g. P2)    -   e) optionally at least one sequence encoding at least one        protein enabling VLP formation (e.g. WHcAg)    -   f) at least one G/C optimized coding region encoding the protein        of interest, preferably as shown in Table 2 Column B,    -   g) a 3′-UTR element comprising the corresponding RNA sequence of        a nucleic acid sequence according to SEQ ID NO: 3205;    -   h) a poly(A) sequence, comprising 64 adenosines;    -   i) a poly(C) sequence, comprising 30 cytosines; and    -   j) a histone-stem-loop structure, comprising the RNA sequence        according to SEQ ID NO: 3207.

3. Preparation of the mRNA Vaccine

3.1. Protamine Complexation:

The mRNA vaccine consisted of a mixture of 50% free mRNA and 50% mRNAcomplexed with protamine at a weight ratio of 2:1. First, mRNA wascomplexed with protamine by addition of protamine-Ringer's lactatesolution to mRNA. After incubation for 10 minutes, when the complexeswere stably generated, free mRNA was added, and the final concentrationof the vaccine was adjusted with Ringer's lactate solution.

3.2. LNP Formulation

Lipid nano particle (LNP)-formulated mRNA was generated using anionizable amino lipid, phospholipid, cholesterol and a PEGylated lipid,similar in composition as described in Thess et al. Mol Ther J Am SocGene Ther. 2015; 23(9):1456-1464.

3.3. CVCM Formulation:

The polyethylene glycol/peptide polymers (HO-PEG5000-S—(S—CHHHHHHRRRRHHHHHHC—S-)7-S-PEG 5000-OH according to formula IV(referred to as PB83) is used for complexation of the inventive mRNAsequences, optional in combination with a lipid or lipidoid as disclosedin PCT/EP2016/063228 (incorporated herewith by reference).

4. Analysis of VP8* Specific Antibodies by ELISA

ELISA plates were coated with 1 μg/ml (for P[4] P2-VP8* and P[6]P2-VP8*) or 10 μg/ml (for P[8] P2-VP8*) protein. Coated plates wereblocked (in 1% milk; 0.05% Tween in PBS) and incubated with serum indifferent dilutions. Binding of specific antibodies to the P2 VP8*protein was detected using HRP (horse radish peroxidase) coupled ratmonoclonal anti-mouse IgG1 or IgG2a using Amplex Ultra Red as asubstrate for detection.

Statistical analysis was done by Mann Whitney test. Asterisks representthe following p values: *p<0.05; **p<0.01; ***p<0.001.

Example 2: Induction of Humoral Responses Upon Vaccination with the mRNAVaccine Encoding the P2 VP8* Protein

Balb/c mice were immunised with mRNA vaccines (as prepared in Example 1)encoding P2-VP8* from serotype P[6] or RiLa (Ringer lactate) as anegative control as indicated in Table 22 below. Intradermal (i.d.)vaccinations were performed on day 0, day 21 and day 42. Blood samplestaken on day 56 were analysed for the presence of VP8* specific IgG1 andIgG2a antibodies by ELISA using P2 VP8* P[6] protein (FIG. 2 A), P2 VP8*P[4] protein (FIG. 2 B), or P2 VP8* P[8] protein (FIG. 2 C) as a coatingreagent (Wen et al., 2014. Vaccine 32, 4420-4427).

TABLE 22 Animal groups and treatment Treat- ment/ Vaccin. Strain/Vaccine Sero- Route/ sched- gender Nr. dose Construct type Volume ule 1BALB/c 8 80 μg Secreted P2- P[6] i. d. d0/21/42 Female R3718 VP8* 2 × 50μl 2 BALB/c 8 80 μg Secreted repeat P[6] i. d. d0/21/42 Female R3720P2-VP8* 2 × 50 μl 3 BALB/c 8 80 μg Transmembrane P[6] i. d. d0/21/42Female R3722 P2-VP8* 2 × 50 μl 4 BALB/c 8 80 μg VLP P2-VP8* P[6] i. d.d0/21/42 Female R3724 2 × 50 μl 5 BALB/c 8 100% — — i. d. d0/21/42Female RiLa 2 × 50 μl

Results

As shown in FIG. 2 A, statistically significant IgG1 and IgG2a responseswere detectable for most groups vaccinated with the mRNA vaccineencoding P2 VP8* when P2 VP8* of serotype P[6] protein was used as acoating reagent. The best antibody responses were detectable in secretedand VLP designs.

FIG. 2 B shows cross-reactive responses in mice vaccinated with P[6]designs with the P[4] serotype P2 VP8* protein used as a coatingreagent. Comparison of the different groups shows that the trend seenfor P[6] coating in FIG. 2 remains unaltered. This result is verysurprising as cross-protection between different serotypes of rotaviruswould not have been expected.

FIG. 2 C shows cross-reactive responses in mice vaccinated with P[6]designs with the P[8] serotype P2 VP8* protein used as a coatingreagent. Comparison of the different groups shows that the trend seenfor P[6] and P[4] coating in FIG. 2 A and FIG. 2 B, respectively,remains unaltered. This result is very surprising as cross-protectionbetween different serotypes of rotavirus would not have been expected.

Example 3: Immunogenicity of New VP8* Designs

Balb/c mice are immunised intradermally with the new mRNA vaccinedesigns encoding P2-VP8* (table 21). RiLa (Ringer lactate) andadjuvanted P2-VP8* protein are employed as a negative and positivecontrol, respectively, as indicated in Table 23 and 24. Vaccinations areperformed on day 0, day 21 and day 42. Blood samples taken on day 56 areanalysed for the presence of VP8* specific IgG1 and IgG2a antibodies byELISA using P2 VP8* P[8] or P[6] protein, respectively, as a coatingreagent as described above.

TABLE 23 Animal groups and treatment part A Strain/ Route/ Gr. genderNumber Treatment Volume Vaccin. schedule 1 BALB/c 6 Negative control i.d. d0/21/42 female 2 × 50 μl 2 BALB/c 6 Positive control i. m. d0/21/42female 4 × 25 μl 3 BALB/c 12 80 μg R3718 i. d. d0/21/42 female 2 × 50 μl4 BALB/c 12 80 μg R5594 i. d. d0/21/42 female 2 × 50 μl 5 BALB/c 12 80μg R5595 i. d. d0/21/42 female 2 × 50 μl 6 BALB/c 12 80 μg R5596 i. d.d0/21/42 female 2 × 50 μl 7 BALB/c 12 80 μg R5597 i. d. d0/21/42 female2 × 50 μl 8 BALB/c 12 80 μg R5471 i. d. d0/21/42 female 2 × 50 μl 9BALB/c 12 80 μg R5473 i. d. d0/21/42 female 2 × 50 μl 10 BALB/c 12 80 μgR5475 i. d. d0/21/42 female 2 × 50 μl 11 BALB/c 12 80 μg R5479 i. d.d0/21/42 female 2 × 50 μl

TABLE 24 Animal groups and treatment part B Strain/ Route/ Gr. genderNumber Treatment Volume Vaccin. schedule 1 BALB/c 6 Negative control i.d. d0/21/42 Female 2 × 50 μl 2 BALB/c 6 Positive control i. m. d0/21/42Female 4 × 25 μl 3 BALB/c 12 80 μg R3718 i. d. d0/21/42 Female 2 × 50 μl4 BALB/c 12 80 μg R5481 i. d. d0/21/42 Female 2 × 50 μl 5 BALB/c 12 80μg R5483 i. d. d0/21/42 Female 2 × 50 μl 6 BALB/c 12 80 μg R5485 i. d.d0/21/42 Female 2 × 50 μl 7 BALB/c 12 80 μg R5487 i. d. d0/21/42 Female2 × 50 μl 8 BALB/c 12 80 μg R5489 i. d. d0/21/42 Female 2 × 50 μl 9BALB/c 12 80 μg R5490 i. d. d0/21/42 Female 2 × 50 μl 10 BALB/c 12 80 μgR5491 i. d. d0/21/42 Female 2 × 50 μl

Example 4: Immunogenicity of New VP8* Formulations

Five mRNA designs are tested as mRNA formulations with LNPs (lipidnanoparticle) and CVCMs formulations. For this, the respective mRNAsequences are formulated as described above and are tested uponintramuscular injection. RiLa (Ringer lactate) and adjuvanted P2-VP8*protein are employed as a negative and positive control, respectively,as indicated in Table 25 and 26 vaccinations are performed on day 0, day21 and day 42. Blood samples taken on day 56 are analysed for thepresence of VP8* specific IgG1 and IgG2a antibodies by ELISA using P2VP8* P[8] or P[6] protein, respectively, as a coating reagent (FIG. 2 )

TABLE 25 Animal groups and treatment LNP formulations Strain/ VaccineRoute/ Vaccin. Gr. gender Number Treatment formulation Volume schedule 1BALB/c 6 Negative control — i. d. d0/21/42 female 2 × 50 μl 2 BALB/c 6Positive control — i. m. d0/21/42 female 4 × 25 μl 3 BALB/c 12 Design 1Protamine i. d. d0/21/42 female 80 μg formulation 2 × 50 μl 4 BALB/c 12Design 2 Protamine i. d. d0/21/42 female 80 μg formulation 2 × 50 μl 5BALB/c 12 Design 3 Protamine i. d. d0/21/42 female 80 μg formulation 2 ×50 μl 6 BALB/c 12 Design 4 Protamine i. d. d0/21/42 female 80 μgformulation 2 × 50 μl 7 BALB/c 12 Design 5 Protamine i. d. d0/21/42female 80 μg formulation 2 × 50 μl 8 BALB/c 12 Design 1 LNP formulationi. m. d0/21/42 female  5 μg 1 × 25 μl 9 BALB/c 12 Design 2 LNPformulation i. m. d0/21/42 female  5 μg 1 × 25 μl 10 BALB/c 12 Design 3LNP formulation i. m. d0/21/42 female  5 μg 1 × 25 μl 11 BALB/c 12Design 4 LNP formulation i. m. d0/21/42 female  5 μg 1 × 25 μl 12 BALB/c12 Design 5 LNP formulation i. m. d0/21/42 female  5 μg 1 × 25 μl

TABLE 26 Animal groups and treatment CVCM formulations Strain/ VaccineRoute/ Vaccin. Gr. gender Number Treatment formulation Volume schedule 1BALB/c 6 Negative control — i. d. d0/21/42 female 2 × 50 μl 2 BALB/c 6Positive control — i. m. d0/21/42 female 4 × 25 μl 3 BALB/c 12 Design 1Protamine i. d. d0/21/42 female 80 μg formulation 2 × 50 μl 4 BALB/c 12Design 2 Protamine i. d. d0/21/42 female 80 μg formulation 2 × 50 μl 5BALB/c 12 Design 3 Protamine i. d. d0/21/42 female 80 μg formulation 2 ×50 μl 6 BALB/c 12 Design 4 Protamine i. d. d0/21/42 female 80 μgformulation 2 × 50 μl 7 BALB/c 12 Design 5 Protamine i. d. d0/21/42female 80 μg formulation 2 × 50 μl 8 BALB/c 12 Design 1 CVCM formulationi. m. d0/21/42 female 10 μg 1 × 25 μl 9 BALB/c 12 Design 2 CVCMformulation i. m. d0/21/42 female 10 μg 1 × 25 μl 10 BALB/c 12 Design 3CVCM formulation i. m. d0/21/42 female 10 μg 1 × 25 μl 11 BALB/c 12Design 4 CVCM formulation i. m. d0/21/42 female 10 μg 1 × 25 μl 12BALB/c 12 Design 5 CVCM formulation i. m. d0/21/42 female 10 μg 1 × 25μl

1. mRNA sequence comprising at least one coding region, encoding atleast one epitope of a protein, or of a fragment, variant or derivativethereof of a virus of the genus rotavirus.
 2. The mRNA sequenceaccording to claim 1, wherein the rotavirus is selected from the speciesA or B or C.
 3. The mRNA sequence according to claim 1 or claim 2,wherein the rotavirus is selected from the species A.
 4. The mRNAsequence according to any one of the preceding claims, wherein therotavirus is selected from the G-serotypes or P-serotypes G1 or G2 or G3or G4 or G9 or G12 or P[4] or P[6] or P[8].
 5. The mRNA sequenceaccording to any one of the preceding claims, wherein the mRNA sequenceencodes for at least one epitope of a protein, or of a fragment, variantor derivative thereof of a virus of the genus rotavirus, which is atleast 60% identical, more preferably at least 70% identical, morepreferably at least 80% identical, more preferably at least 90%identical, more preferably at least 95% identical, or most preferably atleast 99% identical to the wild type protein or to the respectivefragment of the wild type protein.
 6. The mRNA sequence according to anyone of the preceding claims, wherein the protein of a virus of the genusrotavirus is selected from a structural protein of rotavirus, preferablyVP1 or VP2 or VP3 or VP4 or VP6 or VP7, or from a non-structural proteinof rotavirus, preferably NSP1 or NSP2 or NSP3 or NSP4 or NSP5 or NSP6,more preferably VP2 or VP4 or VP6 or VP7 or NSP2 or NSP4.
 7. The mRNAsequence according to claim 6, wherein the at least one epitope isderived from any of the protein sequences according to SEQ ID Nos. 1-80.8. The mRNA sequence according to claim 6 or claim 7, wherein theprotein of a virus of the genus rotavirus is selected from proteinsderived from cleavage of VP4, wherein preferably the cleavage product isVP5* or VP8*, most preferably VP8*.
 9. The mRNA sequence according toclaims 6 to 8, wherein the protein VP7 is derived from the serotypes G1or G2 or G3 or G4 or G9 or G12 and/or wherein the protein VP4 or theprotein cleavage product VP5* or VP8* is derived from the serotypes P[4]or P[6] or P[8].
 10. The mRNA sequence according to claim 9, whereinVP8* is a shortened protein form.
 11. The mRNA sequence according toclaim 9 or claim 10, wherein VP8* is selected from any one of theprotein sequences according to SEQ ID NOs: 41, 45, 47, or 49 or from oneof the shortened forms according to SEQ ID NOs: 173-176, 269-272,365-368, 461-464, 557-560, 653-656, 749-750.
 12. The mRNA sequenceaccording to any one of the preceding claims, wherein the mRNA sequenceadditionally comprises at least one sequence section encoding at leastone helper peptide and optionally at least one sequence section encodinga peptide linker for enhancement of immunogenicity.
 13. The mRNAsequence according to claim 12, wherein the sequence section encodingthe helper peptide is located at the 5′-end of the coding region,encoding the at least one epitope of a protein, or of a fragment,variant or derivative thereof of a virus of the genus rotavirus.
 14. ThemRNA sequence according to claim 12 or claim 13, wherein the helperpeptide is derived from tetanus toxin, or a fragment, variant orderivative thereof.
 15. The mRNA sequence of according to claim 14,wherein the helper peptide comprises or consists of the amino acidsequence according to SEQ ID NO: 3147 or a fragment, variant orderivative thereof.
 16. The mRNA sequence according to any one of claims12 to 15, wherein the at least one coding region encodes at least one ofthe amino acid sequences as shown in Table
 3. 17. The mRNA sequenceaccording to any one of the preceding claims, wherein the mRNA sequenceadditionally comprises at least one sequence section encoding at leastone signal peptide.
 18. The mRNA sequence of claim 17, wherein thesignal peptide is derived from tissue plasminogen activator or albuminor CD5 or HLA-A2 or luciferase or immunoglobulin or IL-2 orchymotrypsinogen or a fragment, variant or derivative thereof.
 19. ThemRNA sequence according to claim 17 or claim 18, wherein the signalpeptide comprises or consists of an amino acid sequence selected fromany one of the amino acid sequences according to SEQ ID NOs: −3148-3159or a fragment, variant or derivative thereof.
 20. The mRNA sequenceaccording to claim 19, wherein the mRNA sequence encodes at least one ofthe amino acid sequences as shown in Table
 5. 21. The mRNA sequenceaccording to claim 19, wherein the mRNA sequence additionally comprisesat least one sequence section encoding the helper peptide derived fromtetanus toxin, preferably according to SEQ ID NO. 3147 or a fragment,variant or derivative thereof.
 22. The mRNA sequence according to claim21, wherein the mRNA sequence encodes at least one of the amino acidsequences as shown in Table
 7. 23. The mRNA sequence according to anyone of the preceding claims, wherein the coding region, encoding atleast one epitope of a protein, or a fragment, variant or derivativethereof, of a virus of the genus rotavirus is mutated to delete at leastone predicted or potential glycosylation site.
 24. The mRNA sequenceaccording to claim 23, wherein at least one codon coding for anasparagine, arginine, serine, threonine, tyrosine, lysine, proline ortryptophan is mutated in such a way that a different amino acid isencoded to delete at least one predicted or potential glycosylationsite.
 25. The mRNA sequence according to claim 24, wherein the at leastone codon codes for asparagine which is mutated to glutamine.
 26. ThemRNA sequence according to any one of the preceding claims, wherein thecoding region, encoding at least one epitope of a protein, or afragment, variant or derivative thereof, of a virus of the genusrotavirus is mutated to delete all predicted glycosylation sites. 27.The mRNA sequence according to any one of claims 23 to 26, wherein thecoding region encodes at least one of the amino acid sequences as shownin Table
 9. 28. The mRNA sequence according to any one of the precedingclaims, wherein the mRNA sequence additionally comprises at least onesequence section encoding at least one transmembrane domain of aprotein, or a fragment, variant or derivative thereof.
 29. The mRNAsequence according to claim 28, wherein the transmembrane domain isselected from the transmembrane domain of hemagglutinin (HA) ofinfluenza virus, or Env of HIV-1, or EIAV (equine infectious anemia), orMLV (murine leukemia), or mouse mammary tumor virus, or G protein of VSV(vesicular stomatitis virus), or rabies virus, or a fragment, variant orderivative thereof.
 30. The mRNA sequence according to claim 23 or claim24, wherein the at least one sequence section encoding a transmembranedomain of a protein, or a fragment, variant or derivative thereof, islocated at the 3′-end of the coding region, encoding at least oneepitope of a protein, or of a fragment, variant or derivative thereof,of a virus of the genus rotavirus.
 31. The mRNA sequence according toany one of claims 28 to 30, wherein the transmembrane domain comprisesor consists of any of the amino acid sequences according to SEQ ID NOs:3160-3171 or a fragment, variant or derivative thereof.
 32. The mRNAsequence according to any of claims 28 to 31, wherein the coding regionencodes at least one of the amino acid sequences as shown in Table 14.33. The mRNA sequence according to any one of the preceding claims,wherein the mRNA sequence additionally comprises at least one sequencesection encoding at least one peptide or protein enabling VLP (viruslike particle) formation.
 34. The mRNA sequence according to claim 33,wherein the peptide or protein enabling VLP formation is derived fromnon-human pathogenic viruses.
 35. The mRNA sequence according to claim33 or 34, wherein the peptide or protein enabling VLP formation isderived from Woodchuck hepatitis virus core antigen (WHcAg) or fromAlfalfa mosaic virus CP (coat protein).
 36. The mRNA sequence accordingto any one of claims 33 to 35, wherein the peptide or protein enablingVLP formation comprises or consists of any of the amino acid sequencesaccording to SEQ ID NO: 3172 or SEQ ID NO:
 3173. 37. The mRNA sequenceaccording to claim 35 or claim 36, wherein the at least one sequencesection encoding at least one peptide or protein enabling VLP formationderived from Woodchuck hepatitis virus core antigen (WHcAg) is located5′ of the coding region, encoding at least one epitope of a protein, ora fragment, variant or derivative thereof of a virus of the genusrotavirus.
 38. The mRNA sequence according to claim 35 or claim 36,wherein the at least one sequence section encoding at least one peptideor protein enabling VLP formation derived from Alfalfa mosaic virus CP(coat protein) is located 3′ of the coding region, encoding at least oneepitope of a protein, or a fragment, variant or derivative thereof of avirus of the genus rotavirus.
 39. The mRNA sequence according to claims33 to 38, wherein the at least one sequence section encoding a peptideor protein enabling VLP formation is separated from the coding region,encoding at least one epitope of a protein, or a fragment, variant orderivative thereof, of a virus of the genus rotavirus by a at least onesequence section encoding a peptide linker.
 40. The mRNA sequenceaccording to claim 39, wherein the at least one sequence sectionencoding the peptide linker is coding for a flexible linker or a rigidinker.
 41. The mRNA sequence according to claim 40, wherein the flexiblelinker comprises at least one stretch of glycine and/or serine residues,wherein preferably the flexible linker comprises more than one stretchof glycine and/or serine residues.
 42. The mRNA sequence according toclaim 40 or claim 41, wherein the peptide linker comprises at least onestretch consisting of four or five amino acids.
 43. The mRNA sequenceaccording to claims 39 to 42, wherein the peptide linker comprises orconsists of any of the amino acid sequence according to SEQ ID NOs:3174-3176.
 44. The mRNA sequence according any of the claims 33 to 43,wherein the coding region encodes one of the amino acid sequences asshown in Table
 16. 45. The mRNA sequence according to any of thepreceding claims, wherein the mRNA sequence comprises at least twocoding regions, each encoding at least one epitope of a protein, or of afragment, variant or derivative thereof of a virus of the genusrotavirus.
 46. The mRNA sequence according to claim 45, wherein the mRNAsequence comprises at least three or four coding regions.
 47. The mRNAsequence according to claim 45 or claim 46, wherein each coding regionencodes at least one epitope of a protein, or a fragment, variant orderivative thereof, of different serotypes of a virus of the genusrotavirus.
 48. The mRNA sequence according to claim 47, wherein the atleast one epitope of a protein, or a fragment, variant or derivativethereof, of different serotypes of a virus of the genus rotavirus isderived from the same protein, preferably from VP8*.
 49. The mRNAsequence according to claim 45 or claim 46, wherein each coding regionencodes at least one epitope of a protein, or a fragment, variant orderivative thereof, of the same serotype of a virus of the genusrotavirus, preferably from VP8*.
 50. The mRNA sequence according toclaim 49, wherein the sequence encodes one of the amino acid sequencesas shown in Table
 18. 51. The mRNA sequence according to any one ofclaims 45 to 49, wherein the at least two coding regions, each encodingat least one epitope of a protein, or of a fragment, variant orderivative thereof of a virus of the genus rotavirus, are separated byintermitting sequences.
 52. The mRNA sequence according to claim 51,wherein the intermitting sequence is an internal ribosomal entry sites(IRES), wherein preferably the IRES is selected from the IRES ofencephalomyocarditis virus and/or by the IRES of foot-and-mouth diseasevirus.
 53. The mRNA sequence according to claim 51, wherein theintermitting sequence is a sequence section encoding a self-cleavingpeptide.
 54. The mRNA sequence according to claim 53, wherein theself-cleaving peptide is selected from F2A peptide derived fromfoot-and-mouth diseases virus, or self-cleaving peptides from equinerhinitis A virus, Thosea asigna virus or porcine teschovirus-1.
 55. ThemRNA sequence according to any one of the preceding claims, wherein themRNA sequence comprises at least one sequence as shown in Tables 2, 4,6, 8, 10-13, 15, 17, and
 19. 56. The mRNA sequence according to any oneof the preceding claims, wherein the G/C content of the coding regionand/or coding sequence sections is increased compared with the G/Ccontent of the coding region of the wild type mRNA, and wherein thecoded amino acid sequence of said G/C-enriched mRNA is preferably notbeing modified compared with the coded amino acid sequence of the wildtype mRNA.
 57. The mRNA sequence according to any one of the precedingclaims, wherein the mRNA sequence comprises additionally a 5′-UTRelement and/or a 3′-UTR element and/or additionally at least one histonestem-loop sequence and/or additionally a 5′-CAP structure and/or apoly(A) sequence and/or a poly(C) sequence.
 58. The mRNA sequenceaccording to claim 57, wherein the mRNA sequence comprises, preferablyin 5′- to 3′-direction: a 5′-CAP structure, preferably m7GpppN; a codingregion encoding at least one epitope of a protein, or a fragment,variant or derivative thereof, of a virus of the genus rotavirus; a3′-UTR element comprising or consisting of a nucleic acid sequence whichis derived from a α-globin gene, preferably comprising the RNA accordingto SEQ ID NO: 3199 or a homolog, a fragment or a variant thereof; apoly(A) sequence, preferably comprising 64 adenosines; a poly(C)sequence, preferably comprising 30 cytosines; and a histone-stem-loop,preferably comprising the RNA sequence according to SEQ ID NO:
 3207. 59.The mRNA sequence according to claim 57, wherein the mRNA sequencecomprises, preferably in 5′- to 3′-direction: a 5′-CAP structure,preferably m7GpppN; a 5′-UTR element which comprises or consists of anucleic acid sequence which is derived from the 5′-UTR of a TOP gene,preferably comprising or consisting of the RNA sequence according to SEQID NO: 3189 or 3191 or a homolog, a fragment or a variant thereof; acoding region encoding at least one epitope of a protein, or a fragment,variant or derivative thereof, of a virus of the genus rotavirus; a3′-UTR element comprising or consisting of a nucleic acid sequence whichis derived from a gene providing a stable mRNA, preferably comprising orconsisting of any of the RNA sequences according to SEQ ID NOs: 3193,3195, 3197, 3199, 3201, or 3203 or a homolog, a fragment or a variantthereof; a poly(A) sequence preferably comprising 64 adenosines; apoly(C) sequence, preferably comprising 30 cytosines; and ahistone-stem-loop, preferably comprising the corresponding RNA sequenceof the nucleic acid sequence according to SEQ ID NO:
 3207. 60. The mRNAsequence according to any one of the preceding claims, wherein the mRNAsequence is prepared for use as a vaccine.
 61. Composition comprisingone or more mRNA sequences as defined according to any one of thepreceding claims and optionally a pharmaceutically acceptable carrier.62. The composition according to claim 61, wherein the mRNA sequenceaccording to claims 1 to 59 is at least partially associated with orcomplexed with a cationic or polycationic compound and/or a polymericcarrier, optionally in a weight ratio selected from a range of about 6:1(w/w) to about 0.25:1 (w/w), more preferably from about 5:1 (w/w) toabout 0.5:1 (w/w), even more preferably of about 4:1 (w/w) to about 1:1(w:w) or of about 3:1 (w/w) to about 1:1 (w/w), and most preferably aratio of about 3:1 (w/w) to about 2:1 (w/w) of mRNA to cationic orpolycationic compound and/or with a polymeric carrier; or optionally ina nitrogen/phosphate ratio of mRNA to cationic or polycationic compoundand/or polymeric carrier in a range of about 0.1-10, preferably in arange of about 0.3-4 or 0.3-1, and most preferably in a range of about0.5-1 or 0.7-1, and even most preferably in a range of about 0.3-0.9 or0.5-0.9.
 63. The composition according to claim 61 or claim 62,preferably comprising one or more mRNA sequences as defined according toany one of claims 1 to 59 and at least one VLP forming protein orpeptide, or a fragment, variant or derivative thereof, and/or a nucleicacid encoding a VLP forming protein or peptide, or a fragment, variantor derivative thereof.
 64. The composition according to claim 63,wherein the VLP forming protein or peptide is a viral matrix protein orpeptide derived from an enveloped virus.
 65. The composition accordingto claim 64, wherein the matrix protein is a gag protein derived from anenveloped virus selected from HIV-1 or EIAV or MLV.
 66. The compositionaccording to claim 64, wherein the matrix protein is the matrix proteinof vesicular stomatitis virus (VSV), Rabies virus or the VP40 proteinderived from an Ebola virus.
 67. Pharmaceutical composition comprisingone or more mRNA sequences as defined according to any one of claims 1to 59 or a composition according to any one of claims 60 to 66 andoptionally a pharmaceutically acceptable carrier.
 68. The pharmaceuticalcomposition according to claim 67, wherein at least one mRNA sequence isat least partially associated with or complexed with a cationic orpolycationic compound and/or a polymeric carrier, preferably cationicproteins or peptides and most preferably protamine.
 69. Thepharmaceutical composition according to claim 68, wherein the ratio ofcomplexed mRNA to free mRNA is selected from a range of about 5:1 (w/w)to about 1:10 (w/w), more preferably from a range of about 4:1 (w/w) toabout 1:8 (w/w), even more preferably from a range of about 3:1 (w/w) toabout 1:5 (w/w) or 1:3 (w/w), and most preferably the ratio of complexedmRNA to free mRNA is selected from a ratio of 1:1 (w/w).
 70. Vaccinecomprising a composition as defined according to any one of claims 60 to66 or a pharmaceutical composition as defined according to any one ofclaims 67 to
 69. 71. The composition as defined according to any one ofclaims 60 to 66, the pharmaceutical composition as defined according toany one of claims 67 to 69 or the vaccine as defined according to claim70 further comprising at least one adjuvant component.
 72. Kit or kit ofparts comprising one or more of the m RNA sequences as defined accordingto any one of claims 1 to 59 or the composition as defined according toany one of claims 60 to 66 or the pharmaceutical composition as definedaccording to any one of claims 67 to 69 or the vaccine as definedaccording to claim 70 and optionally technical instructions withinformation on the administration and dosage of the components.
 73. ThemRNA sequence as defined according to any one of claims 1 to 59 or thecomposition as defined according to any one of claims 60 to 66 or thepharmaceutical composition as defined according to any one of claims 67to 69 or the vaccine as defined according to claim 70 or the kit or kitof parts as defined according to 72 for use as a medicament.
 74. ThemRNA sequence as defined according to any one of claims 1 to 59 or thecomposition as defined according to any one of claims 60 to 66 or thepharmaceutical composition as defined according to any one of claims 67to 69 or the vaccine as defined according to claim 70 or the kit or kitof parts as defined according to claim 72 for use in the treatment orprophylaxis of rotavirus infections.
 75. The mRNA sequence or thecomposition or the pharmaceutical composition or the vaccine or the kitor kit of parts for use according to claim 73 or claim 74, wherein themRNA sequence, the composition, the pharmaceutical composition, thevaccine or the kit or kit of parts is administered by subcutaneous,intramuscular, intradermal, topical or transdermal application, morepreferably by intradermal injection.
 76. A method of treatment orprophylaxis of rotavirus infections comprising the steps: providing oneor more of the mRNA sequences as defined according to any one of claims1 to 59 or the composition as defined according to any one of claims 60to 66 or the pharmaceutical composition as defined according to any oneof claims 67 to 69 or the vaccine as defined according to claim 70 orthe kit or kit of parts as defined according to claim 72; and applyingor administering the mRNA sequence(s) or the composition or thepharmaceutical composition or the vaccine or the kit or kit of parts toa tissue or an organism.
 77. The method according to claim 76, whereinthe mRNA sequence(s) or the composition or the pharmaceuticalcomposition or the vaccine or the kit or kit of parts is administered tothe tissue or to the organism by subcutaneous, intramuscular,intradermal, topical or transdermal application, more preferably byintradermal injection.
 78. The method according to claim 77, wherein theinjection is carried out by using conventional needle injection or jetinjection, preferably by using jet injection.